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Preface 
 
iii 
  
This is not a typical Nanotech PhD. It was not built upon two solid blocks of a BSc and a MSc in physics, but 
laid on the corners of applied spectroscopy, clinical development, chemistry and microbiology. Instead of 
the usual three years, it has taken four, because it was done at reduced time, so I could still have time for 
my family. With educations in food science and technology and my background working in a medical device 
company, I am grateful that Anja trusted ME to work on this fantastic project. 
The work was carried out at Technical University of Denmark, Department of Micro- and Nanotechnology 
(DTU Nanotech), supervised by Professor Anja Boisen and co-supervised by Researcher Tomas Rindzevicius. 
Second co-supervisor was Professor Søren Molin from the Novo Nordisk Foundation Centre for Biosustain-
ability, DTU, in collaboration with MD Helle Krogh Johansen from the Department of Clinical Microbiology, 
Copenhagen University Hospital, Rigshospitalet. Part of the work was carried out at University of 
Copenhagen (KU), Department of Food Science; at the Danish Paediatric Pulmonary Service of 
Rigshospitalet; and at DTU, Department of Systems Biology. 
 
 
Abstract 
 
iv 
Cystic fibrosis (CF) is the most frequently inherited disease in the Western world, and also the one with the 
highest morbidity and mortality. The main reason is chronic lung infections caused by the pathogenic 
bacterium Pseudomonas aeruginosa, which is well-adapted to the thick and dehydrated mucous in the CF 
airways. Established methods to detect P. aeruginosa in young CF children are invasive and lack sensitivity, 
which is why novel approaches are being investigated. P. aeruginosa emits hydrogen cyanide (HCN) gas, 
which can possibly be used as a biomarker for early P. aeruginosa colonisation, if it can be detected in the 
breath. It was investigated if a nanopillar substrate for surface-enhanced Raman spectroscopy (SERS), 
developed in the Nanoprobes group, could be optimised for gas phase detection of HCN. The project 
consisted of 3 steps, of which the first was to establish a chemical method to detect cyanide on the 
substrate in relevant concentrations, preferably in gas. Step I was split up into two parts; one for HCN 
detection in the gas phase, and one for detection of potassium cyanide (KCN) in serial dilutions to reach 
sufficiently low CN concentrations and verify the limit of detection. Once this was done, Step II was to 
measure HCN(g) from emissions of P. aeruginosa; first from the established reference strain, the wild type 
PAO1. Secondly, it was relevant to study clinical P. aeruginosa strains, isolated for the first time from CF 
children (the wild type-like strains), and then compare to SERS measurements on later strains, isolated 
from the same patients after their infection became chronic and the P. aeruginosa had mutated in the lasR 
gene, which is essential to HCN production. Step III was a clinical trial, where children with CF would blow 
into a bag containing the SERS substrate, which was then measured, to see if HCN was detected when a 
new P. aeruginosa colonisation occurred; and data was correlated to culturing of sputum from the patient’s 
lungs. 
The SERS substrate was optimised, and setups were developed for HCN(g) detection, for SERS detection of 
HCN from bacterial volatiles, and for collection and SERS substrate exposure to human breath. Five ppm 
HCN was successfully detected in gas phase, and KCN was detected down to 10-6 M. HCN detection was 
demonstrated from cultures of P. aeruginosa wild types, starting from the end of exponential / beginning of 
stationary growth phase. HCN was also detected from lasR mutated clinical P. aeruginosa strains isolated 
from the airways of children with CF, when the mutation was located at the 5’ terminal (downstream) of 
the gene. P. aeruginosa isolates with a mutation at the 3’ terminal of the lasR gene (upstream) did not emit 
detectable HCN. Application for ethics’ committee was submitted and permission granted to conduct a 4 
months’ clinical pilot study at Rigshospitalet, including 50 CF patients aged 5-17 years and 19 age-matched 
control subjects. One CF patient had a new P. aeruginosa lung colonisation during the trial, and it was 
probably detected on the SERS substrate, which had an increased HCN signal compared to the patient’s 
other visits. Additional cases of increased SERS cyanide signal were seen in the breath of some of the 
children, and it was speculated if they could come from prolonged exposure time or from children being 
exposed to passive smoking at home. The SERS substrate has a background peak in the Raman spectrum, 
which needs to be addressed, because it is located very close to the cyanide peak. 
Sammendrag 
 
v 
  
Cystic fibrosis (CF) er den hyppigste arvelige sygdom in den Vestlige verden, og også den nedarvede sygdom 
med den højeste sygelighed og dødelighed. Den vigtigste årsag er kroniske lungeinfektioner med den 
patogene bakterie Pseudomonas aeruginosa, som er tilpasset den fortykkede og dehydrerede slimhinde i 
luftvejene hos CF patienter. Etablerede metoder til at detektere P. aeruginosa hos små børn med CF er 
invasive og ikke særligt følsomme, og derfor afprøves der nye metoder. P. aeruginosa udskiller hydrogen 
cyanid (HCN) gas, som muligvis kan bruges som biomarkør for tidlig P. aeruginosa kolonisation, hvis det kan 
detekteres i udåndingsluften. Det blev undersøgt, om et ”nanogræs” substrat til surface-enhanced Raman 
spektroskopi (SERS), udviklet i Nanoprobes gruppen, kunne optimeres til gasfase detektion af HCN. 
Projektet bestod af 3 trin, hvoraf det første var at etablere en kemisk metode til at detektere cyanid på 
substratet i relevante koncentrationer, fortrinsvis i gas. Trin I blev opdelt i 2 dele; en til HCN detektion i 
gasfase, og en til detektion af kaliumcyanid (KCN) i fortyndingsrække for at nå ned på tilstrækkeligt lave 
koncentrationer og verificere detektionsgrænsen. Da det var gjort, gik Trin II ud på at måle HCN(g) fra 
emissioner af P. aeruginosa; først fra den etablerede reference-stamme, vildtypen PAO1. Derefter var det 
relevant at undersøge kliniske P. aeruginosa stammer, isoleret for første gang fra CF børn (vildtype-agtige 
stammer), og så sammenligne med SERS målinger på senere stammer, isoleret fra de samme patienter, 
efter deres infektion blev kronisk og P. aeruginosa havde muteret på lasR genet, som er essentielt for HCN 
produktion. Trin III var en klinisk afprøvning, hvor børn med CF pustede i en pose med SERS substratet 
indeni; og det blev efterfølgende målt på, for at se, om HCN blev detekteret, når en ny P. aeruginosa 
kolonisation opstod; og data blev korreleret til dyrkning af sputumprøver fra patientens lunger. 
SERS substratet blev optimeret, og opstillinger blev udviklet til SERS detektion af HCN fra gas og 
bakteriedampe, samt til opsamling af og eksponering for udåndingsluft. Fem ppm HCN blev succesfuldt 
detekteret i gasfase, og KCN blev detekteret ned til 10-6 M. HCN detektion blev demonstreret fra 
dyrkningskulturer af P. aeruginosa vildtyper, fra slutningen af den eksponentielle / begyndelsen af den 
stationære vækstfase. HCN blev også detekteret fra lasR muterede kliniske P. aeruginosa stammer isoleret 
fra luftvejene hos børn med CF, når mutationen var lokaliseret i 5’ enden (nedstrøms) af lasR genet. P. 
aeruginosa isolater med en mutation i 3’ enden af lasR genet (opstrøms) udskilte ikke detektérbart HCN. En 
ansøgning blev sendt til etisk komité, og tilladelse blev givet til at gennemføre et 4 måneders klinisk 
pilotstudie på Rigshospitalet, med 50 CF patienter i alderen 5-17 år og 19 alders-matchede kontroller. Én CF 
patient fik en ny P. aeruginosa lunge-kolonisation i løbet af afprøvningen, og den blev sandsynligvis 
detekteret på SERS substratet, som havde et forhøjet HCN signal sammenlignet med patientens øvrige 
besøg. Flere tilfælde af forhøjet SERS cyanid signal blev set i udåndingsluften fra nogle af børnene, og det 
blev spekuleret, om det skyldtes forlænget eksponeringstid eller, at nogle af børnene blev udsat for passiv 
rygning i hjemmet. SERS substratet har en baggrundstop i Raman-spektret, som skal afhjælpes, fordi den 
ligger meget tæt på cyanidtoppen. 
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1.1: Background and funding 
1.1 Background and funding 
1.1a P. aeruginosa lung infections in cystic fibrosis 
Chronic lung infections caused by the opportunistic pathogen Pseudomonas aeruginosa are mainly seen in 
patients with cystic fibrosis (CF), primary cilia dyskinesia (PCD), and chronic obstructive pulmonary disease 
(COPD) [Gibson et al., 2003; Gallego et al., 2014]. These patients are infected because they are unable to 
clear their airways properly, and mucous inhabited by microorganisms is getting stuck [Sommer et al., 
2016]. P. aeruginosa can be found in soil and water reservoirs, where it does not affect healthy individuals, 
unless they have burn wounds, indwelling catheters or are immunosuppressed [Lorentz et al., 2016]. In CF 
patients chronic P. aeruginosa lung infections are the main cause of morbidity and mortality. CF is the most 
common autosomal recessive genetic disorder, and patients have inherited a defect gene on chromosome 
#7 from both parents. The gene is called the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene and encodes for a protein that regulates salt and water transport across secretory cells in the body, 
leading to sticky and dehydrated secretions. The most common mutation is a double deletion of 
phenylalanine in position 508 (ΔF508) of the CFTR protein [Schwartz et al., 1990]. Speculations about the 
background for the success of this particular mutation concern advantages in surviving e.g. cholera and 
typhoid fever, because the cholera toxin and Salmonella typhi need functional host CFTR channels to enter 
the cells [De Boeck & Ashlock, 2011]. 
Because P. aeruginosa airway colonisation can be difficult to discover in the initial stages and need to be 
treated with antibiotics before they become chronic [Marvig et al., 2015], new methods are being 
investigated. P. aeruginosa emits the poisonous gas hydrogen cyanide (HCN), which can be an advantage in 
killing competitive flora in the surroundings. In this project a nanostructured surface-enhanced Raman 
spectroscopy (SERS) substrate, developed for detection of explosives in the air [Schmidt et al., 2012], is 
optimised for detection of the P. aeruginosa biomarker HCN in the breath of children with CF. The triple 
bond between C and N in cyanide is utilised, because triple bonds give rise to a distinct peak in a Raman 
spectrum. The original SERS substrate is covered with silver (Ag), and the approach in this PhD project will 
be instead to use gold (Au) on top of the nanopillar surface, because of cyanide’s high affinity to Au 
[Murray & Bodoff, 1986; Cho et al., 2002].  At some point, P. aeruginosa starts to adapt to the environment 
in the airways, and a mutation in the lasR gene can mean that it does not produce HCN anymore [Pessi & 
Haas, 2000]. 
1.1b Raman spectroscopy 
Spectroscopy concerns the interaction between light and matter. A beam is directed towards the sample, 
and light is collected after their interaction, providing information about the chemical / physical nature of 
the sample. Raman spectroscopy investigates the inelastically scattered part of the light, i.e. the light 
scattered from the sample that has changed vibrational energy during the interaction. It was illustrated in 
1928 by Raman and Krishnan, who let sunlight through a telescope lens followed by two complementary 
filters. After the complementary filters they placed a sample, and no light could be seen at an angle to the 
sample, because it had all been filtered out. Then they moved the yellow-green filter and placed it after the 
light’s passage through the sample and now light could be seen. Due to the blue-violet filter, only yellow-
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green light was let to the sample, and it could be expected to be filtered out by the yellow-green filter after 
the sample; but the light’s interaction with the sample had changed its wavelength, which is why scattered 
light from the sample could be seen after the yellow-green filter. The spectrum gives Raman intensity as a 
function of exchanged energy, and since strong bonds vibrate at high frequencies, the triple bond between 
C and N in cyanide gives rise to a distinct peak at 2135 cm-1 in the triple bond / cumulated double bond 
region between 2000-2200 cm-1, which is normally flat [Raman & Krishnan, 1928; Smith & Dent, 2005]. 
 
Figure 1.1: Surface-enhanced Raman spectrum (SERS) of 5 ppm HCN(g). 
The triple bond peak is marked by an arrow. 
Because only a small fraction of the scattered light is scattered inelastically (~10-8), there is a need for 
enhancement of the Raman signal. We have optimized the signal by the use of surface-enhancement by a 
nanostructured silicon (Si) surface covered with Au. Even if the region is supposed to be flat, there is, 
however, a background peak on the Au substrate at 2127 cm-1, which is very close to the C≡N stretching 
peak, sometimes confounding the results. The background peak has also been reported elsewhere 
[Premasiri, et al., 2001]. 
1.1c Medical device development 
The aim of the project was to develop a medical device able to detect ppb HCN from human breath. 
Devices cannot be built on test systems, theories and assumptions alone. Medical devices must be taken to 
clinical trials. To communicate with the end users and watch them interact with the device you are 
developing, can give valuable information that had not been thought about before. According to The Lean 
Startup, developers must build a minimum viable product and put it into the “Build – Measure – Learn” 
feedback loop to start learning as quickly as possible. The prototype does not have to be perfect, it must be 
built on a minimal amount of development time and effort and be able to provide valuable feedback from 
those who will be using the product in the future [Ries, 2011]. With a background in the medical device 
industry I know that there is a certain scope of a project (e.g. in terms of time and money), and you must 
prioritise and plan accordingly in order to be able to constantly move closer to the goal. 
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1.1d This project 
The project indeed is multidisciplinary, dealing with product development, chemistry, physics, Raman and 
SERS spectroscopy, cleanroom fabrication, physiology, microbiology, genetics, clinical trial management as 
well as logistics. One person cannot be an expert of all, and I have tried to prioritise the insights necessary 
for the project to keep moving forward, combining the fields as well as I could. In case there are terms, 
which are unfamiliar to the reader, lists of expressions can be found at the beginning of each theory section 
in Chapter 2. The PhD project is part of the Sapere Aude project “NAPLAS”, which is developing in-depth 
understanding of the optical properties and plasmon coupling effects in the nanopillar SERS substrate and 
building miniaturized, label-free sensors for (semi-)quantitative detection of toxic molecules like PCB and 
HCN. It was funded by The Danish Council for Independent Research. 
1.2 Motivation 
In order to detect microorganisms as early as possible and thereby avoid a chronic infection, samples must 
be collected regularly from the airways of CF patients. Today the gentlest way to obtain a microbiological 
sample from the lungs is by spontaneous sputum production, also called expectoration. The patient coughs 
up a sputum sample from the lungs, which is then cultured to detect microbes. Children below the age of 8-
9 years do not produce sufficient amounts of sputum to expectorate, and therefore other methods must be 
taken into use in order to find out whether the child has a bacterial lung infection and needs treatment 
before it settles and causes a chronic infection. In increasing order of invasiveness comes; pharyngeal 
swaps, where a wooden stick holds down the tongue while a nylon or cotton stick is inserted through the 
mouth to the throat to catch what might be colonising the pharynx and surroundings; induced sputum: 
hypertonic saline is sprayed into the airways, causing irritation and inducing coughing, whereby a sputum 
sample is obtained, and there is a high risk of getting the environment contaminated; endo-laryngeal 
suction: a plastic catheter is inserted through the mouth or nose and into the throat down to the larynx, 
provoking a cough reflex, and a sputum sample is obtained through the tube; broncho-alveolar lavage 
(BAL), which is performed under general anaesthesia, where part of the lung is rinsed with sterile saline, 
and subsequently the fluid is cultured. 
 
Figure 1.2: Principle of endo-laryngeal suction, which is used in the CF clinic at Rigshospitalet 
to obtain sputum samples from non-expectorating children [www.nhspathology.fph.nhs.uk]. 
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After a while in the lungs, the body starts to produce signs of persistent bacterial colonisation or infection, 
in terms of e.g. antibodies against P. aeruginosa, which can be detected from a blood sample. The 
motivation is therefore, that children with CF need a more sensitive and less invasive method to detect 
early P. aeruginosa airway colonisation.  
1.3 Review of existing research 
Due to the unpleasant and highly invasive methods to discover P. aeruginosa in the lungs of CF children 
unable to produce sputum, breath analysis may offer a more acceptable, and perhaps even more sensitive, 
way to detect this pathogen. The first step is to discover which specific biomarkers could be used. Secondly, 
moving closer to point-of-care diagnostics, it is relevant to focus on detection in the breath, followed by 
Raman and SERS applications in healthcare and in the detection of HCN. 
1.3a Probing of P. aeruginosa biomarkers 
Many things have happened since Castric’s interesting studies on HCN production by P. aeruginosa in 1975. 
His method was to catch the cyanide headspace onto an alkaline filter strip trap, and for confirmation he 
acidified both the culture and the evolved gas with H2SO4, passed it through AgNO3 / HNO3 and filtered the 
precipitate to a white solid, presumably AgCN, which was added to 10N H2SO4 and heated to 100°C, again 
trapping the gas in base. The trapped material tested positive for cyanide in picrate, Aldridge, and Prussian 
Blue tests [Castric, 1975]. The results are nice, but a simpler and more pleasant test would be preferable to 
verify that HCN is in the culture headspace – or in the breath of a child infected with P. aeruginosa in the 
lungs. Within the last decade several methodologies have been applied, most of which dealing with mass 
spectroscopy (MS) or cyanide ion selective electrodes. In 2005, Carroll and coworkers used selected ion 
flow tube mass spectroscopy (SIFT-MS) to detect HCN and other volatiles in the headspace of P. aeruginosa 
cultures, suggesting that HCN could act as a specific P. aeruginosa biomarker in the breath of infected 
patients [Carroll et al., 2005]. 
Pedersen et al. suggested using immunoproteomics from a blood sample as a means of detecting P. 
aeruginosa. They used circulating antibodies in plasma from CF patients, which were screened against a 2D 
protein macroarray of a P. aeruginosa protein extract. Antigenic Pseudomonas PAO1 proteins were then 
captured by the plasma antibodies and arrayed by 2D gel electrophoresis, from where protein spots were 
proteolytically digested, so the purified peptides could be analysed by MALDI-TOF MS against various 
databases for identification of immunoreactive profiles [Pedersen et al., 2005]. In 2008, Ryall measured CN- 
in sputum of CF- and non-CF bronchiectasis patients with a P. aeruginosa airway infection, using an ion-
selective electrode. They demonstrated for the first time that cyanide could be detected in sputum, with 
levels in sputum from CF patients being higher (up to 130 µM) than in bronchiectasis patients (72 µM), as 
compared to control samples free of P. aeruginosa, where no cyanide was detected. They also mentioned 
that in some of the P. aeruginosa positive sputum samples no cyanide was detected [Ryall et al., 2008]. 
In 2011 Stutz and coworkers stated that cyanide in BAL samples from CF children was not diagnostic for P. 
aeruginosa, because applying a cyanide ion selective electrode, cyanide was found in BAL samples, which 
cultured both positive and negative for P. aeruginosa. They also said that BAL culture was not a very 
sensitive technique, and that the cyanide found could be attributed to inflammatory disease [Stutz et al., 
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2011]. To test a new method, for the outcome to be valid, it is important that the method you are testing 
against is reliable. If the authors are unsure of the sensitivity using BAL, they must be careful not to reject a 
method which has the potential to be even more sensitive. The study by Ryall and coworkers was followed 
up in 2011 by Savelev et al. who measured volatile organic compounds in the headspace of sputum 
samples from P. aeruginosa-infected CF- and non-CF bronchiectasis patients, using solid phase micro-
extraction MS. They concluded that 2-nonanone could be an additional P. aeruginosa biomarker [Savelev et 
al., 2011], which was rejected in 2012 by Jünger et al. who found it in the headspace of several other 
pathogens, including Eschericia coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens, 
as determined by thermal desorption GC-MS [Jünger et al., 2012]. According to Bos et al., 2-nonanone is 
also produced by Staphylococcus aureus, leaving it as a poor biomarker for P. aeruginosa [Bos et al., 2013]. 
Hydrogen cyanide thus seems to be the most promising P. aeruginosa biomarker. But with a molar mass of 
27.03 g/mol, it is difficult to establish a GC-MS technique for the determination of HCN concentrations, 
since most GC-MS systems cannot go below 30 g/mol. Shestivska et al. therefore suggested using methyl 
thiocyanate (CH3SCN) as a possible P. aeruginosa biomarker instead [Shestivska et al., 2012].  
1.3b P. aeruginosa in breath 
In an attempt to diagnose P. aeruginosa noninvasively, Vogelberg and coworkers tried to detect bacterial 
DNA using PCR on breath condensates from 13 young CF patients known to have P. aeruginosa or 
Burkholderia cepacia in their airways. As reference, sputum samples were acquired whenever possible, but 
only the sputum samples and none of the 32 breath condensates contained any bacterial DNA [Vogelberg 
et al., 2003]. This is interesting, because some P. aeruginosa lineages are known to be able to spread 
among CF patients [Marvig et al., 2013], and this could be expected to occur via breath aerosols. Compared 
to sputum culturing, the use of PCR may be a step forward, when it comes to sensitivity. Unfortunately it is 
more expensive, and the method still needs sputum sampling. Using GC-MS, Scott-Thomas et al. in 2010 
detected higher amounts of 2-aminoacetophenone (2-AA) in the breath of CF patients colonised with P. 
aeruginosa than in the control groups and suggested 2-AA as a possible biomarker for P. aeruginosa [Scott-
Thomas et al., 2010]. The year after they found that 2-AA levels in breath can be confounded by food intake 
such as corn products, canned tuna, egg white and beer [Scott-Thomas et al., 2011]. 
In 2013, Zhu et al. published a study on secondary electrospray ionization mass spectroscopy (SESI-MS) on 
the breath of ventilated mice with a P. aeruginosa or S. aureus lung infection. Applying partial least-squares 
regression in combination with discriminant analysis (PLS-DA) to the SESI-MS breathprints they were able 
to completely separate P. aeruginosa-infected mice from S. aureus-infected mice and from a third group of 
control mice. They even said it might be possible at an early infection stage to identify which mice were 
able to clear the infection by themselves and which would need antibiotics. In conclusion, instead of 
looking for single biomarkers, they recommended to use the entire breathprint in the analysis to 
discriminate between the groups [Zhu et al., 2013a]. Dummer et al. used SIFT-MS to quantify HCN in the 
breath of 6 healthy, non-smoking volunteers with a mean age of 35 years, comparing nose- and mouth-
exhaled breath. Due to elevated HCN in mouth-exhaled samples, they concluded that breath samples 
should be exhaled via the nose. Twenty-six CF and non-CF bronchiectasis patients with a mean age of 62 
years delivered nose-exhaled samples and no significant relationship between P. aeruginosa status and end 
exhaled HCN concentrations was found, so they concluded that HCN cannot work as a P. aeruginosa 
biomarker [Dummer et al., 2013]. The fact that the patients included in this study had a relatively high age 
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suggests that many of them possible already had a chronic infection, which again means that their P. 
aeruginosa can have mutated into lasR defect strains, which had ceased to emit HCN. This was the 
experience from the in vitro studies presented in Paper II. 
Gilchrist and coworkers investigated nose- and mouth-exhaled breath from 10 adult chronically P. 
aeruginosa-infected CF patients and compared to 10 adult CF patients without P. aeruginosa, using SIFT-
MS. They detected acetone, ethanol and HCN. Acetone content was used as a measure of consistent 
sampling rate, whereas ethanol is generated in the mouth by enzyme activity of bacteria and saliva. Nearly 
all chronically infected subjects had elevated HCN levels in their mouth-exhaled breath, whereas four of 
their nose-exhaled samples did not. Nevertheless, nose-exhaled breath samples of chronically infected 
patients had significantly higher HCN concentrations than those free from P. aeruginosa; and mouth-
exhaled breath showed the same trend, although some of the HCN was expected to come from bacterial 
activity in the mouth [Gilchrist et al., 2013]. Finally, in 2015 they published a large study on HCN 
concentrations in the breath of 233 children with CF, again using SIFT-MS, but on mouth-exhaled breath, 
collected over two years from 8 centres in UK (The SPACE study). Findings were that half of the 57 children 
with newly acquired P. aeruginosa infections had elevated HCN in their breath, some up to 2 visits prior to 
positive culture, whereas the other half did not. This other half had HCN levels in their breath similar to 
those who remained free from P. aeruginosa. Additionally, there were no significant differences between 
the two groups regarding age or P. aeruginosa status prior to being colonised [Gilchrist et al., 2015]. Like 
the study by Dummer et al. the authors included chronically infected patients; who, with the experience 
gained from this PhD, should probably not have been included in the study. They had not had any positive 
culture for the past 12 months prior to inclusion, which can question the reliability of the swab test used, 
also during the trial [Bonestroo et al., 2010]. To avoid the inconveniences of the presented methods 
pointed out in Papers I and II, our approach was to detect HCN using a Au SERS substrate for cyanide 
adsorption, measured with Raman instrumentation, which has the potential to be down-scaled for home or 
point-of-care diagnostics at an affordable cost. 
1.3c Raman / SERS for diagnostics 
Due to the method’s novelty, the literature on Raman / SERS methodology on exhaled breath is sparse. A 
recent study on a complex gas mixture was published by Jürgen Popp’s group, who used a microstructured 
hollow core photonic crystal fibre (HCPCF) for fiber-enhanced Raman spectroscopy (FERS), simultaneously 
detecting H2, CO2, N2O, O2, CH4, and N2 at ppm levels, combining rotational and ro-vibrational FERS. In the 
colon, E. coli generates high levels of H2 in lactose intolerance and fructose malabsorption, and the goal 
was to apply the method for hydrogen breath testing of these malabsorption disorders [Hanf et al., 2015]. 
The problem with the application of the presented method is its ppm level detection, which for our 
intended use needs to be ppb [Enderby et al., 2009].  
The first attempt to detect bacteria using SERS was probably done in 1998 by Efrima and Bronk, who used 
Ag colloids to enhance the Raman spectrum of E. coli. The bacteria were soaked in NaBH4, centrifuged and 
resuspended in AgNO3, producing a rough film on the outside of the bacterial wall. The resulting SERS 
spectrum was rich in bands that could be attributed to peptidoglycans of the cell wall [Efrima & Bronk, 
1998]. In order to be used for non-invasive detection of P. aeruginosa, the approach of course is too rough, 
and VOC biomarker detection in comparison would be an advantage. In 2007, Alexander and Le used the 
commercially available KlariteTM substrate to identify four different Bacillus spore suspensions deposited 
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onto the substrate and dried at room temperature. Due to unique features in each of the spores’ spectra, 
they could be classified univariately, i.e. based on single Raman bands. For a more general identification of 
bacterial spores the authors recommend using multivariate tools on the entire SERS spectrum, to predict or 
classify each type of spore [Alexander & Le, 2007]. The KlariteTM substrate was also tested in the present 
PhD project. Although high uniformity, it suffered from poor enhancement, and the substrate is not on the 
market anymore. 
There exists some good review papers on Raman applications [Das & Agrawal, 2011]; SERS and SERRS 
applications [McNay, et al., 2011]; medical SERS applications [Xie & Schlücker, 2013]; and potential SERS 
applications for disease detection and treatment [McAughtrie, 2014]. Of special interest are some papers 
from van Duyne’s group, who reported SERS quantification of glucose down to micromolar levels using a 
silver film over nanosphere (AgFON) surface with a partitioning self-assembling monolayer (SAM) of 1-
decanethiol to preconcentrate the glucose close to the Ag surface, which was also protected against 
oxidation by the SAM. Partial least-squares regression, using full cross validation (leave-one-out) was used 
to validate the prediction of glucose from 0-250 mM and 0-25 mM [Shafer-Peltier, 2003]. Using full cross 
validation is probably not the best way to validate a model’s prediction error, because by leaving one 
sample out at a time, and then including it in the next iteration can result in over-optimistic prediction 
errors, and it is probably not what the authors would have applied today [Esbensen et al., 1997]. Later they 
published new results using AgFON SERS, this time without the SAM, detecting the Bacillus subtilis spore 
biomarker calcium dipicolinate to a limit of detection of 2.6 x 103 spores, as a substitute for the pathogenic 
B. anthracis. This time the results were self-explanatory and did not need multivariate analysis to become 
evident [Zhang et al., 2005]. If anthrax spores thus can be detected by means of a fairly simple method, 
much could be gained against microbiological warfare. On top they reported on shelf lives up to 40 days for 
this Ag substrate. This is impressive and can be compared to the tests on our Au substrate, which lasted for 
at least 17 days, but less than 2 months, referring to section 3.2 on SERS substrate optimisation.  
Wu and Cunningham presented a Au SERS sensor able to reversely bind 10 pharmaceutical compounds for 
continuous real-time monitoring of administered drugs in an intravenous tube. Two sedative or pain drugs 
in combination could be monitored simultaneously on the flexible polyester substrate inside the flow cell 
used for the experiments. The assay could be used to monitor drug delivery and prevent overdose, which is 
of tremendous importance to the wellbeing of the patient [Wu & Cunningham, 2014]. 
Presented are different substrates, which have been developed for different purposes. Trans-1,2-bis(4-
pyridol)ethylene (BPE) is a very Raman-active, two-ring molecule with 5 distinct peaks in the region 1000-
1700 cm-1, which is often used to benchmark SERS substrates [Kim et al., 2010]. But to develop substrates 
solely based on the comparison of their BPE signal intensities can be risky, unless the intended application 
for the substrate is BPE detection. At one point I tried a different SERS substrate because, unlike the other 
Au substrates, this did not have the annoying background peak at 2127 cm-1. But when exposed to HCN, the 
triple bond peak was completely absent, because the substrate did not enhance any Raman scattering in 
the region 2000-2200 cm-1, although it was excellent for the enhancement of BPE. In section 3.2, attempts 
are described to optimise the SERS substrate for the specific application of HCN detection at ppb level in 
the gas phase. 
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The PhD project was divided in 3 steps, of which the first was to detect HCN in the gas phase and to 
demonstrate ppb level detection of cyanide (Paper I). The second step was to detect HCN from emissions of 
37 °C P. aeruginosa cultures isolated from paediatric CF patients, to mimic detection in the breath (Paper 
II). The last step was to perform a clinical trial, including children with CF who exhaled into bags with the 
SERS substrate mounted inside, to verify whether it was possible to detect HCN in the breath of children at 
an early stage of P. aeruginosa airway infection (Paper III). The Experimental part is described in chapter 3 
and the papers included in the thesis. 
Chapter 2: Theory 
 
9 
2.1: Cystic Fibrosis 
List of expressions – cystic fibrosis 
 
Allele Variants of a chromosome or gene. 
Autosome Chromosome which is not a sex chromosome. 
BAL Broncho-alveolar lavage; airway rinsing with sterile saline under general anaesthesia. 
Bronchiectasis Abnormal widening of parts of the lung, e.g. the bronchial tubes, accompanied by coughing;  
excess mucus production and coughing up blood. 
Colonisation Initial inhabitation by a pathogen without antibody production or inflammatory reaction, as 
opposed to a chronic infection with an antibody response. 
ΔF508 Deletion of a phenylalanine in position 508 on the CFTR gene; the most common mutation 
causing cystic fibrosis. 
DNA Deoxyribonucleic acid is made of pairs of chromosomes, which are coiled strands of 
biopolymers consisting of the four nucleotides; cytosine (C); guanine (G); adenine (A); and 
thymine (T), arranged in base pairs of C and G, respectively A and T. 
Expectorate Sample coughed up from the lungs for microbiological investigation. 
Fibrosis Scar tissue in the body. 
Gene One gene consists of 1000 nucleotides = 333 amino acids. 
Islets of Part of pancreas where insulin is produced. 
Langerhans   
Mucociliary Movement of the small hair-like structures covering airway mucosa to wipe off bacteria and 
clearance particles. 
Neutrophils White blood cells, involved in the immune response. 
Osteopenia Reduced bone density; precursor of osteoporosis. 
PCR Polymerase chain reaction is used to produce numerous copies of DNA present in a sample. 
Recessive Non-dominant allele of a gene, meaning that if both parents are carriers, then the offspring 
will not necessarily be a carrier or affected by the trait. 
Vas deferens Sperm leading duct in the male anatomy. 
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2.1 Cystic fibrosis 
Cystic fibrosis (CF) is a genetically inherited autosomal recessive disease affecting the exocrine secretory 
glands of the patient. With about 100.000 patients Worldwide it is the most frequently inherited disease in 
the Western world, and also the one with the highest morbidity and mortality. CF is inherited from both 
parents who are carrying the cystic fibrosis transmembrane conductance regulator (CFTR) gene defect. It is 
estimated that about 1 out of 34 Caucasians are carriers, and in the “autosomal recessive” term lies that 
the chances of two carriers getting a CF child is 1:4, while 2:4 will be healthy carriers, and 1:4 will not carry 
any affected genes [Schwartz et al., 1990]. The term “cystic” refers to the cysts developing in the pancreas, 
and “fibrosis” to the fibroses seen in the pancreas and lungs of the patient. 
2.1a Genetics and the CFTR protein 
Since CF is a genetic disease, a short introduction to genetics can be useful. Genes are made of DNA strands 
carrying information about how genetic traits are passed on to the next generation. They are found inside 
the nucleus of living cells. DNA consists of pairs of chromosomes, which are built of (base) pairs of the 
nucleotides cytosine (C), guanine (G), adenine (A), and thymine (T). A nucleotide triplet is called a codon 
and codes for the expression of one amino acid, thus genes can code for proteins. Humans have 23 pairs of 
chromosomes, of which one is the sex chromosomes. The rest are called autosomes. On the long arm of 
chromosome #7, the CFTR gene is present. About 2/3 of all CF patients have the ΔF508 mutation, which is a 
deletion of 3 nucleotides coding for the amino acid phenylalanine in position 508 of the CFTR protein 
[Johansen et al., 1991]. The CFTR protein consists of 1480 amino acids. It is a chloride ion channel 
functioning across secretory cells, and when impaired, it will not fold properly, or may not even reach the 
cell wall, and a salt imbalance occurs due to altered Cl- and water exchange across the cell membrane. 
Secretory cells are found in glands throughout the human body, including sweat glands and mucus glands 
in the intestinal system, airways and vas deferens. 
2.1b Clinical manifestations of CF 
The list of CF manifestations is long, and in the following the most common complications are mentioned. 
The first symptom the parent of a CF child may discover is the salty tasting skin. In the lining of the sweat 
duct, salt is not being reabsorbed as it should, so an excess of Na+ and Cl- ions are led to the skin where 
water evaporates, leaving the skin salty [Quinton, 2007]. Due to blocked pancreatic and biliary ducts, the 
lack of digestive enzymes leads to malabsorption of proteins and lipids, and along with thick and sticky 
intestinal mucosa, this is accompanied by abdominal pain, intestinal blockage (meconium ileus) and fatty, 
frequent stools. Because vitamins A, D, E and K are fat soluble, these will also be malabsorbed, and the 
child fails to thrive [Folkesson et al., 2012]. Once the nutritional losses have been taken care of, the most 
common symptoms come from the airways, where coughing and frequent infections of both the sinuses 
and lungs are seen. The mucociliary clearance is hindered by thick and dehydrated mucus obstructing ciliary 
movement. Excessive absorption of sodium can occur, further enhancing water reabsorption by osmosis 
and complicating airway irritation. The build-up of nutritional enzymes inside the pancreas can cause auto-
degradation of the islets of Langerhans, leading to insulin deficiency and diabetes. Approximately 13% of 
Danish CF patients aged 11-16 years have diabetes [Knudsen et al., 2012]. 
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When the airways are not cleared properly, the immune system recruits an inflammatory response, 
attracting neutrophils (white blood cells) to the site. In order to break down intruding cells, the neutrophils 
release proteases, including elastase, which over time destructs the elastic tissue of the lungs. Already from 
very early in life the neutrophilic inflammation can be persistent, even when no pathogens are cultured 
[Sagel, 2003; Gifford & Chalmers, 2014; Chmiel et al., 2013; Elizur et al., 2008; Heijerman, 2005].  
2.1c Living with CF 
The diet of a CF patient must be high in salt and calories. For digestion, synthetic enzymes and vitamin 
supplements must be taken along with meals. Since CF children do not often die from malabsorption, the 
symptoms from the airways are the dominant signs. Sinus infections are hard to treat, because the bacteria 
grow in microcolonies, where they are difficult to target with antibiotics [Koch & Høiby, 1993]. Sinus 
surgery, removing some of the obstructive tissue and polyps followed by cleansing of the sinuses, has 
proven to be very efficient; also in reducing future lung colonisations [Johansen et al., 2012]. Postoperative 
it is important that the patient keeps the sinuses clear by daily rinsing with saline or perhaps antibiotics 
[Alanin et al., 2016]. To overcome the lack of mucociliary clearance, lung physiotherapy using a PEP mask 
can be life-extending. Some patients use a vest for chest wall oscillation therapy for ½ hour per day, to 
loosen excess mucus. If the inflammation and thereby the degradation of the lung tissue is too severe and 
the lung function is declining markedly, a lung transplant can be necessary. 
In order to postpone the onset of chronic lung infections, each country has a certain programme for 
obtaining sputum samples if the patient is unable to expectorate [Döring et al., 2000; Döring & Høiby, 
2004]. In Denmark the child attends the CF outpatient clinic once a month, where naso-laryngeal suction is 
performed. In very young patients, BAL can be necessary, rinsing the lung to culture what is found in the 
fluid. Sometimes it is also necessary to take a blood sample to monitor the levels of antibodies against 
Gram-negative bacteria infecting the lungs. Once a colonisation is discovered, antibiotic treatment can 
start, including inhalations and pills to swallow. If an infection is severe, intra-venous (IV) treatment under 
hospital admission can be necessary. Danish CF patients with a chronic lung infection spend 2 weeks every 
3 months receiving IV antibiotic treatment [Koch & Høiby, 2000]. Different criteria have been applied to 
define when an infection is regarded as chronic. According to the Copenhagen criteria, six consecutive, 
monthly sputum samples should be cultured positive, or the blood level of precipitating antibodies against 
P. aeruginosa should be ≥ 2 [Høiby et al., 1977]. The Leeds criteria define a chronic infection as when > 50% 
of ≥ 4 collected samples through the past 12 months have been cultured positive [Lee et al., 2003]. In 2008, 
approximately 80% of the Danish CF patients > 25 years suffered from chronic P. aeruginosa airway 
infection [Hansen et al., 2008]. 
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List of expressions – Pseudomonas aeruginosa 
 
Cyanogenesis Cyanide formation 
E. coli Escherichia coli, Gram-negative rod, found as part of the normal flora in the colon. 
Genome Complete set of DNA in an organism. 
lasR Gene coding for the LasR protein, regulating cyanogenesis in P. aeruginosa. 
LB Luria Broth growth medium 
Lysis Cell death 
Mucoid Biofilm-forming, e.g. a mucoid P. aeruginosa forms “slimy” and shining colonies due to 
mucoid exopolysaccharide (alginate). 
OD Optical density, absorbance as a measure of cell density. 
ON Overnight 
Pathogen Microorganism causing disease in e.g. plants or humans. 
QS Quorum sensing; bacteria working as a community, e.g. causing diseases. 
SOP Standard operational procedure 
VOC Volatile compounds 
WT Wild type organism, as it exists in nature. 
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2.2 Pseudomonas aeruginosa 
2.2a P. aeruginosa at a glance 
P. aeruginosa is a ubiquitous environmental bacterium found in soil and water reservoirs and on aquatic 
surfaces. It is a Gram-negative, rod-shaped bacterium; which, unlike human cells, does not have a defined 
nucleus or other membrane-bound organelles. Its DNA can be located all over the cytoplasm, which defines 
bacteria to the class of prokaryotes. It has a highly advanced chemosensing system and can move towards 
attractants by flagellar movement [Stover et al., 2000]. Gram-negative bacteria have an outer bacterial 
membrane, offering better protection against antibiotics than Gram-positives, which only have a thick layer 
of peptidoglycan in the cell wall. The peptidoglycan layer stains Gram-positive bacteria purple, using Gram-
staining, whereas Gram-negative bacteria fail to stay purple after washing, but instead turn red or pink 
when a counterstain is added.  
 
Figure 2.1: P. aeruginosa; grown in the lab (Left); as often presented (Middle) Both: [Pseudomonas.com]; 
Gram-staining, seen in microscope (Right) [https://commons.wikimedia.org/w/index.php?curid=49535]. 
This evolutionary highly adapted pathogen has a large genome size of 6.3 million base pairs (Mbp), as 
compared to e.g. E. coli with 4.6 Mbp. In P. aeruginosa, an estimated 8.4% of the genome is involved in 
regulation, which allows the bacterium to respond to environmental changes and to control virulence, 
causing damage to the host. In addition to toxins, lipases and proteases are secreted, which can possibly 
modify or degrade antibiotics administered to the infected host [Stover et al., 2000]. Biofilm production is 
another challenge, because this slime consisting of DNA, proteins and polysaccharides, enables the bacteria 
to adhere to surfaces and to stick to each other, hiding from antibiotics [Rasamiravaka et al., 2015]. All 
these activities are energy consuming, and P. aeruginosa has been found to possess about 200 cytoplasmic 
membrane transport systems for the uptake of nutrients and other molecules [Stover et al., 2000]. 
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2.2b The lasR gene and cyanide production 
In addition to the inflammatory response of the body, P. aeruginosa also produces toxic compounds, which 
can damage the host. The best known toxin excreted from P. aeruginosa is Exotoxin A, which has a mode of 
action similar to diphtheria toxin, by binding irreversibly to the cell, which then loses the ability to 
synthesise protein [Brock et al., 1994]. P. aeruginosa is the only bacterium of relevance to CF airway 
infections that produces the toxic gas hydrogen cyanide (HCN). It has not been reported to occur in 
concentrations which themselves can cause damage to humans, but it can be advantageous in the fight 
against other microorganisms in the lungs. It is synthesised as a secondary metabolite from glycine, 
probably to regulate the levels of this enzyme, which could otherwise cause lysis of the bacterial cell 
[Castric, 1975]. It is regulated by the Quorum-Sensing (QS) regulators LasR and RhlR, activating the hcnA 
promoter to start transcription of HCN synthase. The lasR gene codes for the expression of the 
transcriptional activator protein LasR, which is the only regulator that is absolutely required for 
cyanogenesis [Pessi & Haas, 2000]. Several pathways have been suggested for the formation of HCN from 
glycine, of which Wissing proposed the glycine dehydrogenase pathway under formation of CO2: 
 
Figure 2.2: Action of HCN synthase or glycine dehydrogenase in the formation of HCN from glycine 
[Wissing, 1974]. 
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List of expressions – Raman spectroscopy 
 
CCD A charge-coupled device is a device converting incoming photons into electron charges and 
subsequently digital values. 
σ Spectroscopic cross section refers to an effective area that quantifies the probability of a 
spectroscopic event to occur, when an incident beam hits the target particles.  It is defined 
as the attenuation coefficient (cm-1) divided by the density of the target particles (cm-3). 
Cumulated double bonds are when one atom has two double bonds, e.g. like =C=. 
Cumulated double bonds and triple bonds both occur in the Raman spectrum in the 2000 – 
2200 cm-1 range [Smith & Dent, 2005]. 
ε A material’s dielectric constant, also known as relative permittivity, is the ratio of the 
permittivity of the material to the permittivity of free space. It is an expression for how 
effective it is for a material to concentrate electric flux.  At optical frequencies it is a complex 
number given by ε(ν) = ε’ + iε’’, where ν is the frequency. 
µ Dipole moment measures the separation of two opposite charges. Its magnitude equals to 
the charge multiplied by the distance between the charges.  
A The electromagnetic field enhancement is defined as |E|/|E0|, where E0 is the incident 
electrical field. According to the Mie theory, in vacuum, for a spherical nanoparticle, the 
electromagnetic field enhancement reaches maximum when ε’ = -2ε0. Metals like Ag and Au 
can significantly enhance the electromagnetic field due to their negative ε’ and low 
damping, and are thus chosen extensively for SERS applications. 
A Notch filter filters out light of same wavelength as the incoming light to avoid Rayleigh line 
from dominating the spectrum. 
α Polarizability is the ability to form instantaneous dipoles. It determines the dynamical 
response of a bound system to external fields. 
SERS Surface-enhanced Raman spectroscopy uses metalized, nanostructured surfaces to 
significantly enhance the Raman scattering signal of the analytes. 
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2.3 Raman spectroscopy 
2.3a Light and its interaction with matter 
Light is described either as waves of electromagnetic radiation or quantum mechanically as photons. The 
energy E of a photon is proportional to its frequency ν: 
  E = h ∗ ν,  (Equation I) 
where h is the Planck constant. h = 6.626 ∗ 10-34 Js. 
When light encounters a sample, it is either; absorbed, transmitted or scattered. Absorption spectroscopy 
like infrared (IR) spectroscopy probes directly the energy gaps between the molecule’s ground and excited 
vibrational states. Raman spectroscopy on the other hand deals with the in-elastically scattered light and 
probes indirectly the vibrational modes of the molecule. Most of the light is scattered elastically and has 
the same frequency as the incoming light. This process is called Rayleigh scattering. In Stokes Raman 
scattering however, the energy of the scattered light is lower than that of the incoming light, whereas in 
Anti-Stokes Raman scattering it is higher. Since Anti-Stokes Raman scattering requires the molecule to be in 
an already excited vibrational energy state, it is less frequent than the Stokes Raman scattering, which is 
normally presented in a Raman spectrum. Raman scattering constitutes about 10-8 of the scattered light, 
leading to molecular cross-sections in the order of 10-31-10-26 cm2 as compared to fluorescence 
spectroscopy with cross-sections of about 10-16 cm2 per molecule [Smith & Dent, 2005; Kneipp, 2007]. The 
Jablonski diagram in Fig 2.3 illustrates the changes in molecular energies for IR absorption; Rayleigh 
scattering; Stokes and Anti-Stokes Raman scattering. 
 
Figure 2.3: Jablonski diagram showing the energy states involved in infrared absorption, Rayleigh- and 
Raman scattering. In IR spectroscopy energy is absorbed, matching the induced vibration. In scattering 
processes the vibration is shifted to a “virtual” energy state after which the photons are re-radiated, 
either at the same frequency (Rayleigh) or at lower (Stokes) or higher (Anti-Stokes) energy levels 
compared to the incoming field [Figure copied from Wikipedia]. 
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2.3b Polarizability and the Raman effect 
The reason why some of the scattered light changes energy is that light can interact with a molecule by 
changing its vibrational state, whereby energy is consumed (Stokes) or taken up (Anti-Stokes Raman 
scattering). In a Raman scattering process, the incident light displaces the electron cloud surrounding the 
molecule and induces a dipole moment. Polarizability α determines the extent to which the electron cloud 
surrounding a molecule can be distorted by the incoming field. It is defined as the ratio between the 
induced dipole moment p and the electric field E producing it: 
p = α ∗ E  (Equation II) 
α is often expressed in cgs units as polarizability volume in cm3 or Å3 = 10-24 cm3. Atoms increase in 
polarizability from right to left in the periodic table due to less filled outer electron shells. In order for 
Raman scattering to occur, the incoming light must change the polarizability of the molecule.  Highly polar 
molecules like water cannot have their polarizability changed substantially, which is why they are not very 
Raman active. In a Raman scattering process, the incoming light interacts with the molecule through its 
polarizability, and introduces a dipole moment which is modulated by the molecular vibration. 
Consequently, the induced dipole oscillates not only at the frequency of the excitation light, but also at two 
side bands, emitting Stokes and anti-Stokes lights. The Raman selection rule is that α must change with 
molecular vibration, and the change is described by the polarizability derivative: 
  δα/δQ  ≠ 0,  (Equation III) 
where Q is the vibrational coordinate. When more atoms are present in the molecule, more vibrational 
modes are allowed. With N atoms in a molecule the possible number of vibrations is 3N-6, except from 
linear molecules (like diatomic) where it is 3N-5. Therefore a water molecule consisting of 3 atoms has 3 
vibrational modes. Additionally, if the vibrational mode has a center of symmetry, it cannot be both IR- and 
Raman active. Therefore IR spectroscopy and Raman spectroscopy are considered complementary 
spectroscopic techniques. [Keresztury, 2002; Kneipp, 2013; Smith & Dent, 2005; Øgendal, 2011].  
2.3c IR absorption 
Unlike Raman-active vibrations, IR-active vibrations require that an electric dipole has an inherent 
asymmetric charge distribution. The dipole moment µ is defined as: 
  µ = d ∗ q,  (Equation IV) 
where d is the distance between the positive and negative charge q. The IR selection rule is: 
  δµ/δQ  ≠ 0  (Equation V) 
So, for a vibration to be IR-active , the dipole moment must change during the vibration. 
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2.3d The Raman spectrum 
A vibrational spectrum gives the signal intensity versus wave number ṽ, which is usually expressed in the 
unit of cm-1. The intensity of the Raman signal is the product of the number of molecules (N) in the probed 
volume, the laser intensity (IL) and the Raman cross section (σ
R): 
PRS  N ∗ IL ∗ σ
R
 (Equation VI) 
A Raman spectrum gives Raman counts in time per unit of laser light, i.e. counts per second per mW as a 
function of the frequency shift away from the Rayleigh line, in wave numbers (cm-1). Anti-Stokes Raman 
scattering would result in positive frequency shifts; but because the Anti-Stokes part of the spectrum is 
rarely used, usually only the Stokes Raman shifts are displayed in a Raman spectrum. For example, fig 2.4 
shows a Raman spectrum of ambient air. The spectrum reveals the stretching modes of O2 and N2, 
respectively near 1600 cm-1 and at 2335 cm-1. The stretching mode of N2 is located at a much higher 
frequency than that of O2. This is because N2 has a lighter molar weight (28 g/mol) and a stronger bond 
(945 kJ/mol) in comparison to O2 (32 g/mol and 497 kJ/mol).  
 
 
Figure 2.4: Raman spectrum of ambient air. The wave band of O2 is found just below 1600 cm
-1, 
whereas the lighter and stronger bonded N2 is located at a much higher frequency. 
2.3e Surface-enhanced Raman spectroscopy 
A major disadvantage of Raman spectroscopy is its low sensitivity due to the extremely small intrinsic 
Raman cross sections, which are 12-14 orders of magnitude smaller than those of fluorescence. Surface-
enhanced Raman spectroscopy (SERS), using nano-sized metal particles is thus developed to enhance the 
Raman signal via surface plasmons (SPs). SPs are collective oscillations and redistributions of charges near 
the surfaces of metallic nanostructures, as is illustrated in fig 2.5. SPs generate electromagnetic hot spots 
which contain highly localized and enhanced electrical fields. In a hot spot, both the incident field and the 
Raman scattering field from molecules are amplified. The intensity of the SERS signal (PSERS) is expressed by 
the following formula: 
PSERS = N * IL * ∣A(νL)
2∣∣A(νS)
2∣ * σRads (Equation VII) 
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N is the number of probed molecules. IL is the intensity of the probing laser. A(νL) and A(νS) are the 
electromagnetic field enhancement factors for the laser and the scattered field. Since νL ≈ νS, it can be 
deduced that the intensity of the SERS signal is proportional to the electrical field enhancement to the 
power of four. σRads is the effective Raman cross-section for the adsorbed molecule, and is known as the 
chemical SERS enhancement factor, which is typically 10 – 100 [Kneipp, 2007]. It is caused by electronic 
interactions between the molecule and metal. The chemical enhancement is regarded as a “first-layer 
effect”. To trigger it, the distance between the molecule and the metal must be <10 nm. 
 
 
  
Figure 2.5: Illustration of surface plasmons (SPs). The negatively charged electric field passes metal 
nanospheres with unattached conduction electrons on the surface, oscillating opposite of the incoming 
electronic wave. [https://gregemmerich.wordpress.com] 
Silver (Ag) and gold (Au) can create the most powerful surface plasmons and thus hot spots with the 
strongest electrical field enhancements, due to their negative dielectric constants and low loss. 
Electromagnetic SERS enhancement factors of higher than 108 are achievable. Therefore, surface-enhanced 
Raman spectroscopy could be ideally denoted “plasmon-supported Raman scattering” [Kneipp, 2007 and 
2013]. The SERS substrate used in this project consists of Si nanopillars topped by Au caps with a total 
height of ~400 nm. When the nanopillars lean against each other, nanogaps are formed between the Au 
caps for hot spot formation and enhancement of the Raman signal [Schmidt et al., 2012].  
2.3f Raman instrumentation 
To perform Raman or SERS experiments, a monochromatic light source is necessary, which is often a 532 
nm (green) or a 785 nm (near-infrared) laser. A typical configuration of a Raman instrument is shown in Fig 
2.6.  
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 2.3: Raman spectroscopy 
  
Figure 2.6: Configuration of a Raman instrument. 
The excitation light passes through an aperture and is then focused on the sample by a lens. Afterwards, 
the scattered light is collected through the same lens, after which it, via mirrors, goes through a notch filter 
so that its Rayleigh component is eliminated. Subsequently, the light is focused onto a monochromator, 
where it is split up into its constituent wavelengths. Finally the light is collected by a CCD detector. For 
instruments with lasers of wavelengths above 1050 nm, another detector, such as InGaAs, needs to be 
used. In addition, when a microscope is used, it is necessary to limit the power density of the laser, because 
illuminating a very small surface area of a sample with a high laser power increases the risk of thermal 
degradation (burning). [Smith & Dent, 2005]. 
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List of expressions – SERS substrate fabrication 
 
e-beam An electron beam melts the target metal, causing it to evaporate, to deposit a thin film of 
evaporation  the metal onto the substrate. 
RIE Reactive Ion Etching; a (dry) plasma etch, forming trenches into silicon, used for micro- and 
nanotechnology. Longer etching time results in deeper trenches in the silicon [Jansen et al., 
1995]. 
XPS X-ray photoelectron spectroscopy. Machine for elemental analysis of a surface, using X-rays 
to free loosely bound electrons of a sample. The energy necessary to free the electrons is 
specific to every element. 
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2.4 SERS substrate fabrication 
The SERS substrate used to enhance the Raman signal consists of silicon (Si) nanopillars (“nanograss”) with 
Au caps and bases. When the pillars lean against each other, electromagnetic SERS hot spots are formed in 
the gap junctions between the Au caps. For illustrations, please refer to fig 2.7 and [Schmidt et al., 2012]. 
 
Figure 2.7: Preparation of the SERS substrate. 
2.4a Nanopillar substrate 
The nanopillars are made by reactive ion (plasma) etching (RIE) on a Si wafer. Depending on the etching 
time, Si nanopillars with different heights are formed. The employed RIE in this project consists of 
alternating SF6 and O2 plasma bombardment onto the Si wafer, respectively etching away Si and protecting 
the emerging nanopillars during the process. The RIE was done at -10°C. For the optimised substrate, three 
minutes of RIE was applied at a pressure of 36 mTorr, followed by 1 min O2 clean. The O2 clean step was 
included to get rid of SiFx compounds which could be present on the substrate after etching, and it was 
important not to make the step too long, because then the metal would stick all the way down to the sides 
of the nanopillars, making them inflexible and difficult to lean [Kaiyu Wu]. Additionally, the SF6 plasma can 
give rise to sulphurous substances, which can compete against cyanide for space on the Au surface [Lewis & 
Shaw, 1986]. 
2.4b Metal deposition 
Using e-beam evaporation under vacuum, 225 nm thick Au was deposited onto the nanopillars at a rate of 
9 Å/s. Immediately after metal deposition the wafer was hydrophilic, making the substrate easy to wet by a 
droplet added for leaning. If too long time passed, it would take longer time to dry because the droplet 
would not spread and become thin. 
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3.1 Project overview 
The project consisted of 3 steps, of which the first was to establish a chemical method to detect cyanide on 
the substrate in relevant concentrations, preferably in gas. Step I was split up into two parts; one for HCN 
detection in the gas phase, and one for detection of potassium cyanide (KCN) in serial dilutions to reach 
sufficiently low CN concentrations and verify the limit of detection. Once this was done, the second step 
was to measure HCN(g) from emissions of P. aeruginosa; first from the established reference strain, the 
wild type PAO1. Secondly, it was relevant to study clinical P. aeruginosa strains, isolated from CF children 
for the first time in each patient (the wild type-like), and then compare to SERS measurements on later 
strains, isolated from the same patients after their infection became chronic and the P. aeruginosa had 
mutated in the lasR gene, which is essential to HCN production. Step III was a clinical trial, where children 
with CF would blow into a bag containing the SERS substrate, which was then measured, to see if HCN was 
detected; and data was correlated to sputum culturing. A schematic of the project flow is given in Fig 3.1. 
 
Figure 3.1: Overview of the project. 
 
The outcome of each step was reported to a scientific journal, and the papers are found at the end of the 
thesis. Throughout the project, the SERS substrate was optimized for breath detection of HCN, which is 
presented in the next section. 
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3.2 Optimisation of the SERS substrate 
3.2a Metal layer and cleaning procedure 
When the NAPLAS project started, the recipe for the SERS substrate was 4 min RIE (no O2 clean step), and 
the metal thickness was 200 nm (always Ag), deposited at a rate of 10 Å/s. Then a droplet of water was 
added for leaning, which could be distributed unevenly across the substrate. With experience it turned out 
that immersion was a better way to lean the pillars. Through the first 18 months, several experiments were 
made to compare Ag and Au substrates, knowing that HCN was used in Au mining and that the Ag 
substrates, although high enhancements, suffered from a poor shelf life due to oxidation, which could be a 
disadvantage for use including people. Cytotoxicity was not an issue, because it was never intended for 
physical contact. Different recipes were tried, varying etching time and cutting the wafers in halves for 
deposition of Ag and Au. 
Because there was a background peak on the substrate close to the cyanide peak, addition of different O2 
and Ar plasma cleaning steps after the RIE were tried. Annealing the substrates at 400°C was also applied to 
try to minimise the background peak. Later, annealing was tried at 800°C in the cleanroom after RIE, and 
nothing helped. The only thing that improved the background a bit was a 1 min O2 cleaning step 
immediately after the RIE. Out of the cleanroom the substrates were cleaned in ethanol, which also helped 
a bit. The cleaning procedure that helped most was immersion into analytical grade ethanol for 3 min 
followed by immersion into analytical grade water for 3 min (Fig 3.2), before the substrates were left to dry 
on a cleanroom tissue. This also induced pre-leaning which was good for gas measurements.  
 
Figure 3.2: Comparison of no cleaning (Red) and 3 min ethanol followed by 3 min H2O immersion (Blue) 
on the background peak at 2127 cm-1, indicated by an arrow. After cleaning the peak is still present, but it 
is less intense. 
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For serial dilution experiments in aqueous KCN, the substrate was immersed into the particular dilution 
directly after the cleaning and rinsing procedure, and the exposed substrates were placed separated from 
each other on cleanroom tissues to dry and lean, to make sure they would not contaminate each other. For 
comparison of the cyanide peak intensity in KCN serial dilution experiments on the Ag and Au substrates, 
see Fig 3.3. 
 
Figure 3.3: Serial dilution of KCN, comparing the 200 nm Ag and Au substrates. Note the logarithmic 
scales, on the X-axes respectively from 10-7-10-3 and 10-8-10-4. It is seen that the Au substrate leads to C≡N 
peak intensities about twice as high as the Ag substrate. 
Because the Au substrate seemed superior for the application, and due to the other advantages 
mentioned, it was decided to continue working only with the Au substrate. In order to see if higher 
enhancements could be obtained, various Au layer thicknesses were tried. The best seemed to be 225 nm: 
 
Figure 3.4: Comparison of SERS on 200 nm (left) and 225 nm (right) Au; 3 min. etch, 1 min. O2 clean, 
before (Blue) and after exposure to 5 ppm HCN(g) (Red). The 225 nm substrate gives about double C≡N 
peak intensity of the 200 nm. 
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Double cyanide peak intensity of the 225 nm substrate, as compared to the 200 nm substrate was not 
always the case; but in general it performed better, which was why it was decided to be used instead. The 
substrates were made with 3 min etch, because this also gave better enhancement of the CN peak than the 
original 4 min etch. Reasons for this could be, that the longer pillars (due to longer etching time) collapsed 
easier, or that the shorter pillars (with shorter etching time) decreased the distance between Au caps and 
bases, which could be more optimal for SERS enhancement [Kaiyu Wu].  
3.2b Attempts to identify the background peak 
Carbon monoxide (CO) is also present in human breath and has a triple bond between C and O, and the 
stretching band could be very close to C≡N. Two times, bags of CO(g) were obtained from DTU Chemistry, 
and the gas was attempted for adsorption on the substrate, but without success. The background peak was 
unchanged, and the spectrum looked like the bare, cleaned substrate. According to Rae & Khan, in order to 
get CO to adsorb onto a AgPd SERS substrate it is necessary to first heat the substrate to at least 100°C and 
then cool it to 20°C before CO can be seen in the spectrum, so the background peak was probably not 
caused by CO [Rae & Khan, 2010].  
The Si wafers are forming a thin glass layer (SiO2) upon contact with atmospheric air [Jörg Hübner]. SiO2 has 
a set of cumulated double bonds (O=Si=O) and could give a peak in the same region as C≡N. But the glass 
substrate being developed in the NAPLAS project does not have a peak there, so glass was probably not the 
cause. Due to the nitrile (-C≡N) bond it was checked whether the background peak could be caused by the 
nitrile gloves normally worn in the chemistry lab, so latex gloves (which were used in the cleanroom) were 
used instead; and this did not change the background peak.  
The staff of DTU Danchip was helpful to make XPS measurements, identifying the surface elements at 
various stages of the procedure. First the bare Si wafer; then after etching (before and after N2 blowing in 
the cleanroom); then after Au deposition (with and without the N2 blowing). They were measured before 
and after cleaning and after immersion into 10-3M KCN (in NaOH), respectively after exposure to 5 ppm 
HCN(g) in N2. The XPS was checking for: Au, C, F, K, N, Na, O, S and Si. There was C in all samples, and 
additionally the following elements were found (Table 3.1). 
Table 3.1: List of detected elements (besides C), using XPS during substrate fabrication and preparation. 
 Si wafer Pillars – N2 Pillars + N2 Au – N2 Au + N2 
Uncleaned 
 
Si, O ↑O,↓Si, F, S ↑O,↓Si, F, S Au, O 
Int. 1.0x106 
Au, O 
Int. 9.0x105 
Cleaned 
 
 ↑O,↓Si, ↓F, S ↑O,↓Si, ↓F, S Au, O, ↑int. 
Int. 1.3x106 
Au, O, ↑int. 
Int. 1.3x106 
Cleaned 
+ 10-3M KCN 
   Au, O, Na, K, N 
Int. 1.1x106 
Au, O, Na, K, N 
Int. 1.1x106 
Cleaned 
+ 5ppm HCN(g) 
   Au, O, (N) 
Int. 1.2x106 
Au, O, (N) 
Int. 1.2x106 
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Carbon was present in all samples, and it is seen that after the Au deposition there was no trace of S or F on 
the substrate surface. In the cleanroom, substrates are often given a blow of N2 before being further 
processed. Therefore, samples were also prepared for investigation with and without this N2 exposure, and 
it is seen that this did not have any influence on the results. The cleaning procedure increased the intensity 
of what was seen on the surface, and N interacted better with the sample in liquid than in the gas phase, 
where pillars had been preleaned. There was more O in the immersed samples than in the ones exposed to 
gas, which was as expected because of O in the water and NaOH of KCN samples. 
According to Jörg Hübner, low amounts of Si may diffuse into the Au, forming some sort of complex, but 
this was not detected from the XPS measurements. In summary, the background peak did not seem to be 
caused by CO, glass or nitrile. With Au on the pillar caps, no Si, S or F was detected on the surface, and N2 
blowing did not have any influence on the resulting elements on the substrate surface. The background 
peak remained unidentified, and more experiments were made to overcome the issue, e.g. deploying the 
fact that the C≡N peak, as a consequence of interaction with the Au surface, would shift to higher 
wavenumbers, away from the background peak. 
3.2c Shelf life and ways to overcome the background issue 
Shelf life was tested during the microbiological experiments. When there are sometimes problems with the 
machine depositing Au in the cleanroom, it is an advantage to know how old substrates can be used. An 
example is given in Fig 3.5, where new substrates with 225 nm Au deposited at 10 Å/s the day before 
measurements were compared to 17 days old substrates, where Au due to issues with the machine had 
been deposited to a thickness of about 205 nm at only 8-9 Å/s. 
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Figure 3.5: Comparison of Au SERS spectra of VOCs from P. aeruginosa 390 + 389 ON cultures on 1-day 
old substrates (new) and 17-days old substrates (old). Although slightly lower overall intensities in the 
old substrates, they seemed to be performing equally well. Old substrates had a lower deposition rate (8-
9 Å/s) and about 205 nm Au, whereas the new ones had a deposition rate of 10 Å/s and 225 nm Au. It 
seems like the parameters of the “old” substrate promoted the cyanide peak’s shift more than the 
parameters of the “new” substrate. 
During metal deposition, it evaporates as atoms and can perhaps have time to diffuse together on the 
surface if the deposition is slow. If it is fast, the layer might become smoother [Silvan Schmid]. Altogether 
this should favour surface enhancement at lower deposition rates and perhaps ease the dissolution of Au, 
when the surface is rough. From the figure it is clear that, although slightly lower intensity, the parameters 
of the old substrate seemed to favour the C≡N peak shift (as explained in Paper I), which could be a huge 
advantage in moving the cyanide peak away from the background peak. The outcome was confirmed in 
seven other P. aeruginosa strains, deliberately comparing the deposition parameters of identical wafers 
broken into halves; and it was decided to change the deposition rate to 9 Å/S. 
It was also clear that 17 days were not too long storage for the substrates to work in this application. 
Comparing two months old substrates to new ones showed that the 2 months old substrates were too old. 
Later, in the clinical trial, there was not sufficient HCN to make the peak shift, and the background peak 
again became an issue. Optimisation of the Au substrate took place throughout the entire project, but 
unfortunately, the background issue was never solved. 
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3.3 Chemical experiments (Step I) 
3.3a HCN gas experiments 
Even though 5 ppm HCN(g) is not very toxic, there was a long  application process for getting permission to 
do the gas experiments in the lab. Rolf W. Berg from DTU Chemistry provided the flow cell seen in Fig 3.6, 
Kristoffer Almdal came up with the design, Søren M. B. Petersen realised the setup, and I applied for 
permission to use it. See Supplementary S1 and Paper I. Finally, permission was given for using the gas tank, 
mounted on a trolley, through a hole in the top table, in a safe lab with restricted access.  
 
Figure 3.6: Flow cell for exposure of the SERS substrate to 5 ppm HCN gas in N2. The O ring was turned, 
the loose glass slide dismantled, after which the chip was placed on the “bridge” in the middle, from 
where it could easily fall off when the gas was on.  
 
The SERS substrate was optimised mostly during the first step of the project, and sometimes the Ag 
substrate was tested again to compare it to Au. In Fig 3.7, the optimised RIE recipe was used, and Ag, 
respectively Au was deposited at 5, 10 and 15 Å/s. It is seen that, although higher background triple bond 
peak, the Au substrate was much better suited for the application, and that 10 Å/s was the best deposition 
rate. For verification of cyanide on the substrate, two additional peaks were seen in the low frequency end, 
respectively assigned to Au-C stretching and Au-CN bending [Murray & Bodoff, 1986; Beltramo et al., 2003 
Senapati et al., 2011]. At this time the gas exposure time had not been optimised, and 10 min flow through 
the cell was applied. Later it turned out that 30 s was sufficient, and through the rest of the project, 30 s 
gas samples were used as reference.  
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Figure 3.7: Comparison of Ag and Au substrates, 225 nm nanopillars, 3 min. etch, 1 min. O2 clean. 
Deposition rate 5 Å/s (Blue), 10 Å/s (Green) and 15 Å/s (Red). Ethanol and water cleaned samples, 
exposed to 5 ppm HCN(g) for 10 min. Au substrates deposited at 10 Å/s are best suited for the 
application. 
 
3.3b Serial dilution of KCN 
HCN detection had been proven in the gas phase, although the concentration was about 1000 times too 
high compared to the breath of a child with a P. aeruginosa airway infection [Enderby et al., 2009]. 
Therefore, serial dilutions of potassium cyanide (KCN) were made to see how low a limit of detection could 
be obtained. Since KCN is toxic, also through the skin or the eye, it was important to keep the lab clear to 
be able to focus on the task, and to have a structured plan to work by. Copies of the chemical risk 
assessment and a detailed work procedure are found in Supplementary S5. The serial dilution experiments 
were repeated between 8 and 10 times, first with droplets of the solution added to the substrate; and later 
with 3 min immersion into the alkaline KCN solution. A detection limit between 10-7 and 10-6 M was found, 
(Paper I). Because 10-4 M KCN resulted in SERS intensities of same order of magnitude as 5 ppm HCN(g); 
with 10-7 M detection, the desired ppb level was expected to be obtained, and it was time to move on to in 
vitro experiments, detecting HCN from emissions of P. aeruginosa cultures. 
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3.4 Microbiological experiments (Step II) 
3.4a The setup 
Optimisation of the procedure for microbiological experiments was done on the reference strain PAO1 in 
the Food Microbiology laboratory of University of Copenhagen (KU), Department of Food Science. The 
Raman measurements were also carried out at KU, in the Quality & Technology laboratory, Department of 
Food Science, where I went for my external stay in the period February-July 2015. Before going to KU, 
preliminary experiments with PAO1 were made at DTU Systems Biology, so that it would be possible to 
transfer the optimised setup to KU. There were, however, some differences between the procedures in the 
two labs: 
1. At KU all broths, etc. should be prepared by oneself. From DTU, e.g. LB broth was taken from the shelf, 
and it had been prepared by the same lab technician who did this all the time. It also turned out that 
the recipes used were different in that at KU it contained 10 g/L NaCl, whereas at DTU it only contained 
4 g/L salt, because it had been optimised for P. aeruginosa growth. 
2. At KU they were not used to pathogens like P. aeruginosa, so in addition to the safety introduction I 
had to write a workplace risk assessment (APV) and 9 SOPs (see Supplementary S11 and S16), carefully 
planning how everything should be handled, before the lab work could begin. Another issue was the 
way ON cultures could be prepared, because I decided to use closed bottles shaking in the incubator to 
be sure not to spill bacteria and cause unnecessary worries to the group. At DTU, work with P. 
aeruginosa took place in every lab, and people were used to handle this as carefully as they should. 
Therefore, at DTU the ON cultures were incubated in flasks with two-holed rubber plugs shaking in an 
open incubator on the lab bench, which turned out to be much more convenient. 
To get bacterial volatiles onto a substrate with the pillars pointing up, it was decided to use a pump and a 
vacuum chamber, as described in Paper II. Inside the vacuum chamber a reusable Teflon bag was placed, 
which was specially designed with one end open for mounting the SERS substrate. The bag was closed by a 
clamp and could be sterilized in an oven at 120°C for 30 min. Because ON cultures at KU were prepared in a 
closed flask (Fig 3.9), ON exposure had to be done before preparation of the time series, in order not to 
lose the vapours inside the flask when it was opened. Similarly, for each exposure of SERS substrates and 
Tenax tubes (see Discussion), one flask was prepared, because the bacterial emissions can only be used 
once. After exposing the SERS substrate to bacterial volatiles, OD was measured on each culture. 
Parameter settings of the Raman were optimised for the 2135 cm-1 peak of a HCN(g) sample. Optimal 
spectra were obtained at 200 mW, 32 scans and a resolution of 8 cm-1, and the C≡N peak position shifted to 
2185 cm-1 during the measurements, as explained in Paper I. The 1064 nm laser gave less fluorescence at 
low frequencies compared to the 780 nm laser system at DTU Nanotech, which was an advantage because 
of some interesting peaks in this region (Paper I). Throughout the period of microbiological experiments, 
several attempts were made to establish a reference method for the quantification of HCN in bacterial 
gases, but they were never successful. 
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3.4b P. aeruginosa PAO1 
The ON culture had to shake vigorously for growth to occur, because the microaerophilic bacteria need 
some O2 to survive. 250 mL Bluecap bottles were used for the incubation of 10 mL ON culture, and the 
large volume above the culture turned out to be sufficient, although no extra air was let in. After 
confirmation of ON culture growth, a water bath and glassware were prepared. One mL of ON culture was 
added to 9 mL LB in a 100 mL Erlenmeyer flask which was plugged with a 2-holed rubber plug (Fig 3.8). 
 
Figure 3.8: Fresh preparation of PAO1 time series. Time = 0, so the culture has not turned green yet. 
From these flasks it was easy to expose the SERS substrates and compare the results across growth times 
and batches. This was not the case for the ON cultures. See Fig 3.9. 
 
Figure 3.9: SERS exposure to ON culture emissions at KU. 
As can be seen, a lid was turned so the tube from the vacuum chamber could come into the bottle. 
Problems were that bacterial emissions could be lost and there was no way to standardise the depth of the 
tube nozzle inside the bottle. Tape was put on the sides of the tube to minimise the opening, but it was not 
optimal, and the results were unreliable. Therefore, it was much better to use the Erlenmeyer flasks and 
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rubber plugs for valid substrate exposure, which was done in the PAO1 time series, except for ON 
measurements (Paper II). 
As can be seen in Paper II, large amounts of HCN were produced from 4 hours’ growth. Fig 3.10 shows 
measurements performed the day after exposure, illustrating how the C≡N peak shifts over time to the 
more stable [Au(CN)2]
- complex at 2187 cm-1. It also shows a trend of an extra peak occurring at 238 cm-1, 
which appeared after 6 and 8 hours’ growth. The very large shift was only seen in quite “old” substrates, 
whose Au deposition had taken place about two weeks back. 
 
Figure 3.10: SERS spectra taken one day after exposure to PAO1 volatiles after 2; 4; 6; and 8 hours’ 
growth. The 2h sample is identical to the LB and lab ref. samples. 4h shows the largest shift, followed by 
6h and 8h samples, which had an additional peak at 238 cm-1. For OD growth curves and “real time” HCN 
emission, the reader is referred to Paper II. 
3.4c Clinical P. aeruginosa strains 
Helle Krogh Johansen has made a collection of 500 P. aeruginosa strains isolated over time from 34 CF 
children followed at Rigshospitalet. From this collection, 13 strains of relevance to the project were 
selected. They were pairs of first isolate (“wild type (WT)-like”) versus a later isolate from the same child 
after the infection had become chronic and adaptation with mutation in the lasR gene had taken place, 
among others coding for HCN production. From one child there was also an additional nonsense mutation. 
Isolates from one child failed to grow twice, so from the children collection 11 strains were examined. For 
comparison, the engineered lasR mutant of PAO1 (SD2) was used as well as the “classic” clinical CF strains 
DK02 from 1973 (WT-like) and the DK02 lasR mutant from 1979. An overview is summarised in Table 3.2. 
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Table 3.2: Summary of clinical and reference P. aeruginosa strains used in the investigation. 
Reference strains    
  WT lasR mutant 
   PAO1 SD2  
Clinical strains    
CF no.  Clone type WT isolate no. lasR mutant isolate  no. 
114/30 02 IMG 140 (1973) IMG 139 (1979)  
     
441 03 318.1 321 
 544 06 13.1 10 
 421 06 294 306 
 499 06 390 389 
 414 12 95 105 
 382 32 244 245 nonsense 246 missense 
     
Red marking means Produced HCN; Green means No HCN detected; Grey means No growth. 
One mL freeze cultures prepared in glycerol were poured directly into 9 mL LB for clinical ON culturing. 
SERS substrate exposure of clinical strains were repeated in two labs; first in the Food Microbiology 
laboratory of KU; and then again in the Infection Microbiology Group (IMG) of DTU Systems Biology. All 
Raman measurements were made in the Quality & Technology laboratory of KU. Mutated isolates were not 
usually seen in the Food Microbiology laboratory, so ON measurements were made from the large Bluecap 
bottles. They were growing more slowly than PAO1, and since the experience from the PAO1 experiments 
was that HCN could still be detected in ON cultures (although in lower concentrations), only ON 
measurements were made. With time more experience was gained, and some of the results were valid, but 
all the experiments were repeated at DTU, preparing ON cultures directly in the Erlenmeyer flasks with 
rubber plugs. Results shown in Figs 3.11 through 3.13 are from DTU.  
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3.4: Microbiological experiments (Step II) 
 
 
Figure 3.11: SERS on overnight cultures of reference strains. The wild type (-like) strains emitted high 
amounts of HCN, as can also be seen in the partly shifted C≡N stretching peak. No HCN was detected 
from the lasR mutated strains, where only the background peak was present. SERS on overnight LB 
growth medium is included for comparison. 
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3.4: Microbiological experiments (Step II) 
 
 
 
Figure 3.12: SERS on clinical overnight cultures from three CF children. All wild type-like strains emitted 
clearly detectable HCN, and the first two lasR mutants too. SERS on overnight LB is included for 
comparison. 
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3.4: Microbiological experiments (Step II) 
 
 
Figure 3.13: SERS on clinical overnight cultures from two children. The last is of a wild type-like; a 
nonsense lasR mutated; and a missense lasR mutated strain from one paediatric CF patient. Apart from 
isolate no. 389 (top Green), all strains emitted clearly detectable HCN. SERS on overnight LB is included 
for comparison. 
All wild type-like strains emitted clearly detectable HCN, and also the lasR mutants, whose mutation was 
upstream (at the 5’ terminal) of the gene. The lasR mutants, whose mutation was downstream (at the 3’ 
terminal) of the gene, did not emit any detectable HCN (Paper II). Since, with the established SERS method, 
HCN could easily be detected from all WT-like cultures, the principle had been proven that the SERS 
substrate was possibly able to detect early P. aeruginosa infections from the vapours produced; so we 
applied the local ethics’ committee and got permission to conduct a clinical trial, involving paediatric CF 
patients free from chronic P. aeruginosa infection. 
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3.5: Clinical trial (Step III) 
3.5 Clinical trial (Step III) 
3.5a SERS measurement on cigarette smoke 
Tobacco smoke is known to contain HCN [Scherer, 2006]. To start the development of a device for 
collection of human breath, and to verify HCN detection from breath, experiments on cigarette smoke were 
made using Tedlar bags, known for their low background and FDA approved for human breath collection. 
The recycled bags used to collect bacterial volatiles were not relevant, because they were hand made from 
Canada and consisted of Teflon, which was impossible to weld, and the side welding was fragile. Tedlar 
bags are expensive, but strong, and they could be ordered in large quantities within short time. But they 
could only have one end open for mounting of the SERS substrate, if a corner was cut off, and the clamps 
from the Teflon bags were reused and disinfected with ethanol between collections. 
Fig 3.14 shows SERS spectra of cigarette smoke blown directly into the bag containing the substrate; smoke 
through a PEP flutter with a SERS substrate mounted in the “chimney” of the PEP flutter’s T-piece; and the 
smoker’s breath into the bag after cigarette smoking. Even 3 days after exposure, the detection of HCN on 
the substrate was clear. Tobacco smoke also contains CO [Scherer, 2006], and due to the experiments 
referred to in 3.2b and the fact that the two extra CN peaks at the low end are seen in the spectra, it is 
expected to be HCN and not CO, which was detected on the substrate. 
 
Figure 3.14: SERS on cigarette smoke measured 3 days after substrate exposure to smoke directly in the 
bag (Red), Smoke into a PEP flutter containing the SERS substrate (Green), the smoker’s breath after 
finishing the cigarette (Blue), and a reference sample (Black). There is a clear C≡N stretching peak in the 
two first, and a smaller one in the smoker’s breath. The 2 extra peaks < 500 cm-1 confirm CN detection. 
Only 3 exhalations were used in the bag, whereas 6 exhalations were conducted through the PEP flutter, 
with similar HCN peak intensity, which led to the decision of using the bags, also so that extra exposure 
time could be applied. Additionally, it was easier to mount the substrate inside the bag than in the PEP 
flutter. And because successful experiments had already been made with the substrate mounted in a bag, it 
was decided that this was the best way to obtain SERS measurements on human breath. 
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3.5: Clinical trial (Step III) 
3.5b Pilot study at Rigshospitalet 
A protocol was agreed on with Kim Gjerum Nielsen (KGN), MD, from the Danish Paediatric Pulmonary 
Service and Helle Krogh Johansen (HKJ), MD, from Department of Clinical Microbiology at Rigshospitalet, 
including 50 CF patients and up to 20 controls aged 5-17 years. The age span of the patients should be 
relevant to the application, and they should be free from any P. aeruginosa infection, because the purpose 
was to catch a new colonisation, when it occurred. The lower age limit was set to be sure that the child was 
able to collaborate and blow correctly into the bag. Copies of the application to Ethics’ Committee, along 
with information to patients and their parents; study protocol, informed consent form and questionnaire 
used, as well as a follow-up letter (all in Danish) are found in Supplementary S25. A very simple device was 
established for the collection of CF children’s breath, connecting a Tedlar bag to a PEP flutter via a 
disposable tube. This way the child breathed through the PEP flutter, which he or she was familiar with for 
daily exercise, and into the bag containing the substrate for direct exposure. (Paper III). 
Conducting a clinical study is a logistic task, because of the many stakeholders, patients, documents, 
machines and time plans to take into account. First of all, it took place in a normal hospital ward, with 
considerations and routines to comply with. CF children and their parents were waiting for their 
appointment with a doctor or nurse. Often they had been underway for a long time, because there are only 
two CF centres in Denmark (Rigshospitalet and Skejby). For young CF children, they knew that during the 
appointment, an endo-laryngeal suction would be made, and the child would be in for a small reward. Then 
came an extra person who would like to invite them to participate in a study on this “nano-chip” to try to 
find out, whether it could be used to detect Pseudomonas in the child’s breath. The parents then had to 
read and sign the documents; and, depending on the infection status of the child, a consultation room was 
assigned, where the child was instructed how to blow into the bag. It had to take place before the child 
made the spirometry test (of lung function), because then the exhalation was forced as long as possible, 
and I was afraid to miss any bacterial HCN, that may have been produced in the airways. 
Before this was possible, the SERS substrates were fabricated in the Danchip cleanroom of DTU, and every 
week Au had to be available in the machine for metal deposition, which should be up and running. Each 
morning, before patients entered the clinic, the substrates were cleaned and prepared in numbered Petri 
dishes; and devices and papers were prepared. The Petri dish was mounted in the Tedlar bag just before 
the child would blow into the device, and Petri dishes containing the SERS substrate were transported to 
the Quality & Technology laboratory, Department of Food Science at KU, for Raman measurements. The 
following week, microbiological results of the sputum culturing were available and imported to the case 
report form. Nanna Bild made this illustration to explain what the study was all about: 
 
Figure 3.15: Illustration used to explain children and parents about the purpose of their participation. 
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3.5: Clinical trial (Step III) 
The first month passed without any sign of HCN in the children’s breath, and it was considered to pivot, 
using breath condensation instead and adding the condensate onto the substrate. Not even the child, 
whose lasR mutated P. aeruginosa isolate emitted HCN, seemed to have any HCN in her breath. If 
condensation was to be applied, it would be necessary to use strong base to make the cyanide stay in the 
condensate [Ma et al., 2010], which was not appealing; and the children seemed to like blowing up the bag, 
plus it would be a challenge to switch in the middle of the study. HKJ informed that the strain had been 
isolated 5 years back, so probably it had mutated even more since. This could explain why there was 
nothing in the patient’s breath, because P. aeruginosa could have turned off the emission of HCN. It was 
therefore decided to persevere and continue according to the protocol. 
Then an intense triple bond signal occurred, which can be seen in the Green spectra of Fig 3.16. Until then, 
all spectra had looked like the Red ones, which came from the same patient at his next visit.  
 
Figure 3.16: First indication of HCN detection in the breath of a CF child with a P. aeruginosa infection 
due to high intensity of the triple bond peak about 2130 cm-1 in the Green spectra. 
The peak was at 2129 cm-1, so it was not shifted. Whether or not HCN had been detected in the breath of 
the patient was uncertain, and it turned out that he had a non mucoid P. aeruginosa infection at both visits, 
and antibiotics had been administered in between. Because his precipitating antibodies against P. 
aeruginosa were 12 (and should have been < 2), he should not have been included in the first place. 
Figure 3.17 is modified from Paper III. The SERS spectra came from a boy who cultured P. aeruginosa in his 
3rd out of 4 visits. In the zoom it is seen that the triple bond peak was also slightly shifted away from the 
background peak, towards higher wave numbers. 
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3.5: Clinical trial (Step III) 
 
Figure 3.17: Mean SERS spectra of breath from patient C mentioned in paper III. The triple bond peak is 
more intense at the 3rd visit, where P. aeruginosa was cultured, and also slightly shifted above 2130 cm-1. 
Unfortunately, at the 3rd visit, the device had been left for 60 minutes before the substrate was evacuated. 
Because there was a probable dependence of exposure time, three bags were filled with breath of a 
healthy volunteer. See Fig 3.18. One was left for 15 min (Red), the second for 60 min (Blue), and the third 
bag was spiked to 20 ppb HCN(g) and left for 15 min. The scales of Figs 3.17 and 3.18 are identical, and it is 
seen that the Green spectrum of Fig 3.17 is more intense than the Blue of Fig 3.18 and as intense as the 
Green in Fig 3.18. 
 
Figure 3.18: Mean SERS spectra of breath from a healthy volunteer. Red means 15 min exposure time, 
Blue is 60 min exposure time (as compared to the Green spectrum in Fig 3.17). The Green bag was spiked 
with HCN(g) to 20 ppb and left for 15 min. Raman intensity to the same scale as the previous figure. 
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3.5: Clinical trial (Step III) 
Exposure time did have an influence on SERS intensity, but it did not seem to explain the entire 
enhancement of the triple bond peak of patient C’s 3rd visit, because the Green spectrum of Fig 3.17 is 
more intense than the Blue of Fig 3.18, both representing mean spectra of 5 repetitions on the substrate. 
A few of the very young control subjects were not blowing very well, probably because they were not used 
to force their exhalation, and this was reflected in their low intensity spectra. In about half of the spectra 
there was an additional peak at ~870 cm-1, which was not assigned. It was speculated whether it could be 
caused by a small bottle of saline, which was often left open inside the laminar air flow (LAF) bench, where 
the substrates were prepared and left to dry, but this was not confirmed. It was also present in the spectra 
of visits 2 and 3 of another patient, in Fig 3.19 denoted patient D. The Red mean spectrum was from visit 1, 
the Blue from visit 2, and visit 3 was represented by two substrates; the Green of a Au substrate and the 
Black of a Ag SERS substrate, which was fabricated using the same RIE parameters. The Green and Black 
substrates were exposed at the same time, sitting beside each other in the same Petri dish, clearly 
demonstrating the superiority of the optimised Au substrate for this application. The Ag substrate had an 
intense O2 peak about 1600 cm
-1, and a smaller CN peak, which on the Ag substrate was located at ~2144 
cm-1. The unidentified 870 cm-1 peak was also more pronounced in the Ag spectrum. 
 
Figure 3.19: Mean SERS spectra on breath of patient D from 3 visits, the last both on Au and Ag 
substrates. Red from visit 1, Blue from visit 2, Green from visit 3 (Au), and Black from visit 3 (Ag). 
The parents of subject D were divorced, and in the questionnaire of the third visit, the tick was set to 
“exposed to indoor passive smoking at home”. At the first visit, it was at “not exposed to passive smoking 
at home”. No P. aeruginosa was cultured from the patient, neither during the trial period, nor in the follow-
up period of five months after the trial. 
The results are preliminary, and more studies need to be made. Several other times the triple bond peak 
was intense, as explained in Paper III. One of the control subjects had an increased triple bond peak, and 
control subjects did not deliver sputum samples. Whether it was a P. aeruginosa lung infection, is therefore 
unknown. Although not a CF, the mentioned patient was too sick and should not have been included in the 
study. 
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3.6: Experimental summary 
3.6 Experimental summary 
A nanopillar SERS substrate has been optimised for the detection of HCN in gas, in bacterial vapours, and in 
human breath. The substrate was invented previously, and the NAPLAS project founded [Schmidt et al., 
2012]. The optimisation was done by changing the metal on top of the nanopillars from Ag to Au, lowering 
the etching time from 4 to 3 minutes and adding a one minute O2 plasma clean step, lowering the metal 
deposition rate from 10 to 9 Å/s and increasing the thickness of the Au layer from 200 to 225 nm. 
Preparation for gas phase detection was done by preleaning the nanopillars, cleaning the substrates by 3 
min immersion in ethanol followed by 3 min immersion in water and subsequent drying. The fragile 
substrates were kept and transported mounted inside small Petri dishes, tightly closed by small zipper bags.  
Setups were developed for HCN(g) detection, for SERS detection of HCN from bacterial volatiles, and for 
collection and SERS substrate exposure to human breath. Five ppm HCN was successfully detected in gas 
phase, and KCN was detected down to 10-6 M. HCN detection was demonstrated from cultures of P. 
aeruginosa wild types, starting from the end of exponential / beginning of stationary growth phase. HCN 
was also detected from lasR mutated clinical P. aeruginosa strains isolated from the airways of children 
with cystic fibrosis (CF), when the mutation was located at the 5’ terminal of the gene. Application for 
ethics’ committee was submitted and permission given to conduct a clinical trial, including 50 CF patients 
aged 5-17 years and 19 age-matched control subjects. One CF patient had a new P. aeruginosa lung 
colonisation during the trial, and it was detected on the SERS substrate, whose HCN signal was increased 
compared to the patient’s other visits.  
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Discussion 
Hydrogen cyanide is a biomarker for the pathogenic bacterium Pseudomonas aeruginosa, which often 
causes chronic airway infections in CF patients. Using the silicon nanopillar substrate for surface-
enhancement of the Raman signal, HCN was detected in the gas phase, although at too high concentration, 
because exact concentrations below 5 ppm could not be guaranteed. It was suggested to dilute the gas in 
the lab. But it was estimated that if the supplier could not promise exact concentrations below ppm, then 
with extra dilution it would be less certain how to conclude on the results both if HCN was and if it was not 
detected on the substrate. Median values of HCN concentrations measured in the breath of children with P. 
aeruginosa lung colonisations had been measured to 13.5 ppb [Enderby et al., 2009], so to be able to 
reduce the cyanide concentration, serial dilutions of potassium cyanide (KCN) were performed. For the 
chemical experiments, Raman measurements were performed on a 780 nm DXR instrument equipped with 
a x10 objective microscope. The microbiological and clinical Raman measurements were made on a 
BRUKER system equipped with a 1064 nm laser. Advantages hereof were that the spectra were less prone 
to fluorescence in the low end; that the BRUKER system was less booked and placed at KU, where the 
external stay took place and relatively close to Rigshospitalet; and because the project was prioritised, 
measurements could take place within short time after substrate exposure. However, due to repair, no 
objective was mounted on the instrument, and low Raman intensities were measured, and it is advisable in 
the future to measure using an objective to improve the efficiency of the SERS measurements. 
Results on HCN production during growth of P. aeruginosa wild type were consistent with literature in that 
HCN emission was maximal at the end of exponential or beginning of stationary growth phase [Castric, 
1975; Blier et al., 2012; Chen et al., 2016]. The clinical WT-like strains also emitted high amounts of HCN, 
which could still be detected in ON cultures. Since initial colonisation usually occurs with a non-mucoid 
strain [Smith et al., 2013], this was in agreement with reports of five times higher HCN emission in non-
mucoid clinical strains isolated from CF patients than in non-mucoid laboratory strains [Carterson et al., 
2004]. Since a functional lasR gene is essential to HCN production by P. aeruginosa [Pessi & Haas, 2000], it 
could be expected that lasR mutant strains would not emit HCN. This was the case in the lasR knocked-out 
strain SD2, and in the clinical 1979 reference strain from the DK02 lineage, which is a “classical” lasR 
mutant [Damkiær et al., 2013]. Therefore, it was surprising that some of the lasR mutated isolates from the 
children collection actually produced HCN. Genome sequencing had previously been made on the isolates 
from CF children [Marvig et al., 2015], and it turned out that the location of the lasR mutation played a role, 
in that mutations downstream of the lasR gene lead to cessation of HCN production, whereas upstream 
lasR mutation did not seem to have any influence on HCN production. This was in accordance with Kiratisin 
et al., who suggested that the LasR protein has two regions, of which the C-terminal region (downstream) 
promotes or strengthens multimerisation, which is its way of action. When this part was mutated, then 
probably therefore no HCN was synthesized [Kiratisin et al., 2002]. 
The microbiological experiments were followed up by a clinical pilot study, where two CF patients who had 
delivered P. aeruginosa strains to the in vitro experiments were also tested in vivo; but no HCN was 
detected from their breath. Using SESI-MS, only 25-34% of the volatile in vitro peaks of P. aeruginosa were 
shared with breathprints in vivo, which is why it is important not to evaluate in vitro volatile fingerprints 
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based on in vivo assumptions [Zhu et al., 2013b]. One new P. aeruginosa colonisation occurred during the 
pilot study, and the SERS C≡N peak was more intense than in the spectra from the patient’s other visits, 
where only the background peak was present. Too long exposure time had been applied to the SERS 
substrate at the visit, where sputum culture was positive, and experiments were made on the breath of a 
healthy control subject, comparing normal (i.e. 15 min) exposure time to prolonged (60 min) exposure 
time. The C≡N peak was more intense after 60 than after 15 min, but not as intense as in the P. aeruginosa-
positive SERS breath spectrum, and also not as shifted above 2130 cm-1 as this sample, whose C≡N peak 
was comparable to healthy breath spiked to ~20 ppb HCN. Additionally, there were more occasions of 
increased CN peak intensity, and for the test to be valid, the false positives must be reduced to a minimum. 
It is important to note, that it is a very sensitive substrate, and possible alternative sources of cyanide, 
triple bond or cumulated double bond compounds need to be investigated. The results are preliminary, and 
more pilot studies and clinical trials are recommended to come up with more concrete statements. 
Working with a novel method, which has a background peak close to the analyte peak, it is relevant to have 
a valid reference method to be sure about the conclusions drawn. Measurements on HCN(g) and KCN in 
dilution had given information about the SERS spectrum of cyanide and how it behaved at different 
concentrations. But working in a microbiological setting, where other factors could play a role, it was 
important to be able to validate that the peak expected to occur from cyanide actually did, because the 
background peak was only a few wavenumbers away. At the Novo Nordisk Foundation, Centre for 
Biosustainability, DTU, a well-established GC-MS method was used to quantify bacterial volatiles, adhered 
to Tenax. The learning was that HCN cannot stick to Tenax, and that regular GC-MS methods cannot go 
below molecular masses of 30 g/mol. In attempts to find another suitable chemical or GC-MS reference 
method, more people were approached, but no reference method was established. 
When sputum was cultured, ideally it should originate from an area where infecting microorganisms were 
growing. Since they thrive in clots, this might not always be the case, and so the culture would be negative. 
Once a sputum sample was obtained, it was transported to the Department of Clinical Microbiology who 
would culture the sample. Depending on internal mail routes and routines this could take up to 24 hours; 
often under sub-optimal conditions for the bacteria to survive, and in the meantime some of them might 
die. This could imply that the culture would be a false negative, and the bacteria could continue to develop 
in the patient’s airways until next visit to the outpatient clinic, where they might be discovered. 
It could be argued that the project has been moving too fast and that more knowledge should have been 
gained within each step before moving on to the next. But the aim of the PhD project was to investigate the 
applicability of the method to a new field, and when results were convincing and consistent, it was time to 
move on to the next level, although it was not completely understood, e.g. exactly what caused the 
background peak. Even though it would have been a huge advantage to solve the issue, it was outside the 
scope of the PhD project. Ideally, optimisation of the Au substrate should have been more advanced before 
or during the course of the NAPLAS project, whose main focus was on optimising the Ag substrate. Since 
then, the RIE recipe for the Au substrate has been optimised further, among other things by lowering the 
chamber pressure for increased density of the nanopillars [Kaiyu Wu].  
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Conclusion and outlook 
The SERS substrate has been taken from basic research, through in vitro studies, and into a clinical setting. 
It can be concluded that the substrate has been improved and is able to detect HCN from human breath. 
With time, it may hold the potential to be developed into a point-of-care diagnostic tool, which, together 
with a portable Raman system, could be placed in the patient’s home or at the general practitioner for daily 
breath testing of the P. aeruginosa biomarker HCN. For this to be realised, the issue with the background 
peak close to the CN peak needs to be addressed, and a standard way of exhaling should be established, 
possibly using condensed breath collected onto the substrate, which should then be alkaline. A disposable 
device (the R-tube) for breath condensation is available from MESM, Ltd. 
It is recommended to conduct more clinical studies, applying different approaches, testing for longer 
periods, possibly also including PCD patients, and including control subjects who are less sick. As reference 
method, instead of sputum culturing, it is recommended to use PCR to upscale the DNA of the sample for 
more sensitive microbiological diagnostics. Until this is applied, the sputum samples should be stored in a 
better way and preferably transported to the Department of Clinical Microbiology right away, and at least 
same day as the sample is obtained, so there is a better chance of culturing possible microorganisms in the 
sample. 
With new drugs on the market, targeting the ion channel defects of the delta F508 and the third most 
common CFTR mutation, G551D; there is hope for a cure to CF, if the annual price of $259,000 or almost 2 
million DKK per patient could become more accessible. 
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a b s t r a c t
Lung infections with Pseudomonas aeruginosa (PA) is the most common cause of morbidity and mortality
in cystic ﬁbrosis (CF) patients. Due to its ready adaptation to the dehydrated mucosa of CF airways, PA
infections tend to become chronic, eventually killing the patient. Hydrogen cyanide (HCN) at ppb level
has been reported to be a PA biomarker. For early PA detection in CF children not yet chronically lung
infected a non-invasive Surface-Enhanced Raman Spectroscopy (SERS)-based breath nanosensor is being
developed. The triple bond between C and N in cyanide, with its characteristic band at 2133 cm1, is an
excellent case for the SERS-based detection due to the infrequent occurrence of triple bonds in nature. For
demonstration of direct HCN detection in the gas phase, a gold-coated silicon nanopillar substrate was
exposed to 5 ppm HCN in N2. Results showed that HCN adsorbed on the SERS substrate can be consis-
tently detected under different experimental conditions and up to 9 days after exposure. For detection
of lower cyanide concentrations serial dilution experiments using potassium cyanide (KCN)
demonstrated cyanide quantiﬁcation down to 1 lM in solution (corresponding to 18 ppb). Lower KCN
concentrations of 10 and 100 nM (corresponding to 0.18 and 1.8 ppb) produced SERS intensities that
were relatively similar to the reference signal. Since HCN concentration in the breath of PA colonized
CF children is reported to be 13.5 ppb, the detection of cyanide is within the required range.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cystic ﬁbrosis (CF) patients have a salt imbalance of the secre-
tory cells leading to excessive, salty sweating and swelling of the
pancreatic duct, accompanied by an insufﬁcient uptake of proteins
and lipids. The most commonly known symptom is swelling of the
bronchial wall due to vastly dehydrated and thickened mucus and
bacterial infections, leading to coughing and loss of breath. Bacteria
often infect the sinuses, and it has been shown that they adapt to
the lower airways in the sinuses and drop into the lungs e.g. during
sleep or viral infections [12,15]. The bacterium most commonly
associated with morbidity and mortality in CF patients is
Pseudomonas aeruginosa (PA) which is harmless to healthy individ-
uals but well-adapted to the oxygen depleted environment in the
upper airways [1]. The intermittent PA lung colonization often
becomes chronic, which is why early detection and eradication is
essential [19].
P. aeruginosa emits the poisonous gas hydrogen cyanide (HCN)
to outmatch competitive microorganisms, and HCN has been sug-
gested as a potential PA biomarker [4,9,16]. Selected ion ﬂow tube
mass spectrometry (SIFT-MS) and other MS based principles are
among the most frequently applied techniques for human breath
analysis, detecting HCN levels between 0 and 81 ppb [2,7,9–
11,21,29]. Because HCN is also formed in the oral cavity of adults
it has been suggested to only use nose exhaled breath for analysis
in adult CF patients. A ‘‘cut-off’’ value of 10 ppb has been suggested
as ‘‘elevated’’, indicative of a PA infection [10]. In the breath of CF
children with a PA airway colonization HCN has been reported to
lie between 8.1 and 16.5 ppb, with a median value of 13.5 ppb
[9]. For a deﬁnition of PA colonization versus chronic infection
please refer to [14].
http://dx.doi.org/10.1016/j.sbsr.2015.07.002
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For mouse model systems secondary electron spray ionization
mass spectrometry (SESI-MS) has been used for in vivo breath diag-
nosis of lung infection models [30,31]. The authors point out that
in vitro studies cannot be expected to mimic in vivo results because
only between 25% and 27% of the in vitro and in vivo PA peaks were
shared. For analysis of sputum and broncho-alveolar lavage (BAL)
samples various electrochemical probes have been used to
measure cyanide content at micromolar level [3,11,22,27]. The
techniques for breath analysis are either, expensive, inﬂexible,
time consuming or they demand a high level of operator skills
[5]. Therefore, there is a need for a fast, inexpensive and sensitive
sensor for the detection of P. aeruginosa in the breath of children
with cystic ﬁbrosis.
Raman scattering spectroscopy is a widely used ﬁngerprinting
method for small molecules. However since it is not a very sensi-
tive method, millimolar concentration seems to be the limit of
detection [6]. Surface-Enhanced Raman Spectroscopy (SERS) using
gold nanoparticles in a sol–gel has been used to detect ppb level
cyanide in waste water [20], and in 2011 Senapati et al. reported
to have detected cyanide in the ppt range by the use of Au SERS
aggregation [26]. In the presence of noble metals, cyanide can be
detected due to its high afﬁnity towards metals. These approaches
demand cyanide to be in solution for SERS detection and there is
much sample preparation. We propose a fast and cheap technique
based on the SERS substrate developed by Schmidt et al. [24] that
can be used both in solution and for the direct detection of cyanide
in gas phase as a precursor for PA breath detection. The substrate
consists of gold coated silicon nanopillars which can be brought
to lean against each other, forming so-called ‘‘hot spot’’ regions
with considerate plasmonic effect for Raman signal enhancement
to take place. It is well-known that Raman is a quantitative method
[25] and in some cases it is also possible to perform quantitative
SERS, although it has yet to be demonstrated to a wider extent [8].
Hydrogen cyanide is a potential PA biomarker. If a point-of-care
device could detect HCN in the breath of young CF patients with a
pulmonary PA colonization, the need for invasive techniques and
repeated anesthesia for obtaining broncho-alveolar lavage to
diagnose PA would be minimized. To make a simple model system
for the presence of HCN in breath, a gas setup with an open ﬂow
cell connected to a tank of 5 ppm HCN(g) in N2 was used. The
SERS substrate was placed inside the ﬂow cell and exposed to
the gas for 30 s. To vary the amount of HCN molecules exposing
the substrate, the pressure through the open system was changed
among samples.
In the present paper SERS measurements on 5 ppm HCN gas and
on serial dilutions of potassium cyanide (KCN) in the region from
10 nM to 1 mM are presented. A KCN concentration range of
100 nM to 1 lM is the region of relevance, corresponding to ppb
gas levels. The aim of the project is to detect PA colonization in
the patients’ breath at an earlier stage than allowed by today’s
conventional methods.
2. Experimental
2.1. SERS substrate fabrication and measurement procedure
Nanopillars were etched into a Si wafer in an Advanced Silicon
Etcher, applying alternate portions of SF6 and O2 plasma (dry etch),
followed by an O2 cleaning step. The resulting nanopillars are
400 nm in height, 50 nm in width, and with a density of approxi-
mately 18 pillars/lm2. A 225 nm thin Au layer was then deposited
onto the silicon nanopillars, producing freely standing Au-capped
Si nanopillar structures (Fig. 1(a)). The wafer was diced into
6  6 mm2 squares using a diamond cutter and the substrates were
used within 1–2 days after Au deposition.
The measurements were conducted in a DXR dispersive
SmartRaman spectrometer with thermoelectric CCD cooling, an
optical microscope and a 780 nm excitation laser from Thermo
Fisher Scientiﬁc. An optical microscope was coupled to a single
grating spectrometer with 5 cm1 FWHM spectral resolution and
±2 wavenumber accuracy. Two times 5 s scan time at a laser power
of 5.0 mW was applied through a 25 lm slit using a 10 magniﬁ-
cation lens. Raman wavenumber shifts were collected in the region
100–3400 cm1. In each experiment all SERS substrates were
prepared from the same wafer. In order to avoid cross contamina-
tion of the sensitive substrates, samples with different KCN
concentrations were left to dry separately and kept in small Petri
dishes for transport and storage. One substrate was prepared for
each concentration and 10 points were measured for each SERS
substrate. In the HCN gas experiments each SERS substrate was
Fig. 1. (a) Illustration of the leaning of nanopillars. When immersed in liquid and
subsequently dried, capillary forces make the pillars lean against each other,
creating SERS ‘‘hot spots’’ for enhancement of the Raman signal. (b) SEM images of
the Au-coated Si SERS substrate, before and after leaning (Courtesy of KaiyuWu). (c)
SERS spectra of HCN(g) and KCN(aq) on the Au SERS substrate and theoretical
Raman spectrum of HCN. (d) Theoretical Au(CN) and Au(CN)2 Raman spectra.
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exposed to different HCN gas ﬂow conditions. The SERS signal was
then recorded from 10 random points from each SERS substrate.
Therefore, the data points in Figs. 2(b), 4(b) and 5(b) show the
SERS signal intensity variations (cyanide peaks) measured for a
given experimental condition from 10 different measurement
points from a single SERS chip. Reference SERS signals were
recorded using water droplets prior to KCN or HCN exposures. In
all cases a weak Raman band close to 2120 cm1 that is likely
due to carbonaceous species on the Au surface is observed [17].
2.2. Gas setup
Five ppm HCN(g) in N2 from the supplier AGA (Linde AG,
Pullach, Germany) was used for cyanide gas exposure. Four ppm
was the lowest stabile concentration the supplier could guarantee.
The setup consists of an open ﬂow cell connected with a pressure
controlled gas inlet, see insert in Fig. 2(a). The meter to the right
indicates the amount of gas left in the tank while the barometer
to the left shows the pressure within the system. The large regula-
tor is for gas ﬂow regulation, and the small one is for opening and
closing the gas ﬂow. Thus, when the gas ﬂow is increased, the pres-
sure inside the system rises which can be read on the barometer.
Via a simple setup using an upturned measuring cylinder in a
water bath it was shown that 0.2 bar in the system corresponds
to 35 mL/s gas ﬂow. The gas ﬂow is expected to correlate with
HCN(g) concentration at low ﬂow-rate. After the regulator, the
gas passes through a steel tube to the ﬂow cell placed in the fume
hood (bottom insert in Fig. 2(a)). The SERS substrate was placed on
a platform inside the ﬂow cell. Prior to gas exposure the SERS
substrate was cleaned by 3 min immersion in very pure ethanol
(Absolute grade, CHROMASOLV, Sigma–Aldrich) followed by
3 min rinsing in water (Molecular Biology Reagent grade, Sigma–
Aldrich) and left to dry on a clean tissue. The drying caused the
nanopillars to lean against each other, see Fig. 1(a) and (b). The cell
was purged with the relevant ﬂow for 2 min before the SERS
substrate was placed in the ﬂow cell and exposed to the gas for
30 s. In all cases the ﬂow was changed in a random order not to
confound the results by sequence of exposure. The gas setup was
used for veriﬁcation of gas detection on the SERS substrate.
2.3. KCN solutions
Aqueous cyanide solutions of potassium cyanide (KCN) were
prepared as a model system for precise control of the concentra-
tion of cyanide in solution. According to Henry’s law either the
temperature should be kept low or pH should be high in order to
keep cyanide in the solution, preventing it from evaporating as
HCN(g) [18]. It would not be feasible to maintain a low tempera-
ture, and the approach with pH adjustment was therefore adopted.
KCN solutions from 10 nM to 1 mM were prepared and their pH
was adjusted to 11 by the addition of NaOH. The SERS substrates
were cleaned by 3 min immersion into ethanol (Absolute grade,
CHROMASOLV, Sigma–Aldrich), followed by 3 min in water
(Molecular Biology Reagent grade, Sigma–Aldrich). From there
they were immersed directly into the KCN solution for 3 min
before drying on a clean tissue, making the nanopillars lean against
each other, ready for measurements. Due to strong gold-cyanide
bonding all cyanide on the substrate is expected to be captured
on the nanopillars while the water evaporates. Water with added
NaOH to pH 11 was used as reference.
2.4. Data analysis
Theoretical Raman spectra in vacuum were calculated using
Gaussian 09W, methods DFT/B3LYP/6-311G and DFT/B3LYP/
LanL2DZ, for HCN and Au(CN)x compounds, respectively (no
scaling applied).
Each spectrum was jointly ﬁtted and baseline corrected using
Voigt proﬁle(s) to ﬁt peaks and a line to adjust for the baseline
[23]. The ﬁtting was done in the local area near peaks so that the
linear baseline was appropriate. The ﬁtting was carried out using
Metropolis–Hastings [13]. Either a mixture of two Voigt proﬁles
or a single Voigt proﬁle was utilized depending on the number of
peaks. In the cases where two Voigt proﬁles were jointly ﬁtted each
peak was constrained to be centered ±5 from the desired location.
The intensity of each Voigt proﬁle was then used as the intensity
response.
3. Results and discussion
3.1. HCN gas experiments
In Fig. 1(c) and (d) the 2133 cm1 vibration is observed in both
gas (HCN) and liquid (KCN) SERS experiments. The HCN theoretical
vibrational spectrum can explain the origin of the 2133 cm1 mode
and corresponds to stretching of C„N, see insert in Fig. 1(c). In
order to understand the origin of experimentally seen vibrations
Fig. 2. a (insertion) Setup for 5 ppm HCN gas exposure, including the ﬂow cell in
the insertion below. (a) Representative Raman spectra of the pre-leaned SERS
substrates exposed to 30 s 5 ppm HCN(g) at 35; 18; and 9 mL/s ﬂow, 30 min. after
exposure. The C„N stretching band at 2134 cm1 is clear and distinct, increasing
with increasing ﬂow. (b) 2134 cm1 peak intensity at various gas ﬂows. Above
35 mL/s the signal saturates, corresponding to a gas concentration of 5 ppm.
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at 290 and 384 cm1, additional calculations involving Au-cyanide
complexes were performed. We ﬁnd that Au(CN) and Au(CN)2
display qualitatively similar vibrational spectra, Fig. 1(d). Results
show that both 290 and 384 cm1 modes originate from HCN
interaction with the Au metal surface, as previously reported by
Senapati et al. [26]. This is in accordance with the Elsner equation
where the aurat (I) ion complex forms when cyanide is added to
gold in the presence of air:
4Auþ 8CN þ O2 þ 2H2O! 4½AuðCNÞ2 þ 4OH
If base is added, cyanide will stay in the CN conﬁguration.
In Fig. 2 the SERS spectra of substrates exposed to different
ﬂows of 5 ppm HCN(g) are shown. The spectra are recorded
30 min after gas exposure. At lower ﬂows (35; 18; and 9 mL/s)
the ﬂow change is reﬂected in the SERS intensity of the C„N
stretching band at 2133 cm1 (Fig. 2(a)). This indicates that some
quantitation is possible at low HCN gas ﬂows. At higher ﬂows
(70; 105; 140 and 175 mL/s, Fig. 2(b)) the SERS intensity seems
to saturate. Part of the explanation could be that above 35 mL/s
most HCN molecules are being ‘‘ﬂushed’’ past the substrate and
out of the ﬂow cell, not leaving much time for AuACN interaction
to occur; and therefore only a fraction of the HCN molecules get in
actual contact with the SERS substrate. After 4 h the samples were
re-measured, and the C„N stretching band had started to shift +50
wavenumbers. Fig. 3 compares the 35 mL/s gas samples after (a)
30 min, (b) 4 h, and (c) 9 days. It seems as if some dynamics have
taken place in favor of the more stable Au(CN)2 (aurat (I) ion)
complex, in Fig. 3 represented by the extra peak at 2186 cm1. In
total, four bands occurred, at 2133 cm1 and 2186 cm1, respec-
tively representing the pure C„N stretching mode of CN and
the Au(CN)2 complex [6,26], and also the Au-C stretching mode
at 384 cm1 and the Au-CN bending mode at 290 cm1 are present
[26]. The results in Fig. 3 are much similar to those obtained by
Premasiri et al. [20] who measured SERS spectra of 0.25–1 ppm
NaCN on an Au sol–gel. They report a +50 cm1 shift of the CAN
stretching band from low to high CN concentration. We believe
the reason for this shift can be that the higher concentrations of
cyanide have had sufﬁcient time for dissociation of the Au, forming
the mentioned dimer complex. If they had repeated the measure-
ments later either the shift would have been more pronounced
or the cyanide would have evaporated as HCN(g). According to
Senapati et al. [26] it took about 60 min for a cyanide ion concen-
tration of 800 ppb to dissociate their Au nanoparticles completely,
whereas for 800 ppt it would take 180 min. Therefore, at high con-
centrations the dimer complex forms at a higher rate. The samples
of our study were measured again after 9 days, and now the C„N
stretching peak is completely shifted to the 2186 cm1 mode
(Fig. 4). It seems as if there is a preference towards the more stable
Au(CN)2 complex, which increases during storage. This again is in
accordance with the results obtained by Senapati et al. [26]. At the
same time the AuACN bending mode at 290 cm1 decreases, prob-
ably due to a restricted space for this type of movement in the
dimer case. It should be mentioned that the reason why the sub-
strate becomes saturated at a relatively low Raman intensity could
be that many hot spots are occupied due to pre-leaning of the
nanopillars.
3.2. KCN serial dilution
Since it is difﬁcult to precisely control low concentrations of
cyanide in the gas phase, aqueous solutions of KCN were prepared
to carry out serial dilution experiments, mimicking lower HCN
concentrations in a controllable manner and producing quantita-
tive SERS. KCN is a water soluble powder, and since it is the CN part
which is interesting to Raman experiments, KCN in solution works
as an optimal model system for precise analysis. To test the
correlation between CN concentration and CN Raman signal, KCN
solutions from 10 nM to 1 mM were prepared.
Representative SERS spectra of the KCN serial solution experi-
ments are presented in Fig. 5(a). The stretching peak of cyanide’s
triple bond is clear and distinct at 2137 cm1 where it decreases
with decreasing cyanide concentration. As reference, the back-
ground spectrum of water (with added NaOH to pH 11) is included
for comparison. In Fig. 5(b) the intensity of the stretching peak of
C„N is plotted as a function of KCN concentration. A linear
correlation is seen from 100 nM to 1 mM, although it is difﬁcult
to distinguish between 100 nM, 10 nM and water. In attempt to
distinguish 100 nM from 10 nM KCN and reference samples,
principal component analyses (PCAs) including all three cyanide
related vibration bands (2137, 384 and 290 cm1) were
performed, see detailed description in supplementary information.
The results indicate that the observed difference between 100 nM
and 10 nM KCN concentrations can be largely attributed to signal
background ﬂuctuations. However, the results showed nearly a lin-
ear relationship between the KCN concentration and the ﬁrst
Principal Component in the 105–107 M KCN concentration range,
see Fig. S.6 in supplementary information. This is similar to results
Fig. 3. Representative SERS spectra of 35 mL/s 5 ppm HCN(g) samples measured
after 30 min; 4 h; and 9 days. The rearrangement of cyanide from the CN
(2133 cm1) to the Au(CN)2 (2186 cm1) conﬁguration is clearly seen. (Not to
scale.)
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reported by Thygesen et al. [28] where only the C„N mode at
2137 cm1 was utilized in the data analysis. In the latter work,
the upper detection limit for a linear relationship between the
C„N band signal intensity and KCN concentration utilizing Au
colloids was close to 105 M while the lower limit was around
106–107 M.
According to Enderby et al. [9] the median value of HCN in the
breath of CF children with P. aeruginosa lung colonization is
13.5 ppb, which corresponds to 0.75 lM in solution. Explanation
is given in the following. Take for instance a 0.05 mL drop of
1 lM KCN weighing approximately 0.05 g. This will contain:
0:05 g=ð18:00 g=molÞ ¼ 2:8  103 mol H2O and
ð1  106 mol=LÞ  ð0:05  103 LÞ ¼ 5:0  1011 mol KCN
nKCN=nH2O ¼ ð5:0  1011Þ=ð2:8  103Þ ¼ 18  109 ¼ 18 ppb:
13.5 ppb/18 ppb = 0.75. So, when quantitative SERS applies, the
SERS intensity of 0.75 lM cyanide in solution is expected to corre-
spond to the median intensity of the breath of a CF child with PA
lung colonization. Breath concentrations for the present application
are thus expected to correspond to aqueous cyanide concentrations
in the range between 100 nM and 1 lM.
As seen in Fig. 2(b),2000 cps seems to be the point of saturation
for cyanide in gas phase. The level is similar to 100 lM KCN(aq),
which with the above calculations would give 1.8 ppm and not
5 ppm aswas the case. This is no surprise as the Au nanopillars used
for gas detection were pre-leaned prior to cyanide exposure.
Therefore fewer molecules could be ‘‘caught’’ in the hot spots
between nanopillars than with cyanide in solution. By letting the
alkaline KCN solution dry, all cyanide on the substrate will get in
contact with the Au nanopillars, optimizing the AuACN interaction,
including the interaction inside the forming hot spots. It is
well-known that pre-leaning of the pillars leads to a lower signal
than leaning post-exposure [24]. This means the signal might be
expected to be 2–3 times lower with breath than with cyanide in
solution; but preliminary tests have shown that the vapor in
people’s breath is sufﬁcient to make the pillars lean, making
pre-leaning unnecessary.
In the serial dilution experiments the C„N stretching band also
shifted during storage, but only when pH had not been adjusted to
11. Like with gas the shift was about 50 cm1 towards higher
wavenumbers. Premasiri et al. [20] measured on NaCN(aq) without
adjusting the pH. This way Au could dissociate and form the
Au(CN)2 complex, which probably has led to the shift of the
Fig. 4. (a) Representative Raman spectra of the HCN(g) exposed SERS substrates re-
measured after 9 days. It is seen that the C„N stretching mode has shifted to the
2186 cm1 Au(CN)2 state. (b) (Blue) 2134 cm1 peak intensity at various gas ﬂows,
re-measured after 9 days. There is not much left of the CN monomer. (Red)
2186 cm1 peak intensity at various gas ﬂows, after 9 days. Based on the mean
response, Pearson correlation of the intensity of the peaks in Figs. Fig. 2(b) and 4(b)
is 0.92. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
Fig. 5. (a) Representative SERS spectra of KCN concentrations from 108 to 103 M
and the reference solvent. (b) Raman intensity of the cyanide stretching peak
around 2140 cm1 as a function of potassium cyanide concentration. Note log scales
on both axes.
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C„N stretching band. When pH is kept high as in the present case,
Au will most likely stay as Au0 and not oxidize to form the aurat (I)
ion.
4. Conclusion
By use of the applied SERS technique we have shown that it is
possible to quantify the amount of cyanide down to ppb level,
which is needed for detection of P. aeruginosa lung colonization
in the breath of children with cystic ﬁbrosis.
It was possible to distinguish samples with different KCN
concentration down to 1 lM (corresponding to 18 ppb) using the
C„N stretching region located close to 2133 cm1, thus the
detection limit was between 18 ppb (detected) and 1.8 ppb (not
detected). Future work includes measurements on bacterial
cultures and patient samples.
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Supplementary information 
 
SERS data on the KCN and water samples were analyzed by Principal Component Analysis (PCA), using MATLAB 
R2014a (The MathWork, Inc.) equipped with the PLS Toolbox 782 (Eigenvector Research, Inc.). PCA is a variance-
based method looking for variations in the dataset (Wold et al., 1987). The direction of largest variance is denoted 
the first Principal Component (PC1). PC2 is perpendicular to PC1, explaining the direction of second largest variance, 
etc. PCA can be used to explore groupings and differences among samples, and to find the variables (wavenumbers) 
or regions of variables where interesting variations occur. Various preprocessing methods were investigated, and the 
best PCA used SNV transformation followed by mean-centering (MC). Prior to applying PCA, the spectra were 
normalized using standard normal variates (SNV) and mean-centering (MC). SNV is a method for transforming the 
spectra in order to minimize the intra-measurement variation resulting in more orderly arranged spectra (Barnes et 
al., 1989). MC is a simple deduction of the average spectrum applied to the data in the current model, enabling 
samples to be presented around the origin of the score plot. In order to avoid over-fit of the models, segmented 
cross-validation (CV) was applied using random subsets with 10 data splits and 5 iterations. In CV some of the 
samples are left out during the calculations and then included for model validation. Fig S.1 is the raw SERS data on 
KCN serial dilution samples, while Fig S.2 is the data after applying the standard normal variates (SNV) 
transformation (Barnes et al., 1989). Fig S.3 is the preprocessed data after SNV and mean centering (MC). The figures 
show how the unwanted baseline effects found in the raw spectra are removed by SNV and what the data looks like 
when mean centering has been applied. The preprocessed 1 mM KCN spectrum almost comprises the first loading of 
the PCA in Fig S.4 (b). 
S.1)    S.2) 
S.3) 
 
 
Figure S.1) Raw SERS data on KCN solutions and 
reference solution. S.2) SERS data after SNV 
transformation. S.3) Data after preprocessing (standard 
normal variate followed by mean centering). It is seen 
that the high concentration KCN spectra comprise the 
main variance. 
Principal component analysis on regions 200-450 and 2000-2250 cm-1  
 
In Fig 5b a univariate analysis based on one single wavenumber out of the entire spectrum is presented. This 
approach is intuitive and straightforward to use, but it can be critical to base results on only one measured band 
intensity e.g. it is very sensitive to interferences and outliers. A way to overcome this, and to make a more robust 
analysis, is by including a higher number of variables. By a multivariate approach more information may be obtained 
as even very small spectral changes can be discovered. Based on the C≡N stretching band alone, quantitation was 
not possible on the 10 and 100 nM KCN and water samples. Therefore PCAs were initially performed on the entire 
dataset to gain knowledge about wavenumbers of significance. Fig S.4 presents a stepwise analysis on the KCN data. 
From the score plot (PC1 vs. PC2) in Fig S.4 (a) it is clear that the samples with the two highest KCN concentrations 
completely dominate PC1 because they contribute most to the variance in data. At the same time those are the only 
ones that can be distinguished, as opposed to the 50 samples inside the circle. The corresponding loading plot in Fig 
S.4 (b) shows that the stretching peak of cyanide (2000-2250 cm-1) and the region for Au-C stretching and Au-CN 
bending from 200-450 cm-1 contribute most to this variance. In order to try to improve the separation, a PCA was 
made including only the 50 samples, which could not be distinguished in Fig S.4 (a), and only the spectral regions; 
200-450 cm-1 and 2000-2250 cm-1. The score plot in Fig S.4 (c) shows a better spread of the samples which in PC2 vs. 
PC3 fall into groups according to their KCN concentrations. The 10 µM KCN samples are seen in the upper right 
region of the score plot, with high scores on both PC2 and PC3. To the opposite, with negative PC2 and PC3 scores, 
the 10 nM and reference samples are found. Between the mentioned groups the samples with “intermediate” KCN 
concentrations are located. The loading plot in Fig S.4 (d) shows that the 10 µM KCN samples have high C≡N 
stretching intensity, while all samples with high PC2 scores have high Au-CN bending intensity. Samples with 
negative PC2 and PC3 scores have more of the 260 cm-1 band and less of C≡N and Au-CN. It is well-known that 
samples in a score plot lying opposite of each other, on a straight line through the plot’s origin, will have opposite 
properties according to the loadings, which goes well along with the observations seen in the PCAs and the 
knowledge we have about the samples. Finally, a PCA was made on the three groups that could not be separated by 
a univariate approach, i.e. only the 10 and 100 nM KCN and the reference samples. The score plot in Fig S.4 (e) 
shows that it is possible to distinguish the groups with SERS, and Fig S.4 (f) shows that this is mainly due to the Au-CN 
band at 290 cm-1 and the Au-O band at 232 cm-1. Au-CN is more intense in the 100 nM samples (with high PC1 
scores), and Au-O (attributed to water) is more pronounced in the 10 nM and reference samples with negative PC1 
scores. PC3 is slightly noisy and should not be ascribed too much significance.  
S.4) 
 
Figure S.4: a) PCA score plot (PC1 vs. PC2) of all KCN data: 70 samples and 3008 variables (wavenumbers). As 
expected, 1 mM and 100 µM KCN samples completely dominate the plot in the direction of PC1 explaining 93.66% of 
the entire variation in the dataset. b) Loading plot of PC1 corresponding to the previous score plot. It is seen that the 
spectral regions 2000-2250 and 200-450 cm-1 contribute most to the variation explained by this PC. c) Score plot of a 
PCA on only the 50 samples inside the circle of a) and the 502 variables (wavenumbers) from inside the circles of b), 
PC2 vs. PC3. High concentration KCN samples are found in the upper right part of the plot, opposite the low KCN 
concentration and reference samples. d) Loading plot corresponding to the score plot in c). It is seen that samples 
with high PC2 and 3 scores have high concentrations of the C≡N stretching and Au-CN bending modes, whereas 
samples with negative PC3 scores are dominated by the 260 cm-1 band. e) Score plot of PCA on only 10 and 100 nM 
KCN and reference samples. PC1, describing 70.61% of the variance, separates 100 nM KCN samples from the 10 nM 
and the reference samples which are separated in the direction of PC3. f) Corresponding loading plot, showing that 
samples with high PC1 scores have high Au-CN, whereas negative PC1 scores correspond to higher Au-O modes. A 
small peak is also seen at 2120 cm-1 which is not dominant in these samples. 
In Fig S.5 a zoom is presented on the averaged KCN spectra. It is seen that the Au-CN band at 290 cm-1 is very difficult 
to determine for concentrations below 10-4 M. 
S.5) 
 
Figure S.5: Zoom on the low end KCN raw data, average of 10 measurements. The Au-CN band at 290 cm-1 is clear in 
the 10-3 and 10-4 M spectra after which it is difficult to determine due to strong fluorescence and interference with 
neighboring peaks.  
Therefore caution must be taken when interpreting the results from the PCA. It looked like it was possible to 
distinguish samples with different KCN concentration down to 100 nM (corresponding to 1.8 ppb) by use of the C≡N 
stretching region and the region for cyanide and water attached to gold. Furthermore, plotting all KCN samples onto 
PC1 of Fig S.4 (f) does not give a straight line, and thus the PCA is inconclusive.  
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Figure S.6: The scores for the entire KCN concentration data set (1 mM – 10 nM) when explained using PC1 from 
Figure S.4(f).  
Principal component analysis on the complementary region 450-2000 cm-1  
 
A PCA was made on the spectral region between the regions used in the data analysis in Fig S.4. Fig S.7 shows the 
scoreplot and Fig S.8 the loadingplot of the initial PCA made on all samples and all variables from 450-2000 cm-1. One 
millimolar and 100 µM samples are mainly seen in the lower left region of the scoreplot (with negative PC1 and PC2). 
The remaining samples are scattered. The loadings are noisy. 
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Figure S.7) PCA scoreplot of all samples in the SERS region 450-2000 cm-1, preprocessed by SNV and MC. S.8) 
Loadingplot corresponding to the scoreplot in S.7. 
In the raw and preprocessed spectra this region presented a more ordered nature for higher concentration KCN 
samples than for low. (S.1-3). The reason is a reduced shot noise, leading to a lower level of noise in the spectra, 
which is why the samples turn out grouped in the scoreplot. Because the samples with highest KCN concentrations 
could almost be grouped, another PCA was made on the samples with KCN concentrations from 10µM and below. 
The resulting scoreplot is scattered, and the loadings are even noisier than before. This means that the applied 
spectral region has a limited significance when it comes to KCN quantification. 
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Figure S.9) PCA scoreplot of all samples with KCN concentrations of 10 nM – 10 µM and reference samples. S.10) 
Loadingplot corresponding to the scoreplot in S.9. 
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ABSTRACT 22 
Pseudomonas aeruginosa is the primary cause of chronic airway infections in cystic fibrosis (CF) 23 
patients. Current methods for P. aeruginosa identification are invasive, and often there are too few 24 
bacteria in the sample to culture. Therefore persistence is seen from the first P. aeruginosa culture 25 
in about 75% of young CF patients, and it is important to discover new ways to detect P. 26 
aeruginosa at an earlier stage. The P. aeruginosa biomarker hydrogen cyanide (HCN) contains a 27 
triple bond, which is utilized in this study because of the resulting characteristic C≡N peak at 2135 28 
cm-1 in a Raman spectrum. The Raman signal was enhanced by surface-enhanced Raman 29 
spectroscopy (SERS) on a Au-coated SERS substrate. After long-term infection, a mutation in the 30 
patho-adaptive lasR gene can alter the expression of HCN, which is why it is sometimes not 31 
possible to detect HCN in the breath of chronically infected patients. Twelve clinical strains isolated 32 
from CF patients were evaluated, and HCN was clearly detected from overnight cultures of all wild 33 
type-like isolates. After lasR mutation in later isolates from the same patients, HCN could only be 34 
detected where the lasR mutation had taken place at the 5’ terminal (upstream) of the gene.  35 
 36 
Abstract word count: 200. 37 
 38 
 39 
40 
INTRODUCTION  41 
Individuals with cystic fibrosis (CF) have an inherited defect in the cystic fibrosis transmembrane 42 
conductance regulator (CFTR) gene, causing thickened, dehydrated mucus to form on mucociliary 43 
surfaces. This in turn increases the risk of e.g. airway infections.  P. aeruginosa lung infections are 44 
the largest threat to the wellbeing and survival of CF patients, and it has been shown for a cohort 45 
of young Danish CF patients that an estimated 75 % have a persistent infection already from the 46 
first detection of P. aeruginosa1.  47 
 48 
If the child is unable to expectorate, today’s methods consist of either a larynx swab, which is 49 
insensitive, or induced sputum (naso-laryngeal suction), which is extremely invasive. P. aeruginosa 50 
can be difficult to detect, especially in children and young adults without a chronic infection 51 
because they have few bacteria in their airways. Therefore more sensitive and non-invasive 52 
methods are being investigated utilizing the fact that HCN is a biomarker for P. aeruginosa2,3,4. In 53 
nature, P. aeruginosa emits the poisonous gas hydrogen cyanide (HCN) in order to kill competitive 54 
microorganisms. This wildtype (WT)-like behavior is also expected to occur in the lungs, at least 55 
during the initial stages of infection. To sustain a persistent colonisation and infection, adaptation is 56 
necessary. In many cases this involves mutations of different genes, so-called “patho-adaptive” 57 
genes. One of the genes that have been suggested as being “patho-adaptive” (i.e. beneficial for P. 58 
aeruginosa to mutate) is lasR5,6. The lasR gene is a transcriptional regulator necessary for HCN 59 
production7. A mutation in the lasR gene can imply a downregulation of the HCN production. 60 
According to the clinical CF program in Denmark, patients are seen once a month in the outpatient 61 
clinic and deliver a sputum sample coughed up from the lungs. Depending on the patient's age and 62 
ability this is either done by expectoration or, as in most young patients, induced by a tube inserted 63 
through the nose into the larynx to provoke a cough reflex after which a sample is obtained through 64 
the tube (naso-laryngeal suction). Sputum samples are then cultured to identify pathogenic 65 
microorganisms.  66 
 67 
Several groups have investigated HCN production by P. aeruginosa in vitro3,8,9. The drawbacks of 68 
all the applied methods are that they need extensive sample handling before measurements can 69 
be obtained, and that it can only be done in solution. Gilchrist and co-workers are investigating the 70 
possibility of detecting HCN in the breath of CF children, collecting breath samples for investigation 71 
by selected ion flow tube – mass spectroscopy (SIFT-MS), which is an expensive and complex 72 
procedure10. An optimal sensor would be a cheap and simple point-of-care device, allowing for 73 
measurements to be carried out directly on human breath, without pre-handling of the samples. 74 
 75 
Raman spectroscopy is a fingerprinting technique that measures the inelastic scattering of 76 
monochromatic light when interacting with matter. The frequency shift (Raman shift) of the 77 
inelastically scattered light corresponds to the energies of the molecular vibrations11. HCN contains 78 
a triple bond between C and N, which will result in a Raman band around 2135 wavenumbers (cm-79 
1). But since the inelastically scattered light is only a tiny part of light scattered from a sample (<10-80 
8), Raman spectroscopy in general has a weak signal-to-noise ratio, and there is a need for signal 81 
enhancement. Using surface-enhanced Raman spectroscopy (SERS) the Raman signal of small 82 
molecules is enhanced by utilizing the collective oscillations of conducting electrons (surface 83 
plasmons) that take place in the vicinity of clustered noble-metal nanoparticles12,13. SERS has 84 
been used in a wide array of medical applications14,15,16. An example hereof is using label free Ag 85 
colloid SERS to detect single-nucleotide mismatch in short DNA sequences to discover even small 86 
nucleotide changes17. Our SERS substrate has Si nanopillars with Au caps18 which lean against 87 
each other for SERS detection of cyanide in liquid or gas phase, as described previously19. In this 88 
study we investigate the capability of our sensor to detect the biomarker HCN(g) in emissions from 89 
clinical early and late P. aeruginosa isolates, to determine its applicability as a non-invasive 90 
diagnostic tool for detection of P. aeruginosa.  91 
 92 
93 
MATERIALS AND METHODS 94 
Preparation of the SERS substrate 95 
The disposable silicon (Si) SERS substrate was etched in a single-side polished Si wafer using 3 96 
min Reactive Ion (plasma) Etching with alternating SF6 bombardment and O2 protection of the 97 
emerging nanopillars, followed by a 1 min O2 cleaning step. Before use, Au was evaporated onto 98 
the Si nanopillars, forming 225 nm caps used for SERS detection. See Fig 1(a). On the day of 99 
exposure the wafer was cut into 6x6 mm chips using a diamond cutter and tweezers. The chips 100 
were cleaned by immersion into ethanol (Absolute grade, CHROMASOLV R, Sigma-Aldrich) for 3 101 
min followed by H2O (Molecular Biology Reagent grade, Sigma-Aldrich) for 3 min and left to dry on 102 
a tissue whereby the pillars would lean to enable SERS detection. For easy handling and 103 
transportation, the SERS substrate was mounted inside a small Petri dish, using double sided 104 
adhesive tape (Scotch), with a Post-It on top, the tacky side facing up for holding the substrate (Fig 105 
1(b, 4). The wall of the Petri dish protected the delicate SERS substrate so it would not get in 106 
contact with the bag and be scratched (See section on SERS substrate exposure to bacterial 107 
emissions). 108 
 109 
P. aeruginosa reference strains 110 
PAO1 is a reference strain commonly used to benchmark various P. aeruginosa strains against. 111 
PA-SD2 is a PAO1 isolate with a knockout mutation in lasR, as described in ref. 20. DK02 is a P. 112 
aeruginosa lineage that spread among Danish CF patients for over 40 years. The earliest isolate is 113 
called DK02-1973, and its lasR mutated strain DK02-197920. 114 
 115 
The clinical strain collection 116 
At the CF clinic at Rigshospitalet in Copenhagen a special collection of bacterial strains has been 117 
sampled from CF children and young adults since 2004, resulting in a unique collection for 118 
genomics and other evolutional studies to be made5,21. From this collection early (lasR WT) and 119 
late (lasR mutant) isolates from five patients have been selected, encompassing three different 120 
clone types, for comparison of adaptations between and within patients. The selected strains 121 
originate from CF patients who today are all chronically infected, and the late isolates represent 122 
various locations of lasR mutations. Selected strains include the first P. aeruginosa isolate and at 123 
least one later isolate from the same patient after onset of chronicity and with detected mutations in 124 
the lasR gene. 125 
 126 
Ethics 127 
The local ethics committee at the Capital Region of Denmark Region Hovedstaden approved the 128 
use of the samples: registration number H-4-2015-FSP. All patients have given informed consent. 129 
For patients below 18 years of age, informed consent was obtained from their parents. The study 130 
was carried out in accordance with the approved guidelines and the University Hospital 131 
Rigshospitalet approved the experimental protocol.  132 
 133 
Identification of mutations in lasR. 134 
Using a modified version of the pipeline previously described in Andersen et al. (2015)22, we 135 
identified mutations in the CF isolates using the sequences of isolates from young CF patients, 136 
previously published by Marvig et al. (2015)5. Briefly: Reads were mapped to the lasR reference 137 
sequence (NP_250121.1) from the reference strain Pseudomonas aeruginosa PAO1, using the 138 
Burrows-Wheeler alignment tool23 (BWA version 0.7.12), with the paired-end reads setting. 139 
Alignments were filtered to remove unmapped reads, sorted, and indexed using SAMtools24. Each 140 
isolate was assigned to a read group using Picard Tools25 (version 1.14) and differences between 141 
isolates and the reference lasR sequence were identified with SAMtools. Mutations were manually 142 
checked using the Integrative Genomics Viewer26 (IGV, version 2.3.68). The functional impact 143 
(missense/nonsense/silent) was determined using the translated sequence of lasR in the IGV. The 144 
full pipeline can be found in Supplementary material.  145 
 146 
Preparation of bacterial cultures 147 
P. aeruginosa strain PAO1, its engineered lasR mutant PA-SD2 and two isolates from the classic 148 
clinical lineage DK02 from 1973 and 197927, as well as pairs of strains from five pediatric CF 149 
patients were stored as pure cultures at -80°C, wherefrom they were streaked onto LB agar plates 150 
and incubated at 37°C over night. One colony was then inoculated in 10 mL LB growth medium (4 151 
% salt concentration) and incubated shaking at an angle of ~45°, 225 rpm overnight. One mL of 152 
the ON culture was added to 9 mL of fresh LB in a 100 mL Erlenmeyer flask, plugged with a two-153 
holed rubber plug, covered with aluminum foil and placed in a 37°C water bath at ~200 rpm, 154 
wherefrom SERS substrates were exposed (Fig. 1(b, 6)). One flask was prepared for each 155 
measurement needed. 156 
 157 
SERS substrate exposure to bacterial emissions 158 
In the setup we used an SK 224-PCMTX4 Universal air sampling pump (SKC Inc., PA, US), 159 
connected via a silicone tube to a large Vac-U-Chamber, 231-939 (SKC Inc., PA, US), Fig 1(b, 1-160 
2). Inside the vacuum chamber a 10 L reusable 60 μm PTFE (Teflon) sample bag (Scentroid, ON, 161 
Canada), equipped with a 1/2" compression fitting was connected to the sample inlet (3). The bag 162 
was specially designed with one end open for mounting the SERS substrate, and closed by a 163 
clamp. The sample inlet of the vacuum chamber was connected via a silicone tube to the 100 mL 164 
Erlenmeyer culture flask (5), plugged with a rubber plug with two holes, one for the tube and one 165 
for air inlet. The pump was operating at ~500 mL/min for 15 min to fill the bag, followed by 5 min 166 
holding time for further substrate exposure. Before pumping out bacterial gases, all fittings were 167 
tested by closing the vacuum chamber and turning on the pump to let in air from the lab to verify 168 
that the bag would inflate and no emissions would be lost when the bacterial culture was 169 
connected to the system. 170 
 171 
OD and SERS measurements 172 
The optical density (OD) was measured at 600 nm in a UV-1800 spectrophotometer (SHIMADZU, 173 
Kyoto, Japan), giving the absorbance as a measure of cell density. SERS measurements were 174 
recorded using a FT-Raman instrument (Bruker VERTEX 70, Bruker Optik, Ettlingen, Germany), 175 
equipped with a 1064 nm laser and an InGaAs detector. Samples were measured in a 180 degrees 176 
backscattering geometry using 32 scans at a resolution of 4 cm-1. Each sample was measured at 5 177 
different positions on the substrate and the 5 spectra were averaged before subsequent data 178 
analysis. 179 
180 
RESULTS AND DISCUSSION 181 
SERS on PAO1 and DK02 ON culture emissions 182 
The DK02 strains were growing much slower than PAO1, and ON cultures were prepared for 183 
SERS exposure and measurements. In Fig 2(a-b) it is seen that PAO1 and the isolate from 1973 184 
both emitted substantial amounts of HCN, as seen in the intense C≡N stretching peak at 2135 cm-185 
1, whereas the lasR mutated PAO1 and the late (1979) isolate did not. This was as expected since 186 
the late DK2 and the lasR mutated PAO1 should not have a functional LasR protein.  187 
 188 
HCN emission from PAO1 during growth 189 
As seen in the growth curve of Fig 3(a), PAO1 has a lag phase of about 2 hours before onset of 190 
exponential growth, with stationary growth, and expected HCN production, beginning after 4-6 191 
hours. According to previous studies HCN production starts at the end of exponential / beginning of 192 
stationary phase8,28. This is due to the fact that HCN production is quorum sensing (QS) 193 
dependent. After a while on the substrate much of the C≡N peak had shifted to 2189 cm-1 because 194 
of sufficient amounts and the fact that it had had some time to interact with the Au-coated SERS 195 
substrate, forming the stabile [Au(CN)2]
- complex, as explained in ref. 19. Fig 3(b) shows the SERS 196 
intensity of the cumulated cyanide peaks at 2135 and 2189 cm-1 from 2 until 20 h (ON). It is 197 
observed that HCN production begins after 4 h growth and is still detectable in the overnight (20 h) 198 
culture, whereas the 2 and 3 h samples only had the same background as the LB reference. The 199 
results in figure 3(b) and the shape of the HCN emission curve with time are very similar to 200 
previous findings8,29. 201 
 202 
Clinical P. aeruginosa strains 203 
Isolates from five CF children were measured with the SERS sensor in the developed setup. All 204 
early (WT-like) strains isolated from CF patients emitted HCN. In Fig 4(a) the intensity of the 2135 205 
cm-1 C≡N stretching band shows that some of the lasR mutated strains also emitted HCN. 206 
D'Argenio and co-workers described in 2007 how different lasR mutations can have a different 207 
effect on the functionality of the LasR protein30. Genome sequencing of the lasR mutated isolates5 208 
showed that isolates with lasR mutations located towards the 3’ terminal of the gene did not 209 
produce HCN (Fig 4(b)), probably because a downstream deletion can be a dominant-negative P. 210 
aeruginosa mutation resulting in altered molecular function31. The other lasR mutations were at the 211 
upstream or central part of the gene, which did not seem to down regulate the expression of HCN. 212 
Furthermore, in CF patient A one lasR mutation was a nonsense which in most cases stops the 213 
protein from functioning, but apparently not in this case where the mutation was located upstream. 214 
In the late isolate there is a clear HCN emission, however the mutation is a nonsense in the 215 
beginning (5’ terminal) of the gene. This type should abolish the functionality of lasR completely. 216 
The continued production of HCN in this isolate is in contrast to what we see in other isolates, 217 
which indicates that it is the 3’ terminal that is important for functionality. The continued production 218 
of HCN could be explained by mutations or changes in regulation of other genes that are also 219 
important for QS and HCN production circumventing a malfunctioning lasR.  220 
 221 
Clinical control strains 222 
To make sure HCN can be used as a specific marker for P. aeruginosa colonisation, we also 223 
tested other clinically relevant species. Fig 5 shows examples of two other bacteria colonising the 224 
lungs of CF patients, and known to be able to cause chronic infections: Stenotrophomonas 225 
maltophilia32 and Achromobacter xylosoxidans33. Clinical isolates of these control strains were 226 
tested in the same setup as P. aeruginosa, but no HCN could be detected. 227 
 228 
229 
CONCLUSIONS AND OUTLOOK 230 
We have developed a SERS-based sensor for detection of HCN from P. aeruginosa cultures, and 231 
a setup for exposure of the SERS substrate to bacterial volatiles. The purpose was to see whether 232 
the wild type like strains were producing HCN in sufficient amounts for detection by the SERS 233 
substrate and to check whether the lasR mutated strains were still producing HCN. For the 234 
reference strain PAO1 HCN production started at the end of stationary phase and was still 235 
detectable in overnight cultures. In all clinical wild type-like strains isolated from the airways of 236 
cystic fibrosis patients there was a clear HCN SERS signal proving the principle that we are able to 237 
detect gases from early P. aeruginosa isolates. After mutation in the lasR transcriptional regulator 238 
gene, HCN could only be detected from the strains having the mutation located at the 5’ terminal or 239 
central part of the gene. P. aeruginosa strains with the lasR mutation located at the 3’ terminal end 240 
of the gene did not emit detectable HCN, which may explain why HCN cannot be detected in the 241 
breath of all patients with a chronic P. aeruginosa airway infection. 242 
 243 
Our results suggest that it is indeed possible to use SERS detection of HCN as an early indicator 244 
of P. aeruginosa infection. The method offers the possibility of a simple, non-invasive point-of-care 245 
monitoring device. 246 
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FIGURES 343 
Figure 1 344 
Setup for SERS measurements on bacterial volatiles. 345 
 346 
 347 
a) SEM images of the SERS substrate before and after leaning for formation of electromagnetic “hot 348 
spots” for SERS enhancement. (Courtesy of Kaiyu Wu. Reprinted with permission from editor of ref. 349 
19). 350 
b) The pump (1) induces a vacuum inside the vacuum chamber (2), leading to inflation of the bag (3) 351 
and exposure of the SERS substrate (4) to volatiles created by the bacterial culture (5) in the water 352 
bath (6).  353 
 354 
355 
Figure 2 356 
SERS on overnight cultures of PAO1, the DK02 lineage and their lasR mutated strains. 357 
 358 
a) SERS on emissions from overnight cultures of P. aeruginosa PAO1, wild type vs. its engineered lasR 359 
mutated strain PA-SD2.  b) SERS on emissions from overnight cultures of the P. aeruginosa DK02 lineage, 360 
wild type from 1973 vs. the lasR mutated strain from 1979. Both wild types show intense CN signals at 2135 361 
cm-1 and also a small peak at 2189 cm-1 due to formation of the [Au(CN)2]
- complex, whereas the lasR 362 
mutated strains emit no HCN. Spectra of LB emissions are included as reference. 363 
 364 
365 
Figure 3 366 
PAO1 HCN emission during growth. 367 
(a) 368 
 369 
(b) 370 
 371 
a) Optical density (OD600) growth curve for PAO1 in LB medium at 37°C. The lag phase takes about 2 hours, 372 
followed by the log phase until about 4-6 hours’ growth after which the stationary state occurs. Final OD 373 
absorbance is about 1.7 at 600 nm. b) Intensity of cumulated cyanide peaks from PAO1 during growth. The 374 
cumulated Raman intensity is the (2135 + 2189) cm-1 SERS intensity on the PAO1 exposed substrate minus 375 
the background signal of the substrate exposed to LB emissions. It is seen that PAO1 starts producing HCN 376 
after 4 hours’ growth, which is at the end of its exponential / beginning of stationary growth phase. After 377 
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20 hours HCN is still detectable, although not as intense as after 4 hours. The shape of the CN curve 378 
resembles previous studies on P. aeruginosa HCN emission during growth8,28. 379 
 380 
381 
Figure 4 382 
Cyanide production of clinical P. aeruginosa overnight cultures from 5 CF patients, as compared to the 383 
location of lasR gene mutations. 384 
 385 
 386 
 387 
a) Cyanide peak intensity of clinical P. aeruginosa overnight cultures from 5 CF patients. The peak intensity 388 
is the SERS signal at 2135 cm-1 minus the background signal of the LB reference samples. It is seen that all 389 
WT-like isolates emitted clearly detectable HCN, and so did also some of the lasR mutated isolates. For 390 
patients with two late isolates (Patients A and C), the left white column represents isolate 1 (i.e. A1 or C1) 391 
and the right white column represents isolate 2 (i.e. A2 and C2). 392 
b) Map of lasR gene mutations in late isolates from the 5 CF patients. It is seen that isolates whose 393 
mutations had taken place at the 5’ terminal (low base pair numbers) or center part of the gene emitted 394 
HCN (high intensity of 2135 cm-1 peak in 4(a), indicated with green), whereas isolates with lasR mutations 395 
at the 3’ terminal (high base pair numbers, indicated with red) did not emit HCN (late isolates from patients 396 
C, D and E). Letters before parentheses refer to the patient, and the notations in parentheses refer to the 397 
position and substitution of base pairs due to the mutation. 398 
399 
Figure 5 400 
SERS on overnight cultures of Stenotrophomonas maltophilia and Achromobacter xylosoxidans.  401 
 402 
SERS on emissions from overnight cultures of S. maltophilia and A. xylosoxidans. None of the bacteria 403 
emitted any detectable HCN, as seen in the low intensity of the triple bond peak at 2135 cm-1. Especially the 404 
S. maltophilia spectrum has different peaks than P. aeruginosa. A spectrum of LB emissions is included as 405 
reference. 406 
 407 
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 11 
#!/bin/bash  12 
ISO=$1 #Input: list of isolate names. 13 
 14 
while read line 15 
do 16 
 17 
 echo "$line is being aligned with BWA (v.0.7.12) aln paired end 18 
function (sampe)" 19 
 bwa aln lasR.fna $line.L*_1.fq.gz > "$line"_read1.sai 20 
 bwa aln lasR.fna $line.L*_2.fq.gz > "$line"_read2.sai 21 
 bwa sampe lasR.fna "$line"_read1.sai "$line"_read2.sai 22 
$line.L*_1.fq.gz $line.L*_2.fq.gz > "$line"_aligned.sam 23 
 24 
 echo "$line is going through round one in SAMtools v.0.1.18" 25 
 samtools view -Shb -F4 "$line"_aligned.sam > "$line"_aligned.bam 26 
 samtools sort "$line"_aligned.bam "$line"_aligned_sort 27 
 samtools index "$line"_aligned_sort.bam 28 
 29 
 echo "$line read groups are added by Picard (v.1.140)" 30 
 java -Xmx2g -jar picard-tools-1.140/picard.jar AddOrReplaceReadGroups 31 
INPUT="$line"_aligned_sort.bam OUTPUT="$line"_aligned.RG.bam RGID=CF 32 
RGLB=CF_LIB1 RGPL=Illumina RGPU=CF_RG1_UNIT1 RGSM=$line 33 
VALIDATION_STRINGENCY=LENIENT 34 
 35 
 echo "$line pileups and raw files are being produced by SAMtools 36 
v0.1.18" 37 
 samtools mpileup -q 20 -C50 -BDSsugf lasR.fna "$line"_aligned.RG.bam 38 
| bcftools view -vg - > "$line"_raw.vcf  39 
done<$ISO 40 
99 
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Abstract 
Background: There is an urgent need for a fast and non-invasive tool to detect early Pseudomonas 
aeruginosa airway colonisation in cystic fibrosis patients unable to expectorate. 
Methods: Fifty CF children and 19 controls aged 5-17 years were included in the pilot study. A 
surface-enhanced Raman spectroscopy (SERS) nanochip optimised for detection of trace amounts 
of the P. aeruginosa biomarker hydrogen cyanide (HCN) was mounted inside a Tedlar bag, which 
the patient breathed into. The SERS chip was then analysed in a Raman spectrometer, 
investigating the C≡N peak at 2130 cm-1 and correlated with sputum cultures. 
Results: One new P. aeruginosa colonisation occurred during the trial period. The C≡N peak 
intensity was enhanced in this sample as compared to the subject’s 3 other visits. Three additional 
patients had intense C≡N SERS signals from their breath, but no P. aeruginosa was cultured from 
their sputum. There was a dependency of exposure time. 
 
Keywords: Pseudomonas aeruginosa, lung infection, Breath detection, Hydrogen cyanide (HCN), 
Surface-enhanced Raman spectroscopy (SERS), Pilot study 
 
Abbreviations: SERS: Surface-enhanced Raman spectroscopy; HCN: Hydrogen cyanide; 
FT: Fourier Transform; CN, C≡N: Cyanide; cm-1: Unit of wave numbers (Raman shift); 
PCR: Polymerase chain reaction; SEM: Scanning electron microscopy.
1. INTRODUCTION 
Pseudomonas aeruginosa airway infections are the major cause of morbidity and mortality in cystic 
fibrosis (CF) patients [1, 2]. The methods that are being used in the CF clinic to discover P. 
aeruginosa are invasive, and often the sensitivity is limited. It has been estimated that 
approximately 75% of all newly discovered P. aeruginosa infections are already persistently 
established [3]. Therefore, there is an urgent need for a sensitive, fast, cheap and non-invasive 
diagnostic tool to detect early P. aeruginosa airway colonisation in CF children who are unable to 
produce sputum or expectorate. P. aeruginosa emits the poisonous gas hydrogen cyanide (HCN), 
which can be an advantage combating other microorganisms in the lungs [4, 5]. HCN is considered 
a potential P. aeruginosa biomarker, and it was detected at median values of 13.5 ppb in children’s 
breath using selected ion flow tube mass spectroscopy (SIFT-MS) [4]. In the SPACE study, 
Gilchrist and co-workers measured HCN in exhaled breath of CF children, also using SIFT-MS [6]. 
So far, this methodology has not been optimized to meet the need for fast detection, and 
measurements were made within 24 hours, whereby some of the exhaled HCN might have been 
lost. Additionally, chronically infected patients were included, whose P. aeruginosa might have 
ceased producing HCN. Previously we have shown that at some point during adaptation P. 
aeruginosa can stop producing HCN, which can explain why the biomarker cannot be detected in 
the breath of most CF patients with a chronic airway infection [7]. 
Between C and N of cyanide there is a triple bond, which gives rise to a distinct peak in a Raman 
spectrum. Raman spectroscopy is a fast and non-invasive analytical technique extensively used for 
molecular fingerprinting. The technique identifies analytes by differentiating their molecular 
vibrational frequencies in the probed Raman scattering signal. However, the limit of detection for 
traditional Raman spectroscopy is in the range of millimolar concentration [8], impeding the use of 
the technique for detecting molecules at concentrations below a millimolar. To indicate P. 
aeruginosa infection, HCN below 20 ppb levels needs to be detected in the breath of patients with 
cystic fibrosis [4]. Surface-enhanced Raman spectroscopy (SERS) may provide a solution. As an 
advance of Raman spectroscopy, SERS probes the significantly enhanced Raman scattering 
signal from analytes sitting on the surface of nanostructures made up of noble metals. The 
enhancement factor can reach 107 to 108, enabling detection of target molecules at ultra-low 
concentrations [9]. In addition, the affinity of cyanide towards gold due to the formation of Au-CN 
complex [10] makes SERS very suitable for detecting trace amount of HCN. For example, colloidal 
gold nanoparticles have been used to detect HCN in liquid phase at ppt levels in waste water [11]. 
However, the employed colloidal system lacks the ability to sense HCN in gas phase. Recently, we 
have demonstrated the fast identification and quantification of gas-phase HCN down to 18 ppb on 
gold coated silicon nanopillar substrates [12], which are manufactured in large-format by a cost 
effective process [13]. Our results indicate that SERS on the nanopillar substrate has significant 
potential towards fast, cheap and non-invasive detection of P. aeruginosa lung colonisation from 
the breath of children with cystic fibrosis. We have also applied the SERS method to detect HCN in 
emissions from P. aeruginosa cultures isolated from CF patients [7]. In this pilot study, we wanted 
to investigate if the SERS substrate could be used for direct detection of HCN in the breath of CF 
children with an early P. aeruginosa colonisation. To compare in vitro results to in vivo breath 
analysis, two chronically infected CF patients were included in the study, which followed 50 CF 
children for four months at the Copenhagen CF centre of Rigshospitalet. Each month the children 
exhaled into 3L Tedlar bags with the SERS substrate mounted inside, which was analysed a few 
hours later. 
 
2. MATERIALS AND METHODS 
 
2.1 Subjects and study design 
Fifty children with CF (median age X years, range 5-17 years) and 19 non-CF, age-matched 
controls were included in the study. CF patients were excluded if their latest total IgG measured by 
an Enzyme-Linked-Immosorbent Assay (ELISA) against Pseudomonas antigens was above 2.39 
ELISA units, or if the number of precipitating antibodies against P. aeruginosa was >2, meaning 
that they had a chronic P. aeruginosa infection [14] The controls were patients and siblings seen in 
the CF outpatient clinic of Rigshospitalet during the study period, which was January-April 2016. 
Controls were not included if they had CF, primary cilia dyskinesia (PCD) or asthma. Enrolment 
took place during the entire study period, and each subject was tested between 1-5 times. Controls 
were only tested once. SERS measurements were compared with sputum sample, obtained by 
endo-laryngeal suction or expectoration, and cultured at Department of Clinical Microbiology at 
Rigshospitalet to investigate if the method was sufficiently sensitive to detect HCN if P. aeruginosa 
was cultured from the patients’ airways. The controls only delivered breath and no sputum sample. 
2.2 The SERS substrate 
The disposable silicon (Si) SERS substrate was etched in a single-side polished Si wafer using 3 
min Reactive Ion (plasma) Etching with alternating SF6 bombardment and O2 passivation for 
protection of the emerging nanopillars, followed by a 1 min O2 cleaning step. Up till 5 days prior to 
use, Au was evaporated onto the Si nanopillars, forming 225 nm caps used for SERS detection 
(Figure 1a). On the day of exposure the wafer was cut into 5x10 mm2 substrates using a diamond 
cutter and tweezers. The substrates were cleaned by immersion into ethanol (Absolute grade, 
CHROMASOLV R, Sigma-Aldrich) for 3 min followed by H2O (Molecular Biology Reagent grade, 
Sigma-Aldrich) for 3 min and left to dry on a tissue whereby the pillars would lean to enable SERS 
detection (Figure 1b). For easy handling and transportation the SERS substrate was mounted 
inside a small Petri dish, using double sided adhesive tape (Scotch), with a Post-It on top, the 
tacky side facing up for holding the substrate. The wall of the Petri dish protected the delicate 
SERS substrate so it would not get in contact with the Tedlar bag used for breath collection and be 
scratched (Figure 1c). 
 Figure 1: The SERS substrate. 
a) Scanning Electron Microscopy (SEM) image of the freely standing nanopillars before leaning. 
b) SEM image after leaning of the nanopillars. 
c) Petri dish with a gold (Au) SERS substrate mounted inside. 
d) The filled collection device with the SERS chip inside, being exposed to exhaled breath. The tip 
of the PEP flutter is seen to the right. The fitting on top and the clamp at the bottom keep the 
Tedlar bag closed. 
 
2.3 The collection device 
Three L Tedlar sample bags with polypropylene fittings (SKC, Pennsylvania, USA) were used for 
breath collection, with one large corner cut off, so the Petri dish containing the SERS substrate 
could be mounted inside (Figure 1d). The bag was closed with a clamp (Scentroid, Ontario, 
Canada). Part of a disposable latex tube (Philips Respironics, Colorado, USA) was used to 
connect the inlet of the Tedlar bag to the PEP flutter (Intersurgical, Berkshire, UK) that the child 
would blow through, equipped with a 3.5 mm resistance (Wellspect Healthcare, Mölndal, Sweden). 
2.4 Sample collection 
Every child filled the Tedlar bag with 1-5 deep exhalations. The bag was closed and left for 15 
minutes before evacuation in a laminar air flow bench. The lid was put on the Petri dish, which was 
then secured tightly in a small zipper bag for transportation. A short questionnaire was also filled in, 
regarding present well-being, coffee intake and smoking, because it is known that these stimulants 
can influence the amount of HCN in the breath [15, 15a]. 
2.5 Raman measurements 
SERS measurements were recorded using an FT-Raman instrument (Bruker VERTEX 70, Bruker 
Optik, Ettlingen, Germany), equipped with a 1064 nm laser and an indium gallium arsenide  
(InGaAs) detector. Samples were measured in a 180 degrees backscattering geometry using a 
laser power of 200 mW with 32 scans at a resolution of 4 cm-1. Each sample was measured at 5 
different positions on the substrate. 
2.6 Data analysis 
The five spectra obtained from different positions on the substrate were averaged in order to 
increase the signal to noise ratio. The average per sample was subsequently pre-processed using 
Standard Normal Variate (SNV) [16]. SNV eliminates off-sets and slopes from spectra with similar 
spectral features aiding visual inspection as well as reducing complexity of later data analysis. 
Principal component analysis (PCA) [17] was performed using the PLS_toolbox (Ver. 7.9.5, 
Eigenvector Research, USA) in Matlab 2015a (MathWork, USA) on the pre-processed data both 
on the full spectral range and a reduced data set with only the HCN peak around 2135 cm-1. In 
figures, the background was subtracted and curves were shifted up for clarity. 
2.7 Ethical approval 
The local ethics’ committee approved the pilot study, which was assigned the number H-15016027. 
Informed consent was obtained from the parents or from the children aged 15 years or older. 
 
3. RESULTS 
3.1 Demographics 
A total of 50 CF patients and 19 controls were included in the pilot study (Table 1). With 4 months 
and 50 CFs, about 2 new cases of P. aeruginosa colonisation were expected (according to the 
outcome of [6]), but a few patients with chronic infections were included, leaving fewer naïve 
cases. 
Table 1. Demographics of included CF patients and controls 
Cystic fibrosis patients 
Median age, years (range)  11 (5-17)  
Gender, number (%) Males 23 (46) Females 27 (54) 
No. of visits by the patients in total: 87 
 
Controls 
Median age, years (range)  8 (5-17)  
Gender, number (%) Males 12  (63) Females 7 (37) 
No. of visits by the controls in total: 19 
Underlying diseases of the controls: Phacomatoses, Secondary pulmonary condition, Cough, 
Pneumonia, Pulmonary atelectasis, Stridor, Pulmonary hemoptysis, Acute bronchitis. 
 
3.2 Comparison of in vitro and in vivo SERS 
Previously, in vitro SERS measurements were made on P. aeruginosa cultures isolated from 
chronically infected paediatric CF patients in the outpatient clinic [7]. Two of these patients were 
also included in the pilot study because their isolates represented two different trends in the in vitro 
study. In the in vitro study, all first (wild type-like) isolates emitted detectable HCN. After it had 
turned into a chronic infection, subject A had a lasR mutated P. aeruginosa isolate which still 
produced HCN (Figure 2a), while subject B’s lasR mutated P. aeruginosa isolate had turned off the 
expression of HCN (Figure 2b). Therefore, it was interesting to investigate whether this trend was 
also seen in vivo. The isolates were obtained five years before, so the bacteria could possibly have 
mutated further in the meantime. As seen in the figures, no HCN was detected from their breath.  
Although chronically infected, patient A only cultured Stenotrophomonas maltophilia and no P. 
aeruginosa from sputum, whereas patient B cultured both mucoid and non-mucoid P. aeruginosa. 
 
 
Figure 2: In vitro and in vivo SERS on P. aeruginosa isolates and breath from two CF patients who 
today are chronically infected. (A) Both the wild type-like (Green) and the lasR mutated isolate 
(Red) emitted HCN, which can be seen from the intense C≡N peak at 2135 cm-1, whereas no HCN 
was detected from the patients’ breath (Blue). (B) The wild type-like isolate emitted HCN, which did 
neither the lasR mutated isolate, nor the breath sample. SERS on headspace of Luria Broth (LB) 
growth medium is included as reference (Black). There is a background peak in the SERS spectra 
close to where the cyanide peak is located. 
 
3.3 Four cases of elevated cyanide signal 
There was one new case of P. aeruginosa during the 4 months’ trial period. The subject was a 15 
year-old male with a positive sputum culture at his 3rd out of 4 visits. Figure 3 shows the SERS 
spectra from his four visits, with a more intense triple bond signal about 2130 cm-1 from visit no. 3. 
A zoom on the peak in Figure 4b shows that the peak is slightly shifted towards higher wave 
numbers, away from the background signal. After antibiotic eradication therapy between the third 
and fourth visit to the outpatient clinic, the background peak is back to where it started.  
 
Fig 3: Zoom on the triple bond peak about 2130 cm-1 from subject C’s visits. The intensity is 
increased at visit no. 3, and the peak is slightly shifted towards higher wave numbers. 
Three additional times during the trial period the SERS triple bond signal was elevated in breath 
samples,but none of these subjects had P. aeruginosa cultured from their sputum. In one of the 
cases, the Tedlar bag had been left for 60 min before the SERS substrate was taken out, and it 
turned out that this had also been the case in the 3rd visit of subject C, and it is uncertain if this had 
an effect. Two of the incidents were from children whose parents were smoking in-door at home, 
which may have been detected on the chip. 
 
DISCUSSION 
We included 50 patients with CF, of which two were known to have a chronic P. aeruginosa lung 
infection, while the rest were completely free, or P. aeruginosa naïve. The reason to include two 
patients with chronic infections was that we wanted to compare our in vitro results [7] on their first 
colonising strain and later lasR mutated isolate to in vivo breath analysis, because these cannot be 
expected to be the same [18]. Only one centre was included, to be able to follow the patients 
closely and register anything that could influence the results. 
The pilot study holds significant learnings. The HCN peak height may depend on exposure time, 
which needs to be further exploited. One approach could be to leave the device for e.g. 60 minutes 
for complete exposure to occur. In the in vitro study 15 min exposure time was applied, which was 
sufficient, and it is a learning to take to the next clinical trial. Another way to overcome the 
exposure time issue could be to condensate the breath directly onto the SERS substrate. 
Disposable devices for this are available (like the R-Tube from MESM Ltd.) [19], but it can be 
speculated whether patient compliance would be affected by having to breathe into a “chimney” 
device like this instead of into the applied “balloon-like” device which most of the children thought 
was fun. It could also be considered to make the substrate alkaline, so that a maximal amount of 
the cyanide would be expected to stay on the Au surface (according to Henry’s Law [20]). 
Patient A, whose lasR mutated P. aeruginosa isolate emitted HCN, was 8 years old; and at the 
time the strain was isolated she was 3. An explanation to why no HCN was detected in the breath 
of this patient could be that the bacteria have mutated even further since the isolate was cultured 
back in 2011. Even though this CF patient has about 25 precipitating antibodies against P. 
aeruginosa, no P. aeruginosa had been cultured from her last 3 sputum samples. Only when naso-
laryngeal suction was performed, mucoid P. aeruginosa was cultured; and it can be questioned 
whether young patients are able to expectorate properly. In the SPACE study, 21 chronically 
infected patients were included, who had not been cultured positive in their swab or sputum 
samples for the last 12 months [6], and it can be questioned what the probability would be to 
culture positive during the trial period. In future studies we will suggest to consider using a more 
sensitive reference method, such as PCR instead of just sputum culture to detect whether P. 
aeruginosa is present in the sputum sample or not. Another issue regarding bacterial culturing is 
the transportation conditions of the sputum samples which could be optimized to better secure 
survival of the microorganisms. Samples should be either cooled down or kept at 37°C and 
transported immediately to the clinical microbiologists and not wait up till 24 or 48 hours due to 
internal mail delivery.  
In the P. aeruginosa case cultured during the trial, the size of the Raman shift was not outside the 
normal shift seen across patients; however, the patient specific shift (assuming a given patient has 
an individual peak position) can be an indication. More similar cases are necessary to investigate 
or reject this hypothesis. Two of the 3 patients with false positive cyanide SERS signal were 
children whose parents were smoking in-door at home. The third patient had an immediate 
microscopy result indicating few Gram-negative rods, but when the final microbiological result 
came, it was Moraxella catarrhalis, which is a diplococcus, that can hardly be mistaken for a Gram-
negative rod. The question is, whether Gram-negative rods were present in the beginning but not 
cultured subsequently. Another observation was, that these children can be exposed to passive 
smoking as they enter the CF centre, which is located on the main floor, where people are standing 
right outside, smoking, because this is prohibited inside the hospital. 
A major drawback of the applied method is the background signal on the Au SERS substrate, 
which has also been reported elsewhere [21]. It seems to be enhanced by the warm and moist 
breath. The three cases with intense triple bond signal and negative sputum culture were followed 
for five months after study termination, and none of them cultured P. aeruginosa during the follow-
up period, suggesting the increased triple bond peak must have been false positives. Regarding 
the control subjects, these need to be selected more carefully. Some were too sick, and some 
might have had P. aeruginosa in their lungs, and their sputum was not cultured. Ideally, the study 
period should have been longer or more patients should have been included to obtain more new 
positive P. aeruginosa cultures. To ease logistics and keep it to one centre, primary ciliary 
dyskinesia (PCD) patients could have been included, too. The PCA analyses did not show strong 
trends in the pre-processed spectral data. It is important to remember that the spectral 
measurements as well as the sputum sample results carry large uncertainties due to exposure time 
differences, delayed analysis of sputum possibly leading to increased number of false negative 
results, etc., making it challenging to relate the two. 
Due to a limited number of includable patients, only one new case of P. aeruginosa was cultured 
during the trial, and the SERS cyanide signal was increased compared to the patient’s three other 
visits. There was a dependency of exposure time, and it seemed like passive smoking could also 
be detected from the children’s breath. 
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Handling and storage of cyanide compounds  
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Complete the form on the basis of your experience both of the work process/directions and of the relevant 
safety data sheets. 
DETAILS OF THE WORK PROCESS 
Firstly, remember always to reduce the handling of cyanide compounds to a minimum. 
 To work with cyanide: prepare yourself well, inform the people around you, and have all the items 
ready before taking the cyanide out of the cabinet. 
 Remember to start the emergency suction of the fume hood before cyanide powder is brought into 
the fume hood. 
 Once you have weighed the amount needed, put the powder back into the locked cabinet. 
 
To make a 1.5x10-3M dilution of KCN: 
 Remember to put on lab coat, extra length gloves and goggles. 
 Make a sign clearly stating: “TOXIC ! CYANIDE” (e.g. on a single-use towel) and place it inside the 
fume hood. 
 Turn on the scales inside the fume hood. 
 Calibrate the scales with a 50 mL measuring flask on it. 
 Turn on the emergency suction. 
 Take out the KCN from the toxic cabinet underneath the fume hood. Close the cabinet and leave it 
unlocked with the key sitting in the lock. 
 Use a single-use spatula to transfer 5 mg KCN into the measuring flask.  
 Close the lid of the KCN powder. 
 Take the flask out of the scales and put on the lid. 
 Drag the gloves off your hands, enclosing the spatula inside the gloves. Do it carefully so the spatula 
does not penetrate the gloves. Throw the gloves with spatula into the black (toxic) waste bin.  
 Wash your hands and put on a new set of gloves. 
 Lock the KCN powder into the toxic cabinet. 
 Add water to the mark of the measuring bottle, put on the lid and turn 10 times. 
 Throw the gloves into the normal bin and wash your hands before putting on a new set of gloves. 
 Turn off the emergency suction of the fume hood. 
 
Store the solution well marked in a ventilated cabinet. 
Supplementary 
 
 
S7 
 
 
CHEMICALS 
Potassium cyanide (KCN) 
Milli-Q water 
HAZARDS FROM CHEMICALS 
Potassium cyanide is an extremely toxic chemical due to its inhibition of metal-containing enzymes, leading 
to cessation of cell respiration, and death. It can enter the human body through the integument, which is 
why skin exposure to cyanide can be lethal.  
Include only the most hazardous substances – describe their hazardous properties and type of exposure– 
e.g. toxic if inhaled, carcinogenic when in contact with the skin and flammable. Give the quantities if they 
differ significantly from normal laboratory patterns. 
HAZARDS FROM THE WORK PROCESS 
Handling of potassium cyanide must be reduced to a minimum. Exposure to skin, eyes, mouth or nose can 
be lethal. 
E.g. laser, vacuum, mixing of chemicals, other equipment – e.g. glass equipment under vacuum with risk of 
explosion. 
RISK OF EXPOSURE 
Always working in the fume hood and carefully following these guidelines will reduce the risk of exposure 
to a minimum. It is also essential to work in a clean, quiet and not too crowded environment while handling 
this toxic chemical. The addition of NaOH to pH 11 will reduce the risk of inhaling toxic HCN formed from 
aqueous KCN. 
Assess the real risk in respect of the work process. The fact that the chemicals are dangerous if inhaled 
does not necessary mean that there is a risk of inhalation during this work process. Consider where in the 
work process the relevant risk resides: is it present throughout the process or only in a discrete sub-
process. 
SUBSTITUTION  
None possible. 
Describe here what attempts and deliberations have been made as to the substitution of hazardous 
chemicals or work processes. Remember that using small rather than large amounts also counts as 
substitution. 
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NECESSARY SAFETY MEASURES 
Ventilation 
Fume cupboard:   x 
Local exhaust: 
LAF bench: 
Other: 
Are the items listed necessary throughout the work process or only for 
certain procedures? Give details: While making serial dilutions of KCN it is 
essential to work in the fume hood. When using KCN(aq) solutions below 10-
7M it can done on the table. 
Chemical gloves  
(Give approx. penetration 
time if possible) 
Which: Nitrile gloves with extra length to fill the gap between the hands and 
the sleeves of the lab coat. 
Penetration time: 
Are the gloves necessary throughout the work process or only for certain 
procedures? Give details: Nitrile gloves are necessary throughout the entire 
process since the solutions will be adjusted to pH 11. 
Other personal protective 
equipment 
Overalls / protective clothing: No 
Safety goggles: YES 
Breathing equipment (state filter): No 
Special footwear (state type): Closed, firm footwear. 
Other: __________________________________________________ 
Are the items listed necessary throughout the work process or only for 
certain procedures? Give details: Always 
Other safety precautions 
 
Specific sources of heat in the event of risk of fire: No 
Other: Let the people around you know that you will be working with KCN 
before you start to reduce the risk of being interrupted unnecessarily.  
Special emergency 
equipment:  
 
Special fire-fighting equipment: No 
Any antidotes: 
Other: AMBU mask for ventilation in case of an accident. No mouth-to nose 
with person intoxicated by cyanide. 
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Special training or 
instruction: 
 
Statutory training; specify: 
Instruction in the use of particularly dangerous equipment; specify: 
Other: Before starting to work with cyanide ask someone capable of giving 
you correct instructions to come along the first time. 
WHAT TO DO IN THE EVENT OF AN ACCIDENT OR SPILLAGE 
 Get the person out in the fresh air. 
 Be careful not to get intoxicated yourself. 
 Start ventilating the person using the AMBU mask. 
 Call 112 and ask for an ambulance. Let them know it is cyanide poisoning 
Detail steps to be taken in the event of relevant accidents, the clearing up and disposal of spillages, the 
procedure for information on accidents etc. 
WASTE 
There is a certain container only for cyanide waste with base placed in the right toxic cupboard under the 
fume hood. Cyanide waste must be handled with care, of course inside the fume hood, taking all the 
precautions mentioned above. 
Instructions on labelling waste bins – which waste group, UN no., etc. – poss. brief details re subsequent 
delivery of waste to chemical waste collection point (name). 
PREGNANT AND BREASTFEEDING WOMEN 
Is the work process/area safe for pregnant or breastfeeding women? 
Yes: __________    reasons: _____________________________________ 
No: _________   reasons: _____________________________________ 
PROPOSAL(S) FOR IMPROVING SAFETY: 
If people working in the lab would clean up after themselves the better space would make working with 
cyanide safer. 
This item is seen as input into a general Workplace Assessment for the institute/department. 
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Procedure: 
 Fill Milli-Q water into the 1L measuring flask, leaving at least 100 mL unfilled. 
 Turn on the Emergency suction of the fume hood. 
 Weigh 5 mg of KCN directly in the 100 mL measuring flask and fill up with Milli-Q water. 
 Empty the 100 mL measuring flask into the 1L measuring flask and fill up with Milli-Q water. 
 Place the large Petri dish in the fume hood and a “TOXIC! CYANIDE” sign with it. 
 Place SERS substrates on top of the backside of the small Petri dish or lid. 
 Fill 20 mL of the KCN solution into a measuring cylinder, and from there into the large Petri dish. 
 The lid is put on the Petri dish which is left for 2 minutes for equilibrium state to be met. 
 Place the small Petri dish with the SERS substrates inside the large Petri dish. 
 Put on the lid immediately, and set the timer to minutes’ exposure time. 
 When finished, take out the small Petri dish from the large one and leave to dry in the fume hood. 
 Place the SERS substrates in the holder for transportation to the Raman microscope. 
 Add drops of 0.5 M potassium permanganate to the glassware containing KNC solution until red. 
 Now the solution can be emptied into the sink in the back of the fume hood. 
 Rinse all glassware with Milli-Q water over the sink in the back of the fume hood. 
 Turn off the Emergency suction. 
 Wash the glassware in the large sink and rinse with Milli-Q water before drying. 
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1) Which organisms are involved? 
Pseudomonas aeruginosa PAO1 and clinical isolates of PA. 
2) Facts about the organism 
If working with other organisms than those mentioned above check 
http://arbejdstilsynet.dk/da/regler/bekendtgorelser/b/biologiske-agenser-57/bilag-8-klassifikation-af-
biologiske-age.aspx to determine biosafety class of the organism(s) you are working with 
Refer to http://arbejdsmiljo.ku.dk/bioarbmiljo/biologiskeagenser/ for information about biological 
APV. 
 
Pseudomonas aeruginosa 
All work with Pseudomonas aeruginosa must be carried out in a Biological Class 2 lab. 
Pseudomonas organisms are flagellated, rod-shaped bacteria that can cause disease in humans and 
animals. It is a Gram-negative, aerobic or facultative anaerobic bacterium in which case it can use nitrate as 
electron acceptor. Most human illness is caused by one species, called Pseudomonas aeruginosa, and 
mainly in immuno-suppressed humans and patients with (burn) wounds or cystic fibrosis. In healthy 
individuals colonization or infection is mainly due to hot tubs or poorly maintained pools. These bacteria are 
wide-spread in nature, including water and soil, and on medical equipment (like catheters). They can even 
grow at 42°C and in diesel and jet fuel (Wikipedia). Due to a high rate of resistance and to its ability to form 
biofilms, Pseudomonas aeruginosa can be tricky to eradicate. If a Pseudomonas aeruginosa infection is not 
treated successfully, sepsis and death can occur. 
Source: http://www.cdc.gov/hai/organisms/pseudomonas.html 
3) Working conditions 
Detailed instructions can be found in “Instructions for working, disinfecting and dealing with accidents in  
gene technology Class I laboratories”.  
Most importantly: Work with a high standard of hygiene. 
Receipt of organisms: 
When we receive a foreign organism, most of them are either freeze-dried, on agar plates or in small tubes, 
where they grow on solid media.  
If the organism is freeze-dried, dissolve it in broth and cultivate it. Afterwards inoculate it in either broth or on 
solid media. 
Freezing of cultures: 
Prepare a mixture of the bacterial / yeast culture and glycerol. 1 ml mixture will be frozen in small tubes at  
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-80 ° C. 
Propagation: 
A freeze culture or a scrape from a freeze culture is grown in broth or agar plates. We scrape with a plastic 
spreader. Incubate the culture. 
Growth experiments / CFU: 
Growth experiments can be done in many ways, but the main features is that the organism inoculates in 
broth to a certain concentration. After that, the growth is followed by either measuring the OD or CFU 
calculations. The usual amount is typical 100 µl - 1 ml for each sampling. Work with care and avoid formation 
of aerosols by gentle pipitting, only vortexing/mixing closed tubes/containers etc. 
If you transport organisms between workstations, they should be kept in closed containers, such as bottles 
or tubes with lids.  
If you perform operations not described here, you should fill out the "table of the workflow" and "flow 
diagram" (see Annex). 
All work with these organisms will be performed in a Class 1 GMO laboratory (Biological Class 2 lab). 
5) Quantity  
Normally we work with volumes from 100 µl to 2 liters of growth culture. 
6) Harmful aspects  
The mentioned organisms can cause illness if you either get them in the mouth or mucous membranes or if 
you stick yourself with an infected needle. It’s important to avoid formation of aerosols, because there is a 
risk of infection. 
 7) Pregnant and lactating 
No particular risk.  
8) Cystic Fibrosis 
Areas where work with P.aeruginosa is performed must be indicated with appropriate signs and separated 
from other laboratories where CF patients work. 
9) Safety – (how do you avoid being exposed) 
(Refer to the instruction: “Instructions for working, disinfecting and dealing with accidents in  
gene technology Class I laboratories”). 
Protective clothing such as fastened lab coats must be worn whilst working in classified areas. Protective 
clothing should be taken off and stored in classified laboratories, whenever leaving the room, unless material 
is being transported between two different classified areas. 
To avoid contamination of the water in water baths, a chlorine tablet may be added. 
When incubation of cultures is taken place on shakers, it is important not to set too fast rotation to avoid 
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spillage and formation of aerosols. 
It is forbidden to eat, drink, smoke and to store food in the laboratories. 
Infected liquids (cultures, washing buffer etc) must not be poured down the sink. 
Pipetting by mouth is strongly forbidden. 
Staff must wash their hands when temporarily leaving the lab (e.g. for coffee break, lunch or the toilet) and 
also at the end of the work day.  
Pipettes should be mechanical in nature.  
Care should be taken to minimize formation of aerosols.  For example, centrifugation should be in closed 
containers, and heated inoculation loops should not be used unless they are cooled first. It is also a good 
idea not to use the Bunsen burner, especially when you work with Campylobacter . 
Hypodermic needles and sharp objects should be used with caution. 
Pouring of cultures into centrifuge tubes and decanting of supernatant after centrifugation may only take 
place in classified areas. 
 
The following disinfectants can be used: 
Chloramine: 1 chloramine tablet per 5 l distilled water 
Sodium hypochlorite: 10 ml sodium hypochlorite (15%) per 5 l distilled water 
70 % ethanol: 700 ml. 96 % ethanol adjusted to 960 ml with distilled water 
Use granules for absorption of spillages. 
 
Use yellow clinical waste bags for disposal of infected waste. These must be closed properly.  
 
Bacterial cultures, etc. 
 Liquid cultures:  These should be inactivated with chloramine (1 tablet per l) or chlorine (10 ml 
per l) for at least 30 min before disposing down the lab sink; alternatively, they 
may be autoclaved in sealed containers. 
 Petri dishes (plastic): These should be disposed of in the yellow bag. 
 Petri dishes (glass):         These should be collected in autoclave bags, which should then be securely 
closed and decontaminated by autoclaving. 
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10) Accidents - (what do you do) 
(Refer to the instruction: “Instructions for working, disinfecting and dealing with accidents in  
gene technology Class I laboratories”). 
 
Spilled cultures should be absorbed as much as possible using granulates/cloths/paper towels, and the area 
should then be disinfected. Absorbents are discarded in the yellow bag. 
 
If the spillage occurred down the drain or sink, then the spilled culture should be inactivated using the 
appropriate disinfectant (usually hypochlorite, but this should not be used in connection with acids). 
The area around the accident should be disinfected. 
 
If you work with faeces always wear gloves and perform your work in a fume hood, because you don’t know 
what kind of organism it contains. When your work with faeces is done decontaminate all your equipment 
with 70 % ethanol. 
 
If you are unlucky enough to stick yourself with a needle that is contaminated with one of the organisms 
mentioned above you should contact a doctor. This also applies if you get infected material in your mouth. 
 
Accidents should be reported to the project manager and to the employees’ safety officer. They should be 
informed of which culture was involved, and the quantity involved, as well as the time of the accident, and 
the measures taken to counteract the accident. 
 
The project manager and the employees’ safety officer should note details of accidents in the laboratory log 
book and, if necessary, report them to the authorities. Introduce necessary precautionary measures to 
prevent repetition of that type of accident. 
 
11) Signature and Date 
 
 
Dennis Sandris Nielsen and Marina Bjørklund 08/05-2012 
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SOP 1: Cleaning of external equipment. 
 
 
 
In room T-474. 
External equipment consists of: 
 2 pumps incl. adapters and extra tools: To be wiped with 70% ethanol. 
 1 vacuum box: To be wiped (in- and outside) with 70% ethanol. 
 1 Teflon bag incl. Petri dish with SERS chip inside: Teflon bag is sterilized for 30 min in a 
120°C oven. Closing devices (stick and clamp) are rinsed in 70% ethanol. 
 Rubber plugs: To be rinsed in 70% ethanol. 
 Silicone tubes and connectors: To be rinsed in 15% sodium hypochlorite. 
 ATD tube: To be wiped with 70% ethanol. Caps for ATD tubes are rinsed in 70% ethanol.  
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SOP 2: Bring external equipment into the lab. 
 
All external equipment (see SOP 1) is brought into the lab on a trolley. Small items such as tubes and 
connectors are in sealed plastic boxes. If necessary, wipe again with 70% ethanol. E.g. these laminated 
SOPs. 
Before entering a Class 2 lab, put on a lab coat and change it when inside the lab and put on bags to cover 
the shoes. Make sure the hair is uptight and wear goggles and nitrile gloves.  
When leaving the lab, wash the hands and put dirty lab coats in autoclave bags, marked “GMO Kl.2”, which 
is disinfected on the outside before being sent to the autoclave. Used gloves and shoe bags are thrown into 
a steel bucket which is then disinfected on the outside with 70% ethanol prior to being brought to the 
autoclave. At the autoclave, autoclave tape is being put onto the items. 
Prior to leaving the corridor use the disinfectant gel on the hands. 
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SOP 3: Set up in- and external equipment. 
 
 
In room T-474: 
1. A water bath is filled with demineralized water till 1 cm above the bottom of the flasks, and set to 37°C, 
low shaking. 
2. A charged pump is connected to the outlet of the vacuum box via a silicone tube. 
3. The vacuum chamber is purged for 20 min. 
4. The other charged pump is through a silicone tube connected via a rubber plug and an ATD tube to an 
empty Erlenmeyer flask (for reference GC-MS). Before this there is a T piece whose other end is 
connected to another silicone tube which goes on another ATD tube sitting in a rubber plug for the 
bacterial emission (sample). 
5. A SERS chip is mounted in a small Petri dish inside a PTFE (Teflon) bag which is then closed and tightly 
connected to the inlet of the vacuum box. 
6. After each pump a tube is connected which ends in a bath of 15% sodium hypochlorite to avoid 
eventual aerosol formation. Each pump is also connected to a net adapter for continued function 
overnight. 
7. Two suspensions of PAO1 are prepared. Refer to SOP 5. 
1 
2,6 
3 4,6 
5 
7 
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SOP 4: Check the system for leakage. 
 
As there can be problems with this junction, prior to exposure it should be ensured that it is tight. 
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FORSØGETS FORMÅL 
Baggrund 
Patienter med cystisk fibrose (CF) danner tykt, sejt slim i lungerne, som let koloniseres med den 
mikroaerofile bakterie Pseudomonas aeruginosa. Hvis der ikke sættes tilstrækkeligt tidligt ind med 
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antibiotika, kan denne lungeinfektion blive kronisk, med yderligere nedsættelse af livskvalitet og –længde . 
Derfor skal patienterne hver måned afgive en prøve med ekspektorat (opspyt), som kan blive analyseret for 
tilstedeværelsen af Pseudomonas aeruginosa. Børn yngre end syvårsalderen kan ikke uprovokeret lave et 
ekspektorat. De må fastholdes og få en slange ført gennem næsen og ned i svælget til fremkaldelse af en 
hosterefleks, så prøven kan suges op4. Denne skal efterfølgende undersøges og dyrkes i 2-3 dage, før 
resultatet foreligger og evt. behandling kan sættes ind5. 
Pseudomonas aeruginosa (PA) er en af de få bakterier, der producerer hydrogencyanid6. Hydrogencyanid er 
en giftig gas, som antages at bibringe bakterien en fordel i den økologiske niche, den tilhører, og som 
velvilligt binder til metaller. Hvis hydrogencyanid kunne detekteres i udåndingsluften hos patienter med 
cystisk fibrose inficeret med PA i luftvejene, ville der kunne spares tid og pinsler for disse patienter og deres 
forældre, og rettidig behandling ville kunne iværksættes for at undgå, at infektionen bliver kronisk. 
Der er på DTU udviklet et SERS (Surface-Enhanced Raman Scattering) substrat, der kan forstærke Raman-
signalet op til 1.000.000 gange7. Raman er en spektroskopisk metode, der bl.a. bruges til at måle 
sporkoncentrationer af uønskede stoffer i fødevarer m.v.8  Substratets overflade er dækket med et lag af 
guld, som hjælper til at forstærke signalet. Det er vist, at cyanid let binder sig til denne guldoverflade og, at 
det kan detekteres ved hjælp af det nævnte substrat9. Endvidere har forsøg over kliniske PA isolater givet 
meget lovende resultater (Data endnu ikke publiseret). 
Cyanid indeholder en trippelbinding mellem C- og N-atomerne, hvilket giver anledning til et signal i 
området 2000-2200cm-1, hvor der kun ses trippelbindinger og såkaldt kumulerede dobbeltbindinger10 (med 
2 dobbeltbindinger til samme atom). 
Formål 
Formålet med dette forsøg er at teste, om hydrogencyanid kan detekteres i udåndingsluften hos børn med 
cystisk fibrose, der endnu ikke har en kronisk PA lungeinfektion og sammenligne med udåndingsluften fra 
lunge-raske, frivillige forsøgspersoner. Der henvises til protokol J.nr.: H-3-2012-059, som blev godkendt i 
2012 men ikke gennemført, fordi substratet dengang ikke ansås at være klart.  
FORSØGETS METODE 
Intermitterende koloniserede CF-patienter i alderen 5-18 år, som behandles og går til regelmæssig klinisk 
kontrol i Dansk BørneLungeCenter og CF Center København afsnit 5003 på Rigshospitalet tilbydes at deltage 
i forsøget. Desuden tilbydes alders-svarende lunge-raske personer at deltage som kontroller. Prøver af 
udåndingsluften opsamles fra alle deltagerne, mens det kun er CF patienterne der leverer sputum til 
mikrobiologisk dyrkning, som en del af den kliniske kontrol, idet raske ikke anses for at have PA. Efter 
                                                          
4
http://www.rigshospitalet.dk/menu/AFDELINGER/Juliane+Marie+Centret/Klinikker/BoerneUngeKlinikken/Dansk_Boe
rnelungecenter/Cystisk+Fibrose-center+København/Behandling_og_kontrol.htm#larynxsug 
5
 http://www.ssi.dk/Diagnostik/DiagnostiskHaandbog/100-199/101.aspx 
6
 Enderby, et al. (2009): Pediatr Pulmonol, 44, 142-147 
7
 Schmidt, et al. (2012): Adv Mat, 24, 10, OP11-18  
8
 Thygesen et al. (2004): Appl Spec, 58, II, 212-217 
9
 Lauridsen, et al. (2015): Sensing and Biosensing Research, 5, 84-89 
10
 Williams & Fleming: Spectroscopic Methods in Organic Chemistry, 5
th
 Ed., The McGraw-Hill Companies, UK, 1995, 
pp. 35, 44f 
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databehandling vil resultaterne fra patienter og kontroller blive sammenlignet. Det forventes, at deltagere 
med P.aeruginosa vil have et kraftigere Raman-signal i det nævnte område end deltagere uden 
P.aeruginosa. Herudover kan raske personer også have lave cyanidkoncentrationer i udåndingsluften11, 
hvorfor det er relevant at inddrage kontroller. Hydrogencyanid findes tillige i mundhulen efter kaffedrikning 
samt i tobaksrøg12, hvorfor kaffedrikning, rygning og passiv rygning i hjemmet i dette studie er 
eksklusionskriterier. 
Før udåndingstesten 
Forsøgsdeltagerne udfylder et kortfattet spørgeskema vedrørende alder, køn, infektionsstatus, 
kaffedrikning, rygning samt passiv rygning. 
Selve testen 
Udåndingstesten gennemføres blandt CF-patienter samt lunge-raske frivillige på Rigshospitalet. 
Udåndingsluften opsamles dels fra lungerne, hvor børnene selv puster i en teflonpose; og dels fra næsen, 
hvor der trækkes ca. 10 mL luft gennem en filter ”oliven-probe”, der sættes hen til næseboret, og som 
forbindes til en engangssprøjte. I teflonposen og på sprøjtens stempel er der anbragt en nanochip (SERS 
substratet), der kan opfange og forstærke cyanid-signalet for disse bakterier. Der skal ikke være nogen form 
for fysisk kontakt mellem forsøgspersonen og substratet. 
Efter udåndingstesten 
Samme dag som udåndingstesten bringes SERS-substratet til Københavns Universitet, Science fakultetet, 
hvor der findes et Raman spektroskop med en 1064nm laser, der er særligt velegnet til dette substrat. 
Signalet mellem 2000-2200cm-1 inspiceres for tilstedeværelse af en top, og dennes størrelse (Højde/areal) 
beregnes. Substraterne kasseres umiddelbart efter endt måling, hvorved der ikke oprettes nogen form for 
forskningsbiobank. 
Mål 
Det primære mål er, at bestemme om det er muligt at differentiere mellem koloniserede og ikke 
bakterieinficerede CF patienter ved hjælp af SERS-analyse af udåndingsluft opsamlet på denne nanochip. 
Det sekundære mål er at opnå erfaring med håndtering af instrumentet i forbindelse med målinger på 
patienter og den videre udvikling. 
STATISTISKE OVERVEJELSER 
Antallet af forsøgsdeltagere er bestemt ud fra, hvad der synes muligt og rimeligt på det aktuelle 
udviklingsstadium. Idet der er tale om et eksplorativt studie til bestemmelse af metodens sensitivitet og 
specificitet, forventes dette at kunne danne basis for powerberegning til senere studier i børnegruppen.  
                                                          
11
 Schmidt, et al. (2011): J Breath Res, 5, 046004, 1-10 
12
 Roemer, et al. (2004): Toxicology, 195, 31-52 
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FORSØGSPERSONERNE, HERUNDER INKLUSIONS- OG 
EKSKLUSIONSKRITERIER 
Antal og fordeling 
70 deltagere, heraf 50 CF-patienter uden kronisk P.aeruginosa lungeinfektion samt 20 lunge-raske, frivillige. 
Så vidt muligt 50% af hvert køn. Alder 5-18 år. 
Inklusionskriterier 
 5-18 årige CF patienter, som følges i Dansk BørneLunge Center og CF Center København på 
Rigshospitalet 
 Intermitterende PA koloniseret 
 5-18 årige lunge-raske kontroller 
Eksklusionskriterier 
 Øvrige strukturelle lungelidelser som f.eks. astma el. PCD 
 Kronisk PA inficerede CF patienter 
 Antistoffer mod PA (≥2,39 Elisa-enheder) 
 Antibiotisk behandling mod PA indenfor de seneste 6 måneder 
 Ikke i stand til at puste korrekt 
 Graviditet eller amning 
 Kaffedrikning samme dag som pusteprøve 
 Rygning eller massiv passiv rygning (rygning inden døre i hjemmet) 
RISICI, BIVIRKNINGER OG ULEMPER 
Der forventes ingen risici, bivirkninger eller ulemper for deltagere i forsøget. Det sikres, at deltagerne ikke 
kan komme i fysisk kontakt med SERS-substratet, der let kan beskadiges og som ikke bør berøres. Det er 
kun Investigator, som håndterer substratet, og altid iført nitril-handsker og med pincet. Opsamlingen af 
prøver af udåndingsluften fra CF patienter og kontroller er en non-invasiv procedure, som kan udføres uden 
at påføre nogen skade eller ubehag. Oplevelsen af ubehag under opsamlingen af udåndingsluft resulterer i 
omgående ophør af proceduren. Deltageren, forældre eller deltagerens værge kan til ethvert tidspunkt 
under forsøget annullere det informerede samtykke. 
RESPEKTEN FOR FORSØGSPERSONERNES FYSISKE OG MENTALE 
INTEGRITET SAMT PRIVATLIVETS FRED 
For at sikre, at deltagerne lever op til in- og eksklusionskriterierne (jf. pkt. 4.2 og 4.3), kan det blive 
nødvendigt at indhente de pågældende oplysninger fra deltagernes journal. Data vil blive registreret på PC 
under overholdelse af lov om behandling af personoplysninger. Projektet anmeldes til den kontaktperson i 
Region Hovedstaden, der har kontakt til Datatilsynet. 
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ØKONOMISKE FORHOLD 
DTU Nanotech, afdeling for Mikro- og Nanoteknologi, har ansvaret for alle udgifter i forbindelse med 
forsøget. Rikke Kragh Lauridsens PhD studie er finansieret af Det Frie Forskningsråds Sapere Aude bevilling 
”NAPLAS”, hvorunder udgifter afholdes løbende af et budget på 2 mio. kr. Novo Nordisk fonden har 
bevilget Helle Krogh Johansens forskningsstipendium. Ingen af de projektansvarlige har nogen økonomisk 
interesse i projektet. Det er de projektansvarlige, som har taget initiativet til projektet. 
VEDERLAG ELLER ANDRE YDELSER 
Der ydes intet vederlag eller kompensation for deltagelse. Forsøgets varighed forventes ikke at overstige 15 
minutter per deltager, alt inklusive. 
HVERVNING SAMT FORLØB FOR INDHENTELSE AF INFORMERET 
SAMTYKKE 
For patienter: Der gives en mundtlig information af overlægerne Kim G. Nielsen, Marianne Skov, Frederik 
Buchvald eller Tanja Pressler når patienterne er på afdelingen til deres rutinemæssige kontrol. Disse læger 
kender patienterne i forvejen, og det formodes, at de har de pædagogiske forudsætninger for at formidle til 
børn og, at samtalen i forbindelse med dette besøg kan foregå uforstyrret. Det oplyses, at de har ret til at 
have en bisidder ved samtalen, hvis de skønner det nødvendigt. Den skriftlige deltagerinformation 
udleveres og bringes med hjem, hvor de kan gennemlæse den i ro og mag. Hvis der er behov for yderligere 
oplysninger, kan de kontakte en af de forsøgsansvarlige, før de beslutter sig, om de ønsker at deltage. Hvis 
de gerne vil, kommer de til test i forbindelse med deres næste kontrol på afdelingen, som foregår en 
måned senere, hvor der vil være et særligt rum indrettet til testen, og hvor den nærmere instruktion 
foregår.  
Særligt vedr. de 15-17-årige: Der indhentes informeret skriftligt samtykke hos samtlige forsøgsdeltagere 
eller disses forældre/værger. Idet testen betragtes som sikker og non-invasiv, forventes det at 15-17-årige 
selv kan afgive informeret samtykke, hvortil der hermed anmodes om dispensation jf. Komitélovens § 9, 
stk. 1. Der er udarbejdet skriftlig information til unge mellem 15 og 17 år, som vil blive udleveret. 
Projektet kan alene gennemføres ved at inddrage 5-18-årige CF-patienter, og projektet har direkte udsigt til 
at kunne overføre meget store fordele til den patientgruppe, og indebærer minimale risici og gener for 
deltagerne.  
 
TILGÆNGELIGHEDEN AF OPLYSNINGER 
Deltagerne kan altid kontakte en af de projektansvarlige for flere oplysninger: 
 
 Klinisk ansvarlig Investigator                               
Kim G Nielsen 
Overlæge, dr. med. 
Rikke Kragh Lauridsen 
PhD studerende 
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Leder, 
Dansk BørneLunge Center  
Pædiatrisk Klinik I 
afsnit 5003  
Rigshospitalet 
Blegdamsvej 9 
2100 København Ø 
Tlf.nr.: +45 3545 1353 
Fax: +45 3545 6717 
Email: kgn@dadlnet.dk 
DTU Nanotech  
Ørsteds Plads 
Bygning 345B 
2800 Lyngby 
Tlf.nr.: 4525 6397 
Fax:  4588 7762 
Email: rkla@nanotech.dtu.dk  
 
 
OFFENTLIGGØRELSE AF FORSØGSRESULTATER 
Positive, såvelsom negative og inkonklusive resultater af dette studie vil blive offentliggjort i et 
videnskabeligt tidsskrift. 
VIDENSKABSETISK REDEGØRELSE 
Der er ikke forbundet ubehag eller skader med opsamlingen af prøver fra udåndingsluften. I studiet 
undersøges en nanochip, som muligvis kan forbedre diagnostikken af luftvejsinfektioner hos CF patienter, 
hvorved antibiotisk terapi kan startes tidligere, hvilket har en positiv effekt på bevarelsen af 
lungefunktionen. Dermed kan metoden være med til at øge livskvaliteten og forlænge livet for patienter 
med CF. 
 
Hvis det skulle vise sig, at den nye metode ikke er tilstrækkeligt følsom, standses afprøvningen efter 5 falske 
negativer. Det vil sige, at hvis der i 5 tilfælde ikke detekteres cyanid på nanochippen, hvor den samtidige 
mikrobiologiske dyrkning af sputum viser sig positiv for PA, afbrydes studiet. Der vil til den tid være gjort 
vigtige erfaringer med patient-device interaktioner samt håndtering af prøverne, som ikke ville kunne 
opnås på anden vis. 
OPLYSNING OM ERSTATNINGS- ELLER GODTGØRELSESORDNINGER 
Patienter er i forsøgsmæssig sammenhæng dækket af Rigshospitalets forsikring.  
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Deltagerinformation til forældre eller værger til lunge-syge børn om deltagelse i det 
videnskabelige forsøg: 
 
Påvisning af Pseudomonas aeruginosa hos patienter med cystisk fibrose ved hjælp af SERS måling 
af hydrogencyanid i udåndingsluften 
 
 
Vi vil spørge jer om tilladelse til, at jeres barn deltager i et videnskabeligt forsøg. Nedenfor følger 
en beskrivelse af forsøget og de undersøgelser, der indgår i det.  
Før I beslutter, om I vil lade jeres barn deltage i forsøget, skal I fuldt ud forstå, hvad forsøget går ud 
på, og hvorfor vi gennemfører forsøget. Vi vil derfor bede jer om at læse denne deltagerinformation 
grundigt. 
I vil blive inviteret til en samtale om forsøget, hvor denne deltagerinformation vil blive uddybet, og 
hvor I kan stille de spørgsmål, I har om forsøget. I er velkomne til at tage et familiemedlem, en ven 
eller en bekendt med til samtalen. 
Hvis I beslutter jer for at jeres barn skal deltage i forsøget, vil vi bede jer om at underskrive en 
samtykkeerklæring. Husk, at I har ret til betænkningstid, før I beslutter, om I vil underskrive 
samtykkeerklæringen.  
Deltagelse i forsøget er frivilligt og I kan når som helst og uden at give en grund trække jeres 
samtykke tilbage. Tilbagetrækning af samtykket vil ikke have nogen konsekvenser for jeres barns 
videre behandling. 
 
Baggrund for forsøget 
Vi vil undersøge en metode, som gør det muligt at diagnosticere luftvejsinfektioner med 
Pseudomonas aeruginosa (PA) hurtigere og nemmere end med de nuværende metoder. I metoden 
indgår et apparat - en nanochip - som i udåndingsluften kan registrere den kemiske forbindelse 
hydrogen cyanid, som dannes af PA. Denne tilgang til diagnosticering af nedre luftvejsinfektioner 
har potentiale til at gavne flere patientgrupper, men da patienter med lungesygdomme som cystisk 
fibrose (CF) relativt ofte kommer til klinisk kontrol og hyppigt lider af nedre PA luftvejsinfektioner, 
er det indlysende at afprøve metoden på CF patienter.  
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Formål med forsøget 
Forsøgets formål er at undersøge den diagnostiske nøjagtighed af en nanochip i diagnosticeringen af 
nedre samt øvre luftvejsinfektioner. Det vil sige, at vi vil undersøge, hvor god denne nye metode er 
til at opspore luftvejsinfektioner ift. de kendte metoder. Hermed får vi kendskab til metodens 
anvendelighed i klinisk sammenhæng fx på hospitalet eller derhjemme. På længere sigt er formålet 
at skaffe en hurtigere og nemmere metode til opsporing af luftvejsinfektioner, som forhåbentligt 
muliggør bedre behandling af luftvejsinfektioner i fremtiden. 
 
Plan for forsøget 
Forsøget bliver gennemført fra 01/01/2016 til 30/04/2016. Omkring 50 CF patienter og 20 lunge-
raske kontroller bliver tilbudt deltagelse i forsøget. Jeres barn og de øvrige deltagere i forsøget skal 
undersøges, når de alligevel kommer til kontrol på Rigshospitalet, hvor de vil blive bedt om at 
afgive en puste-prøve og får suget en luftprøve fra næsen. Udåndingsluften analyseres, og ingen 
prøve opbevares efter at rå-data fra analyserne er gemt på computeren. Efter rutinemæssige kontrol 
hentes oplysninger om mikrobiologiske dyrkningssvar
13
 og sygdomsstatus fra deltagende CF- 
patienters journaler.  
Forsøget foregår på Rigshospitalet afsnit 5003. Deltagelse i forsøget vil vare ca. 15 minutter, hvor 
der er afsat tid til puste-prøver og udfyldning af et kortfattet spørgeskema om alder, køn, 
helbredsstatus, brug af kaffe og rygning samt passiv rygning. 
Det er vigtigt at deltagerne faster 2 timer før afgivelse af pusteprøverne. Dvs. jeres barn må ikke 
indtage kaffe, fast føde eller mælkeprodukter 2 timer før pusteprøverne, men de må gerne drikke 
rent vand.  
 
Før gennemførelsen af forsøget sikres det, at den informerede samtykkeerklæring er underskrevet 
og, at I samt jeres barn er informeret om hvad der skal ske. Selve forsøget foregår i følgende trin: 
 
1. Barnet puster i en pose, hvori der er anbragt en nanochip. 
2. Barnet puster i en ”party-fløjte”, imens der opsamles 10mL luft i en engangssprøjte fra det 
ene næsebor gennem en ”oliven-probe”, der føres hen til næseboret. På sprøjtens stempel er 
der anbragt en nanochip til detektion af gasser fra luften. 
3. Herefter skal jeres barn gennemgå den almindelige kliniske undersøgelse, herunder 
afgivelse af ekspektorat, der bruges til at sammenligne med resultater fra nanochips’ne.  
4. De 2 nanochips transporteres til Københavns Universitet, hvor de måles og undersøges for 
en særlig top (cyanid), der stammer fra PA. 
 
 
 
 
                                                          
13 Laboratorie-undersøgelser af opspyt fra lungerne.  
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Nytte ved forsøget 
Det er meget eftertragtet at kunne udføre og tilbyde denne metode til diagnosticering af PA 
infektioner, da det er en hurtigere, mindre invasiv og mere følsom metode end de gængse. Derfor er 
der både en økonomisk såvel som en klinisk gevinst i beherskelse af denne metode til 
diagnosticering af PA luftvejsinfektioner. Hvis resultaterne af denne kliniske afprøvning er lovende, 
så har patienterne en metode, som kan gøre de kliniske kontroller lettere og muliggør en hurtigere 
og mere sensitiv diagnostisk af PA luftvejsinfektioner. Hurtigere diagnostik medfører hurtigere 
behandling, som er med til at forhindre udviklingen af kroniske infektioner. Dette kan på længere 
sigt være med til at bevare lungefunktionen og dermed forbedre livskvaliteten samt øge den 
forventede levetid for CF patienter. 
Ubehag, risici og komplikationer 
Der forventes ingen komplikationer ved deltagelse i forsøget. Det eneste jeres barn kommer i 
kontakt med er mundstykket, hvor der skal åndes igennem, og en ”vat-tut”, der sættes hen til 
næseboret.  
Der kan være risici ved forsøget, som vi endnu ikke kender. Derfor opfodrer vi jer til at fortælle os, 
hvis der opstår problemer med jeres barns helbred, mens forsøget står på. Hvis vi opdager 
bivirkninger, som vi ikke allerede har informeret om, så vil I naturligvis blive orienteret med det 
samme, og I vil skulle tage stilling til, om jeres barn skal fortsætte i forsøget. 
 
Udelukkelse fra og afbrydelse af forsøg 
Hvis der skulle opstå ubehag under opsamlingen af udåndingsluft, så afbrydes forsøget omgående. I 
dette tilfælde vil vi påminde jer om retten til at trække jeres samtykke tilbage på et hvert tidspunkt 
uden følger. 
 
Videregivelse og behandling af oplysninger 
Jeres samtykke omfatter også adgang til nødvendige oplysninger om jeres barns helbredsforhold, 
for at sikre overholdelse af protokollens in- og eksklusionskriterier.  
 
Oplysninger om økonomiske forhold 
Forsøgsansvarlige og de tilknyttede videnskabelige medlemmer har taget initiativ til forsøget. Det 
Frie Forskningsråd støtter Sapere Aude projektet “NAPLAS”, som Rikke Kragh Lauridsens PhD 
projekt er en del af. Novo Nordisk fonden har bevilget Helle Krogh Johansens 
forskningsstipendium. 
 
Adgang til forsøgsresultater 
Negative, positive såvel som foreløbige resultater fra forsøget vil blive offentliggjort. Forsøget 
forventes at være afsluttet i juli 2016, hvor resultaterne af forsøget vil blive offentliggjort i en 
videnskabelig artikel. 
 
Vi håber, at I med denne information har fået tilstrækkeligt indblik i, hvad det vil sige at deltage i 
forsøget, og at I føler jer rustet til at tage beslutningen om jeres barns eventuelle deltagelse. Vi 
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beder jer også om at læse det vedlagte materiale ”Forsøgspersoners rettigheder i et 
sundhedsvidenskabeligt forskningsprojekt” udfærdiget af Den Nationale Videnskabsetiske Komité. 
Hvis I vil vide mere om forsøget, er I meget velkomne til at kontakte overlæge, dr. med. Kim 
Gjerum Nielsen, Rigshospitalet, afsnit 5003, kgn@dadlnet.dk, 35 45 50 06. Rigshospitalets adresse 
er: Blegdamsvej 9, 2100 København Ø. 
Med venlig hilsen 
Overlæge Kim Gjerum Nielsen, overlæge Helle Krogh Johansen og PhD studerende Rikke Kragh 
Lauridsen. 
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Informeret samtykke vedrørende deltagelse i det sundhedsvidenskabelige forskningsprojekt: 
 
Påvisning af Pseudomonas aeruginosa hos patienter med cystisk fibrose ved hjælp af SERS måling 
af hydrogencyanid i udåndingsluften 
 
 
Erklæring fra forsøgspersonen: 
Jeg har fået skriftlig og mundtlig information, og jeg ved nok om formål, metode, fordele og 
bivirkninger til at give mit samtykke. 
Jeg ved, at det er frivilligt at deltage, og at jeg altid kan trække mit samtykke tilbage uden, at jeg 
mister mine nuværende eller fremtidige rettigheder til behandling. Jeg har endvidere modtaget og er 
blevet opfordret til at læse ”Før du beslutter dig” og ”Forsøgspersoners rettigheder i et 
sundhedsvidenskabeligt forskningsprojekt” udfærdiget af Den Centrale Videnskabsetiske Komité. 
Jeg giver mit samtykke til at deltage i forskningsprojektet og har fået en kopi af dette samtykkeark 
til eget brug. 
 
 
Forsøgspersonens navn:  
 
____________________________________________________________. 
 
 
Dato: ___________ Underskrift:  
 
_____________________________________________________ 
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Ønsker du at blive informeret om forskningsprojektets resultater samt eventuelle konsekvenser for 
dig?: 
 
Ja __________ (sæt X)   Nej __________ (sæt X) 
 
Hvis ja, så udfyld venligst en af de følgende: 
 
Telefonnummer: ____________________________ 
 
E-mail adresse: _____________________________ 
 
 
 
Erklæring fra den, der afgiver information: 
Jeg erklærer, at forsøgspersonen har modtaget mundtlig og skriftlig information om forsøget. Efter 
min overbevisning er der givet tilstrækkelig information til, at der kan træffes beslutning om 
deltagelse i forsøget. Indehaveren af forældremyndigheden til unge deltagere mellem 15-17 år har 
modtaget den samme information som den unge og er inddraget i den unges stillingtagen til 
deltagelse i projektet. 
 
 
Navn på den, der har afgivet information:  
 
______________________________________________ 
 
Dato: ___________ Underskrift:  
 
_____________________________________________________ 
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Spørgeskema til deltagere i forsøget: 
 
Påvisning af Pseudomonas aeruginosa hos patienter med cystisk fibrose ved hjælp af SERS måling 
af hydrogencyanid i udåndingsluften 
 
 
 
Udfyld venligst spørgeskemaet med det samme med kuglepen (sæt X): 
 
 
Alder: _____ år 
 
Køn: Mand ___ Kvinde ___ 
 
 
Helbredstilstand: 
Cystisk fibrose: Ja ___ Nej ___ 
 
Anden lunge-sygdom: Ja ___ Nej ___  (Hvis ja, hvilken?    ) 
 
Har du oplevet noget af følgende den sidste uge? 
 
Feber: Ja ___ Nej ___ 
 
Hoste: Ja ___ Nej ___ 
 
Utilpashed: Ja ___ Nej ___ 
 
 
Brug af kaffe: 
Har du drukket kaffe i dag? Ja ___ Nej ___ 
 
Hvis ja: Ca. hvad tid? Klokken  
 
 
Rygning: 
Ryger du? Ja ___ Nej ___ 
 
Udsættes du for passiv rygning i hjemmet? Ja ___ Nej ___ 
 
 
Dato: _________ Navn: _________________________________CPR-nr.: _________________ 
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Lyngby, den 31. oktober 2016. 
Kære deltagere samt forældre. 
Tak, fordi I deltog i den første afprøvning af vores nanosensor til at ”fange” gasser fra Pseudomonas. Jeg 
kan fortælle, at der i alt var 50 deltagere med CF og 19 raske kontroller med i forsøget, som løb fra januar 
til april måned 2016.  
Deltagerne blev set alt imellem 1-5 gange i perioden, og der opstod ét nyt tilfælde af Pseudomonas, som 
ikke var hos en i forvejen kronisk inficeret deltager med CF. Det gode var selvfølgelig, at ekstremt få fik 
Pseudomonas i perioden. Omvendt, så giver et enkelt nyt tilfælde mig ikke meget data at arbejde med, og 
en anden gang vil vi forlænge forsøgsperioden, for at få chancen for at ”fange” noget mere. Chippen fra 
den patient, der fik dyrket Pseudomonas, havde et forhøjet signal, mens de øvrige prøver (hvor der ikke 
blev fundet Pseudomonas) fra den samme patient havde et normalt signal. 
I løbet af de 4 måneder var der yderligere 2 gange, hvor jeg troede, at jeg havde set spor af Pseudomonas, 
men der blev ikke dyrket noget fra de 2 CF patienters sputum-prøver. Derfor kan det være, at der er 
mulighed for et ”falsk positivt” signal på chippen, og det er selvfølgelig ikke meningen. Da jeg senere fik en 
ny pusteprøve fra de samme 2 patienter, var signalet igen normalt. 
Der var også 2 andre deltagere med CF, hvor man kunne se på pusteprøverne, at der blev røget i deres 
hjem. Tobaksrøg kan nemlig give det samme signal i udåndingsluften (også hos passive rygere) som 
Pseudomonas. En anden erfaring er, at selve luften i rummet, hvor barnet puster, eventuelt også kan have 
en betydning. Det er en ganske følsom chip, og det ser altså ud til, at der er en forskel på ”baggrunds-
luften”, der afhænger af hvilket rum patienten har pustet i.  
Der var desværre nogle, som havde forstået, at kaffe-drikning kunne give Pseudomonas. Jeg vil gerne 
beklage min formulering i brevet og understrege, at dette IKKE er tilfældet. Kaffe kan give den samme gas i 
udåndingsluften, som Pseudomonas kan; og det var derfor, at deltagerne ikke måtte have drukket kaffe 
inden de pustede. 
De 4 måneder på Dansk BørneLungeCenter har lært mig, at det ikke er ligegyldigt hvor længe posen får lov 
til at ligge med chippen indeni. Jeg havde på forhånd besluttet, at den skulle ligge i 15 minutter, men nogle 
gange fik den lov til at ligge længere, bl.a. fordi rummet, hvor posen skulle tømmes, var optaget. 
Der sker nogle gange det, at en sputum-prøve kan være et stykke tid undervejs til mikrobiologerne, som 
skal dyrke den. Her ser der ud til at være en mulighed for forbedring af metoden til at ”fange” 
Pseudomonas, hvis denne tid bliver optimeret. 
Jeg skal til at afslutte min PhD, og det er min forhåbning, at der er en anden forsker, som kan overtage 
projektet, når jeg stopper. Jeg ønsker jer alt det bedste fremover. 
 
Mange hilsner fra 
Rikke Kragh Lauridsen. 
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